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ABSTRACT 
 
METFORMIN AND/OR EXERCISE TRAINING AFFECT METABOLIC HEALTH IN 
MEN AND WOMEN WITH PREDIABETES  
 
MAY 2011 
 
STEVEN K. MALIN, B.S., KING’S COLLEGE 
 
M.S., UNIVERSITY OF DELAWARE 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
DIRECTED BY: PROFESSOR BARRY BRAUN  
 
Prediabetes is defined by elevated blood glucose concentrations not high enough to meet 
criteria for type 2 diabetes. Exercise or metformin, a common “anti-diabetes” medication, 
may attenuate the progression from prediabetes to type 2 diabetes by improving insulin 
sensitivity and cardio-metabolic health. Because each treatment has its primary action in 
different tissues, combining exercise (muscle) with metformin (liver) may further enhance 
insulin sensitivity and cardio-metabolic health. Purpose: To determine the efficacy of 
combining exercise training with metformin on insulin sensitivity and cardio-metabolic health 
in men and women with prediabetes. We hypothesized that the combined treatment would 
improve insulin sensitivity and cardio-metabolic health more than either treatment alone. 
Methods: Thirty-two men and women with prediabetes were placed in placebo (P), 
metformin (M), exercise training and placebo (EP), or exercise training and metformin (EM) 
groups. Pill distribution was double-blind, and the groups were well-matched for age, weight, 
and fitness. There were no baseline differences in any characteristic. Subjects were 
provided P or 2000mg/d of M for 12 weeks and EM and EP underwent a progressive 
training protocol. Insulin sensitivity was measured 28-30hr post-exercise with a euglycemic 
hyperinsulinemic clamp. Traditional cardio-metabolic measures were also collected in the 
 vii 
fasted state (e.g. blood pressure, blood lipids and inflammation). Group means were 
compared using a 2-way repeated measures analysis of variance. Results: Relative to 
baseline, all 3 interventions increased insulin sensitivity (p < 0.05), however, EP increased 
insulin sensitivity approximately 25-30% more than either EM or M. Compared to control, EP 
and M both lowered systolic blood pressure and C-reactive protein (p < 0.05, p = 0.06) and 
these reductions were approximately 15% more than EM.  Each treatment raised HDL (p < 
0.05). Enhanced insulin sensitivity was associated with increased non-oxidative glucose 
metabolism (i.e. glucose storage) (r = 0.85; p < 0.01). Conclusions: Despite more weight 
loss (4 kg), metformin blunted, rather than accentuated the effects of training on enhancing 
insulin sensitivity and lowering systolic blood pressure and inflammation. Given that 
metformin and physical activity are widely recommended treatments for prediabetes, it is 
important to better understand the mechanisms and ramifications of the combined 
treatment. 
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CHAPTER 1 
 INTRODUCTION 
 
In the United Sates (U.S.), approximately 24 million individuals have type 2 diabetes. 
The mortality and medical costs associated with type 2 diabetes make this disease an important 
public health concern and have prompted much research to determine effective interventions 
that prevent and/or delay the onset of type 2 diabetes. In 2002, the U.S. Diabetes Prevention 
Program (DPP) demonstrated that low-fat diet and regular physical activity, or treatment with 
metformin, a common anti-diabetes drug, could prevent and/or delay the progression from 
prediabetes to type 2 diabetes. Individuals with prediabetes are at high risk for type 2 diabetes 
because their blood glucose concentrations are elevated but not high enough to meet criteria for 
type 2 diabetes. Approximately 57 million individuals in the U.S. have prediabetes and it’s likely 
that the incidence will increase if daily living habits are maintained (e.g. sedentary and positive 
energy balance). Current recommendations suggest prescribing both exercise and metformin to 
prevent and/or delay the onset of developing type 2 diabetes in some individuals with 
prediabetes. To date however, but no previous study had directly assessed the efficacy of this 
treatment in men and women with prediabetes. Optimizing treatment for prediabetes requires a 
better understanding of how interventions, such as exercise and metformin, improve metabolic 
health. Metabolic health is defined as the status of metabolic variables (e.g. fasting blood 
glucose levels, insulin sensitivity, etc.) that are predictive of type 2 diabetes. Thus, targeting 
men and women with prediabetes is of utmost importance for reducing the incidence of type 2 
diabetes. 
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Purpose: 
The overall purpose of this study was to understand the effect of combining exercise 
with metformin on metabolic health in men and women with prediabetes. Although the cause for 
prediabetes remains unknown, an important component includes insulin resistance and 
disturbances in substrate metabolism. Specifically, disturbances in ability to utilize carbohydrate 
and fat during the fasted, fed and exercise state is associated with insulin resistance. Therefore, 
the specific aims of this proposal were: 
 
1. To evaluate the effect of exercise training with metformin, compared to either treatment 
alone, on whole-body insulin sensitivity and substrate metabolism in 32 individuals (16 
men and 16 women) with prediabetes. 
The outcomes included: 
a. Whole-body insulin sensitivity (i.e. rate of glucose disposal divided by steady-
state plasma insulin).  
b. Hepatic insulin sensitivity (i.e. decreased rates of glucose appearance during 
insulin stimulation). 
c.  Adipose tissue insulin sensitivity (i.e. suppression of non-esterified free fatty 
acids during insulin stimulation).  
d. Basal hepatic glucose output (i.e. rate of glucose appearance in the fasted state).  
e. Non-oxidative glucose disposal (i.e. reflects glucose storage as glycogen) 
compared to glucose oxidation during insulin stimulation.  
f. The magnitude of the shift from whole-body fat to carbohydrate oxidation during 
the fasted to insulin stimulated state (i.e. metabolic flexibility).  
 
Hypotheses: It was expected that exercise training with metformin would enhance whole-
body insulin sensitivity more than either treatment alone. Exercise training with placebo was 
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expected to increase whole-body insulin sensitivity more than metformin, while metformin 
would have enhanced whole-body insulin sensitivity more than the control (i.e. placebo). 
Enhanced insulin sensitivity was expected to be associated with increased non-oxidative 
glucose metabolism. Exercise training with metformin was expected to reduce rates of 
glucose appearance and lower non-esterified free fatty acid concentrations compared to 
either treatment alone. Exercise training with placebo was expected to have little impact on 
hepatic and adipose tissue insulin sensitivity, but metformin was expected to improve 
hepatic and possibly adipose tissue insulin sensitivity. Exercise training with metformin was 
expected to reduce basal hepatic glucose output (HGO) more than either treatment alone. 
Exercise training with placebo and metformin were expected to reduce HGO similarly more 
than placebo. Combining exercise with metformin was also expected to enhance metabolic 
flexibility (i.e. magnitude of the shift from primarily fat oxidation during the fasted state to 
primarily carbohydrate oxidation under insulin stimulation) compared to either group alone (a 
summary of these expected results may be found on page 44).  
 
2. To evaluate the effect of exercise training with metformin, compared to exercise training 
with placebo on exercise substrate metabolism in 16 individuals (8 men and 8 women) 
with prediabetes. 
The outcome measures included:  
a. Whole-body carbohydrate and fat oxidation (i.e. respiratory exchange ratio 
(RER), rate of carbohydrate and fat oxidation, and the relative percentage of 
energy from carbohydrate and fat). 
b. Glucose flux (i.e. rates of glucose appearance and disposal) 
c. Blood metabolites and hormone: non-esterified free fatty acids, glycerol, glucose, 
lactate, and insulin concentrations. 
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Hypotheses: Exercise training with metformin was expected to raise fat oxidation during 
exercise compared to exercise training with placebo. The effect of metformin to elevated fat 
oxidation was expected to be related to increased non-esterified fatty acid and glycerol 
concentrations and decreased plasma insulin. Exercise training with metformin was also 
expected to cause greater decreases in the rate of glucose appearance, disposal, and 
estimated muscle glycogen utilization compared to exercise training and placebo (a 
summary of these expected results may be found on page 46).   
 
 
Significance 
 
Many health professionals are targeting people with prediabetes to reduce the incidence 
of type 2 diabetes.  The American Diabetes Association currently recommends combining 
metformin with exercise in some men and women with prediabetes (86). Exercise and 
metformin each improve insulin sensitivity and the capacity to utilize fat for energy. Because 
each treatment targets a different tissue, it is possible that the combined treatment would 
improve metabolic health more than either treatment alone. Therefore, the goal of this study 
was twofold: first, to determine the effect of exercise training with metformin on insulin 
sensitivity; second, to determine the effect of metformin on exercise substrate metabolism in 
these same individuals. Information from this study will provide a better metabolic understanding 
of how exercise and metformin interact to potentially reduce diabetes risk, allow future studies to 
more specifically target mechanisms that affect insulin sensitivity, and ultimately design better 
treatments that lower risk for type 2 diabetes. 
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CHAPTER 2 
 LITERATURE REVIEW 
 
Introduction 
 Exercise training and metformin each affect blood glucose regulation through changes in 
insulin sensitivity and substrate metabolism in individuals with prediabetes. Prediabetes is 
defined by impaired fasting blood glucose concentrations and/or impaired glucose tolerance. 
Although blood glucose is affected by distinct tissues in the fasted (e.g. brain and kidney) and 
insulin stimulated state (e.g. digestive tract, liver, muscle and adipose tissue), blood glucose 
homeostasis is in general a balance between endogenous glucose production and glucose 
uptake. Endogenous glucose production consists of hepatic glucose output with small 
contributions from the kidney (approximately 15-20%). Blood glucose uptake is mainly a result 
of insulin and occurs in peripheral tissues, like skeletal muscle (approximately 80%). An inability 
of insulin to mediate glucose regulation in tissues, such the liver and skeletal muscle, is referred 
to as insulin resistance (see Figure 2.1).  Insulin resistance is a hallmark characteristic of type 2 
diabetes. Exercise enhances skeletal muscle insulin stimulated glucose uptake, whereas 
metformin reduces hepatic glucose output. Thus, combining exercise with metformin may 
enhance blood glucose regulation, compared to either treatment alone, because each therapy  
Figure 2.1. Metabolic characteristics associated with insulin resistance. Exercise or metformin improves insulin sensitivity. 
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targets a different tissue. Improvements in carbohydrate and fat metabolism may contribute to 
the improvements in insulin sensitivity with exercise and metformin. Therefore, the overall 
purpose of this literature review was to discuss the effects of exercise training and metformin on 
metabolic health. Metabolic health was defined as the status of metabolic variables that are 
predictive of type 2 diabetes. Given that sedentary behavior is such an important component of 
metabolic health, this literature review starts by discussing the importance of replacing 
sedentary behavior with physical activity. Then the independent effects of exercise training and 
metformin on insulin sensitivity and substrate metabolism were discussed. Finally, this literature 
review concluded with a discussion on the current body of literature pertaining to the combined 
effect of exercise with metformin.  
 
Sedentary behavior and metabolic health.  
Matthews et al (79) reported that Americans, regardless of age and/or ethnicity, spend 
approximately 8 hours a day in sedentary behavior (e.g. sitting, reclining, lying, etc). Sedentary 
behavior (defined as <1.5 METS or lack of whole body movement) has been linked to several 
adverse metabolic health conditions, including heart disease and diabetes (42). Helmerhorst et 
al. (46) showed that fasting insulin concentrations, which were used as a surrogate for insulin 
resistance, were positively associated with time spent in sedentary behavior, independent of 
time spent in moderate to vigorous activity. Preventing sedentary behavior has the potential to 
maintain or improve metabolic health. It’s been shown that breaking up prolonged periods of 
sitting, by reducing time spent in uninterrupted sedentary behavior, has the potential to prevent 
weight gain and improve metabolic health (42). Further, increased breaks in sedentary behavior 
are also beneficially associated with a lower waist circumference, body mass index (BMI), and 
2-hour blood glucose concentration (42). Thus, preventing/minimizing sedentary behavior is a 
viable strategy for maintaining metabolic health.  
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Physical activity and metabolic health 
Lifestyle modification, consisting of increased physical activity, prevents and/or delays 
the progression from prediabetes to type 2 diabetes (35, 70, 88, 94, 116). Physical activity is 
defined as any bodily movement (Metabolic equivalent: (MET) between 1.5 and 3.0) that 
substantially increases energy expenditure above resting conditions. Exercise is defined as 
structured activity (MET values >3.0) with purposes of caloric expenditure for health and/or 
performance. This distinction is important because changes in physical activity, independent of 
exercise, may alter the blood glucose regulation and metabolic health.  
Time spent in light to vigorous activity (30, 43) promotes metabolic health. Physical 
activity reduces blood glucose concentrations in response to a carbohydrate load (31, 44) and 
lowers fasting glucose, insulin, and triglycerides in sedentary adults with a family history of type 
2 diabetes (32) or the metabolic syndrome (106). In other studies, total physical activity (44) or 
time spent in light and moderate-vigorous activity (43) did not reduce fasting blood glucose 
concentrations. These findings suggest that physical activity may be more effective at regulating 
post-prandial glucose concentrations compared to fasting blood glucose concentrations. Balkau 
et al (4) observed an association between total physical activity, independent of light, moderate 
or vigorous activity, and improved whole-body insulin sensitivity measured by the 
hyperinsulinemic-euglycemic clamp in normal weight men and women. These findings indicate 
that the improved responses to carbohydrate loads (31, 44) are often attributable to enhanced 
insulin sensitivity. Together, these findings may have important clinical and public health 
implications as most Americans spend greater than 50% of their time in sedentary behavior; 
substituting sedentary behavior with activity may improve metabolic health.  
 
Exercise and insulin sensitivity 
Despite the importance of physical activity on metabolic health, major health 
organizations, such as the American Diabetes Association, recommend both aerobic and 
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resistance exercise for metabolic health. Aerobic (25, 49, 66, 98) and resistance exercise (83, 
109) are well known to improve metabolic health since physically trained individuals have 
enhanced insulin sensitivity compared to their weight-matched untrained counterparts (47, 80).  
  Single bouts of aerobic exercise improve insulin sensitivity (5, 27, 28), but this effect is 
transient (approximately 24-hours) (45, 81, 103). Therefore, to maintain this enhanced insulin 
sensitivity, it is necessary to perform repeated bouts of exercise (i.e. exercise train). Holloszy et 
al (49) demonstrated that exercise training for 12 months (5-day/week at 70% VO2max) not only 
improved insulin sensitivity, but also reversed prediabetes. Skeletal muscle accounts for 
approximately 80% of the improved insulin sensitivity (26), although there are contributions from 
the liver and adipose tissue (97). Skeletal muscle is therefore the major tissue causing the 20-
30% increase in whole-body insulin sensitivity seen after most aerobic training programs (69).  
Most exercise training interventions have been aerobic based and consist of individuals 
training 3-5 days per week at a moderate intensity exercise (e.g. >60% VO2max) for a total of 
approximately 200 minutes (see Table 2.1). Although public health recommendations suggest 
Table 2.1. Effect of aerobic exercise training on insulin sensitivity 
 Subject 
Population 
Exercise Dose Hours 
Measured 
Post-exercise 
!  in Whole-body 
Insulin Sensitivity 
 
 
 
Houmard  et al 2004 
 
 
Overweight/obese 
6mo 12mi 40-55% VO2peak 170min, 
12mi 65-85% VO2peak 110min, 22mi 
65-85% VO2peak 170min 
 
 
24 hr  
" 80% 170min 
conditions 
 
" 35% 110min 
Gan et al 2003 Overweight and 
obese men 
10 wk; 4-5d/wk for 40min at 55-70% 
VO2peak 
24-36 hr  " 16% 
DeFronzo et al 1987 Obese men insulin 
resistant 
6 wk; 4-5d/wk at 65% VO2peak for 
60min on cycle or treadmill 
 
48-72hr  
" 31%  peripheral 
 
Christ-Roberts et al 
2004 
Overweight with 
and without T2D 
8wk 3-4d/wk for 20-45min at 60-75% 
VO2peak on cycle 
 
24 hr  
" 14% overweight 
 
"  27% T2D 
Hughes et al 1993 IGT men and 
women 
12wk 50-75% HR reserve for 
55min/d 4d/wk 
96 hr  " 11% 
Solomon et al 2008 Overweight elderly 
IGT men and 
women 
12wk walking/cycling 5d/wk for 60min 
at 75% VO2peak 
 
48 hr  
 
" 60% 
 
Bruce et al 2004 T2D men 8 wk cycling 3d/wk 60min at 70% 
VO2peak 
36-48hr  " 30% 
 
Segal et al 1991 
 
Lean, obese IR, 
T2D men 
12 wk 70min 4d/wk at ventilatory 
threshold (~50 % VO2peak). 
Treadmill 
 
72 – 120 hr  
 
No change 
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that individuals exercise 30 minutes per day on most days of the week, the optimal exercise 
prescription for metabolic health remains unclear. Houmard et al (55) demonstrated that 170-
minutes of exercise per week, (i.e. volume), independent of exercise intensity (approximately 
45% vs. 70% VO2max), improved insulin sensitivity compared to 115 minutes of exercise in 
overweight insulin resistant individuals. Hughes et al (56) also demonstrated that there were no 
differences in insulin sensitivity between moderate (50% VO2max) or high (75% VO2max) 
intensity training conducted for a total of 220 minutes a week in older overweight individuals with 
prediabetes. These findings suggest that time spent exercising is an important for insulin 
sensitivity than intensity; however, they do not indicate how exercise improves insulin sensitivity.  
The mechanism by which exercise affects insulin sensitivity remains unclear. Cross-
sectional studies in healthy lean trained individuals have demonstrated relationships between 
insulin signaling proteins (e.g. IRS-1 and PI3K) and insulin sensitivity (54, 68). However, studies 
conducted in individuals with insulin resistance (112) and type 2 diabetes (18) do not support 
such relationships. Thus, in clinically relevant populations (i.e. obese, insulin resistant 
individuals), it is thought that exercise training enhances insulin sensitivity through alternative 
mechanisms. Some of these alternative mechanisms include: weight/fat loss and increased 
skeletal muscle oxidative capacity.  
Exercise may contribute to weight loss, and reductions in body weight may contribute to 
enhancing insulin sensitivity (101, 110). When energy balance is maintained during aerobic 
training, minimal improvements in insulin sensitivity are observed (101, 104). Segal et al (104). 
Segal et al (104) showed that maintaining energy balance while training had no effect on 
enhancing whole-body insulin sensitivity in lean or obese men with or without type 2 diabetes 
despite 27% increases in cardio-respiratory fitness. Compared to weight loss, when energy 
expended during exercise is fed back to maintain body weight, obese men (101) and women 
(102) do not improve insulin sensitivity. Weight loss enhances whole-body insulin sensitivity, in 
part, by decreasing amounts of body fat and increasing GLUT-4 protein and/or translocation. 
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There are training studies however that show improvements in insulin sensitivity independent of 
weight loss (14, 56). One possible explanation for these conflicting results may be due to 
decreases in total body fat and/or visceral fat. 
Elevated body fat, particularly visceral fat, is associated with insulin resistance. Training, 
independent of weight loss, reduced visceral fat in obese individuals (73). Hughes et al (56) 
demonstrated that aerobic training at either 50% or 75% VO2max without weight loss also 
decreased waist to hip ratio, which is indicative of reduced visceral fat. This latter finding was 
significantly related to improved insulin sensitivity (r = 0.70; p < 0.05). Gan et al (38) measured 
visceral fat through use of magnetic resonance imaging (MRI) and observed reductions in 
visceral adipose tissue after 10 weeks of aerobic training.  Reductions in visceral fat were 
significantly associated with improvements in insulin sensitivity (r = -0.54; p < 0.05). Decreasing 
visceral fat may lead to reductions in circulating non-esterified fatty acid (NEFA) concentrations 
that are delivered to the liver and periphery. Elevated NEFA concentrations contribute to 
elevated hepatic glucose output and reductions in skeletal muscle glucose uptake (64). Thus, 
treatments that reduce body fat may contribute to improving insulin sensitivity. However, other 
factors, independent of weight/fat loss, may promote skeletal muscle glucose uptake.  
Aerobic training promotes changes in intracellular fat metabolites that, at least partially, 
mediate improvements in insulin sensitivity. Kim et al (65) demonstrated that 12 weeks of 
aerobic training reduced intramuscular triglycerides (IMTG) in individuals with prediabetes. 
Reduced IMTG concentrations were inversely related to GLUT-4 protein concentrations. This is 
potentially important because increased expression of GLUT-4 protein is related to enhanced 
glucose uptake (18). Bruce et al (13) examined the effect of exercise training on IMTG and 
insulin sensitivity in individuals with type 2 diabetes. Aerobic training in individuals with type 2 
diabetes reduced IMTG concentrations to lean control concentrations, but this reduction in 
IMTG failed to normalize insulin sensitivity. This finding suggests that IMTG concentrations 
likely serve as a marker of insulin resistance and not a direct role in mediating insulin sensitivity. 
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For example, trained athletes have similar IMTG concentrations as individuals with type 2 
diabetes, yet trained athletes have higher insulin sensitivity (39). This phenomena is likely 
explained by the observation that trained individuals have an increased capacity to oxidize fat 
(39). Lower fat oxidation may not only increase IMTG concentrations, but it may also increase 
fatty acid intermediates (e.g. DAG and ceramides) that directly impair insulin sensitivity (64).  
Individuals with insulin resistance are characterized by reduced oxidative capacity and 
elevated fat uptake compared to their insulin sensitive counterparts (63, 64, 107). Bruce et al 
(15) indicated that oxidative capacity was the strongest predictor of insulin sensitivity, compared 
to skeletal muscle lipid status, across a wide range of metabolic phenotypes (e.g. lean healthy 
to type 2 diabetes). More recently, it was demonstrated in animals that exercise training 
enhanced the capacity of skeletal muscle to oxidize excess fat and reverse high fat feeding 
induced insulin resistance. It’s thought that reduced oxidative capacity under states of excess 
fat intake leads to decoupling between ß -oxidation and the Krebs cycle, and this mismatch 
between metabolic pathways increases the production of “incomplete” lipid species. These 
incomplete lipid species have been associated with impaired insulin signaling (71). Therefore, it 
seems likely that the training induced improvements in insulin sensitivity are partially mediated 
through to the ability to balance fat storage and fat oxidation.  
Despite exercises clinical benefit, long-term adherence is often poor. The exact reason 
for this is unclear, but it is often attributed to feelings of tiredness and a lack of self-motivation 
(113). Resistance exercise may be an attractive alternative to aerobic exercise because it can 
be done in shorter periods of time and it enhances muscle strength. Improvements in strength 
may lead to improved physical function in individuals with low cardio-respiratory fitness (17, 62) 
and subsequently lead to greater compliance with aerobic based programs. Unfortunately, there 
little is known regarding the effects of resistance training on enhancing insulin sensitivity.  
Resistance exercise enhances insulin sensitivity in individuals along the continuum of 
insulin resistance to type 2 diabetes (see Table 2.2; 51, 52, 60, 82, 83). Miller et al (82) first 
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demonstrated the beneficial effects of resistance training on blood insulin responses to a 
carbohydrate load in healthy individuals. Ishi et al (60) showed that resistance training 
enhanced insulin sensitivity by 48% when scaled to fat-free mass, independent of VO2max 
Table 2.2 Effect of resistance exercise training on insulin sensitivity 
  Study Population Exercise training 
Hours measured 
post-exercise 
! in Whole-body 
Insulin Sensitivity 
 
Eriksson et al 1998 Pre-diabetes 3d/wk: 3 x 8-10 repetitions at 50% 1 
RM for 10 weeks compared to 3d/wk 
at 60% HRmax for 1hr per session 
 
96 hour 
" 23% circuit 
training only 
 
Holten et al 2004 
Lean 
 
T2D 
6wk; 3/dwk one legged exercise. 1-
2wk = 10 repetitions 50% 1RM; 3-6wk 
= 10-12 repetitions at 80% 1 RM;  
 
16 hr  
 
" 30% both 
Ishi et al 1998 Nonobese T2D 4-6wk; 5d/wk 2 x 10-20 repetitions of 9 
exercises 
48 hr  " 48% 
Miller et al 1984 Healthy males 10wk; 3d/wk; 3 x 8 repetitions: no 
intensity reported 
48hr  " 18% 
Miller et al 1994 
 
Elderly Insulin 
resistant men 
 
3d/wk; 3-4 repetitions at 90% 
1RM and 15 repetitions; 16wk 
 
22-24hr 
 
" 22% 
 
 
or body composition in individuals with type 2 diabetes. Eriksson et al (34) measured insulin 
sensitivity by using the hyperinsulinemic-euglycemic clamp and showed that circuit-resistance 
training increased insulin sensitivity by 23% in overweight men with prediabetes. Miller et al  
(82) also determined the effectiveness of resistance training on insulin sensitivity in insulin 
resistant men and observed a 24% improvement in insulin sensitivity when normalized to fat-
free mass. Scaling insulin sensitivity to fat-free mass (i.e. skeletal muscle), was important 
because it suggested that skeletal muscle adaptations, not skeletal muscle mass per se, were 
responsible for the enhanced insulin sensitivity. Holten et al (51) later demonstrated that 6 
weeks of one-legged resistance training enhanced insulin sensitivity in individuals with type 2 
diabetes and was, in part, due to increased insulin signaling proteins: GLUT-4, insulin receptor, 
and Akt protein. There were no changes in oxidative enzymes concentrations (citrate synthase 
or ß-HAD), suggesting that resistance training enhances insulin sensitivity through increasing 
insulin signaling proteins.  
Given that major health organizations recommend performing both aerobic and 
resistance exercise, it is surprising so few studies have investigated the effect of combining 
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such exercises on metabolic health. Wallace et al (121) compared the effects of aerobic and 
resistance training to aerobic training only on fasting insulin concentrations (used as a surrogate 
for insulin sensitivity) in individuals with insulin resistance. Aerobic and resistance training 
lowered fasting insulin (8!U/ml vs. 3!U/ml) and glucose concentrations (11.1mg/dl vs. 6mg/dl) 
more than aerobic training. Aerobic and resistance training improved triglycerides, blood 
pressure and high-density lipoproteins, compared to aerobic training only. Cuff et al (22) also 
observed greater improvements in insulin sensitivity after performing 16 weeks of aerobic and 
strength training compared to aerobic exercise only in postmenopausal women with type 2 
diabetes.  A limitation, however, with the aforementioned studies is that individuals performing 
both modes of exercise usually exercised 30 minutes longer each day. Consequently, the 
improvements in metabolic health may be a result of increased energy expenditure and/or 
greater weight loss and not the combination of aerobic and resistance exercise itself. Despite 
this limitation, these data demonstrate that combining exercise modalities are favorable for 
insulin sensitivity. To date, however, no study has been published characterizing the efficacy of 
aerobic and resistance training on insulin sensitivity in individuals with prediabetes.  
In summary, aerobic and resistance exercise is known to improve insulin sensitivity in 
individuals at risk for type 2 diabetes. This suggests that exercise is a vital treatment for 
improving the ability to clear blood glucose in individuals with prediabetes. Under insulin 
stimulated states, skeletal muscle clears approximately 70-90% of the blood glucose (69). 
Although this highlights the importance of skeletal muscle in response to insulin, it suggests that 
other tissues are responsible for the remaining 20-30% improvement in insulin sensitivity. 
Perhaps adding a therapy that targets liver tissue, thereby reducing endogenous blood glucose 
production, may accentuate improvements in insulin sensitivity.  
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Metformin and hepatic glucose metabolism   
 The U.S. Diabetes Prevention Program (DPP) demonstrated that metformin effectively 
prevents and/or delays the onset of type 2 diabetes in individuals with prediabetes (70). 
Metformin is an orally administered drug and is routinely used to lower blood glucose 
concentrations in individuals with type 2 diabetes (67).  
Metformin reduces fasting blood glucose concentrations approximately 30% in 
individuals with type 2 diabetes by, in large part, reducing hepatic glucose output (HGO) (23, 58, 
111). Although the exact mechanism by which metformin reduces HGO is unclear, it appears 
related to reductions in gluconeogenesis (58).  
Metformin likely reduces gluconeogenesis through two possible mechanisms by either 
decreasing gluconeogenic precurosors and/or enhancing hepatic insulin sensitivity. Metformin 
had been reported to lower lactate uptake and decrease the conversion of alanine to pyruvate in 
animal models (67). Consistent with decreased lactate uptake, elevated fasting blood lactate 
concentrations have been reported in some (58) but not all (23, 111) studies. Metformin also 
lowers non-esterified fatty acid (NEFA) concentrations by 10-30% at rest and during insulin 
stimulation (67). Since NEFAs act as a gluconeogenic stimulators through increasing the 
availability of acetyl-CoA, lower NEFA concentrations could also contribute to reducing HGO 
(67).  
Alternatively, metformin may enhance hepatic insulin sensitivity (i.e. decreased rates of 
glucose appearance during insulin stimulation) and reduce post-prandial (24, 33) and day-long 
glucose concentrations (1, 123). Wu et al (123) showed that metformin lowered blood glucose 
concentrations by 25% over the course of the day (from 0800 to 1600 hours) in individuals with 
type 2 diabetes. There were no differences in insulin stimulated glucose uptake, suggesting that 
the majority of the blood glucose improvement was a result of HGO suppression. Lower NEFA 
concentrations are one possible explanation for how metformin enhanced hepatic insulin 
sensitivity. Perriello et al (92) showed that metformin suppressed NEFA concentrations by 17% 
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and lowered lipid oxidation 25% during a glucose clamp in individuals with type 2 diabetes. 
Reduced NEFA concentrations during the glucose clamp were significantly associated with 
HGO suppression (r = 0.70; p <0.001) but not increased glucose uptake. Riccio et al (96) also 
showed that 4 weeks of metformin treatment lowered fasting plasma NEFA turnover rate and 
NEFA oxidation by 27 and 24%, respectively, in individuals with type 2 diabetes. 
The mechanism by which metformin enhances hepatic insulin sensitivity is unclear. Zhou 
et al (124) demonstrated that metformin increased hepatic fat oxidation and reduced fat 
synthesis in isolated hepatocytes. This suggests that metformin may decrease hepatic fat 
storage and remove the deleterious effects of hepatic fat metabolites on insulin resistance. 
However, Tiikkainen et al (114) demonstrated that 16 weeks of metformin treatment did not 
affect hepatic fat content in individuals with type 2 diabetes, despite enhanced hepatic insulin 
sensitivity. A reasonable explanation for the differing results in hepatic fat content is likely 
because the dosage used by Tiikkainen et al (114) was considerably lower, although more 
clinically relevant, than the pharmacological dose used previously (124).  
Independent of hepatic fat content, it’s possible that changes in fat turnover could play a 
role in ameliorating hepatic insulin resistance (39). Cleasby et al (19) demonstrated that 
metformin opposed the development of lipid-induced insulin resistance in rat liver tissue through 
activation of AMPK. AMPK is associated with increased phsophorylation of acetyl-CoA 
carboxylase (ACC), which is related to decreasing malonyl-CoA synthesis and increasing the 
entry of fat into the mitochondria for oxidation. Thus, perhaps improving the flux of fatty acids is 
more important than decreasing hepatic fat content for enhancing hepatic insulin sensitivity.  
 
Metformin and whole-body insulin sensitivity  
Metformin lowers insulin concentrations at rest (24, 85) and during carbohydrate loads 
(24, 33), suggesting improved insulin sensitivity. Metformin improves whole-body insulin 
sensitivity in some (24, 29, 74, 96), but not all studies (105, 111, 123). Differences between 
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these studies may be related to pre-treatment body weight and fasting blood glucose 
concentrations. For example, the most favorable effects on insulin sensitivity are often observed 
in individuals with excess body weight and elevated blood glucose concentrations (3). 
Dorella et al (29) showed that 4-weeks of metformin enhanced whole-body insulin 
sensitivity by approximately 30% in overweight-insulin resistant hypertensive individuals. 
Lehtovirta et al (74) demonstrated that 6 months of metformin treatment also enhanced insulin 
sensitivity by 20% in impaired glucose tolerant individuals.  
A possible mechanism by which metformin enhances insulin sensitivity is by causing 
weight loss. Metformin decreases body weight by approximately 1-5kg (24, 78, 85), of which 
90% is body fat (111). Tiikkainen et al (114) showed that metformin decreased subcutaneous 
body fat in individuals with type 2 diabetes with average waist-to-hip ratios of 0.98 (obesity 
defined as: >0.95 for men and >0.86 for women). Pasquali et al (90) demonstrated that 
metformin significantly reduced total body fat and visceral fat in women with polycystic ovarian 
syndrome (PCOS). Weight and/or fat loss has been shown to increase GLUT 4 protein 
expression (85) and/or its translocation to the cell membrane under insulin stimulated conditions 
in skeletal muscle (57). Consistent with enhanced insulin sensitivity, metformin has been shown 
to increase non-oxidative metabolism (85) thereby increasing glycogen storage in skeletal 
muscle (2, 85) and hepatic tissue (114).  
Metformin may also enhance insulin sensitivity because it reduces skeletal muscle fat 
content. Collier et al (21) demonstrated that metformin limited muscle lipid storage in rat skeletal 
muscle and improved the coupling between fat uptake and oxidation by reducing FAT/CD36 
transporter. Reduced FAT/CD36 transporter could potentially lead to decreased fat uptake in 
skeletal muscle and decrease the synthesis of DAG and ceramide concentrations that are 
associated with insulin resistance (108). Thus, improvements in skeletal muscle fat oxidation 
and/or storage may contribute to the improved insulin sensitivity with metformin treatment.  
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In summary, metformin lowers blood glucose concentrations by primarily reducing 
hepatic glucose output, improving hepatic insulin sensitivity, and to a lesser extent, stimulating 
insulin mediated skeletal muscle glucose uptake. The mechanism by which metformin improves 
hepatic glucose metabolism is unclear, but may be due to weight loss and/or fat metabolism. 
Given the beneficial effects metformin have on the liver, combining metformin with exercise 
training may accentuate metabolic health in individuals with prediabetes.  
 
Role of substrate metabolism on insulin sensitivity.  
The mechanism underlying the development of insulin resistance has yet to be fully 
elucidated. However, it is clear that disturbances in carbohydrate and fat metabolism are 
involved (16, 64). Individuals with high insulin sensitivity are characterized as metabolically 
flexible and able to switch from predominately fat utilization in the fasted state to chiefly 
carbohydrate utilization during the insulin-stimulated state. Metabolic “inflexibility” is a 
characteristic found in individuals with insulin resistance. Insulin resistant individuals utilize less 
fat for energy during the fasted state and do not switch to carbohydrate use under insulin-
stimulated states, compared to insulin sensitive individuals (64). Elevated fat oxidation under 
insulin-stimulated conditions suggests that insulin does not suppress adipose tissue lipolysis. 
High rates of lipolysis under insulin stimulated conditions would lead to increased 
concentrations of NEFAs and impair HGO suppression and glucose uptake (64).  Exercise may 
overcome this “inflexibility” by increasing the capacity to oxidize fat during and after bouts of 
exercise (110, 119).  Thus, interventions that increase fat utilization may enhance insulin 
sensitivity by: reducing lipid species (14, 39) and/or improving “complete’ fat oxidation (71).  
 
Exercise and substrate metabolism.  
Endurance training increases the reliance on fat and decreases the dependence on 
carbohydrate utilization during rest (99, 115) and exercise (12, 20, 37, 59). Few studies however 
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have characterized the effect of exercise training on carbohydrate and fat oxidation in 
overweight and/or obese individuals. Exercise training effects on fat utilization in overweight 
and/or obese individuals is summarized in Table 2.3.  
When individuals exercise at 65% of pre-training VO2max (i.e. ~55% post-training 
VO2max), lower RER values (indicating elevated fat use) are observed in obese individuals (13). 
Bruce et al (14) demonstrated that exercise training increased skeletal muscle mitochondrial fat 
oxidation 120% and was related to enhanced insulin sensitivity. Muscle biopsies demonstrated 
that elevated mitochondrial fat oxidation was related to reductions in diacylglycerol (DAG) and 
saturated DAG fat species. These observations suggest that improved fat oxidation may, at 
least partially, be related to enhanced insulin sensitivity. Venables et al (120) compared interval 
training to a novel training protocol eliciting Fatmax on fat oxidation and insulin sensitivity in 
obese men. These men exercised at their Fatmax (i.e. approximately 45% VO2max) for 30-60  
Table 2.3. Exercise training on substrate use in overweight individuals.  
Study Population Exercise  
Training 
!Whole-body 
substrate use during 
exercise 
Bruce et al 2004 Type 2 diabetes 5d/wk for 60min @ 65% 
VO2max for 8 weeks 
" Fat Use 
Venables et al 2008 Hyperinsulinemic 
Obese men 
5d/wk for 30-60min @ 
45% VO2max for 4 
weeks 
" Fat Use 
Dumortier et al 2003 Metabolic syndrome 3d/wk for 40min @ 45% 
VO2max for 8 weeks 
" Fat Use 
Van Aggel-Leijssen et al 2001 Overweight men 3d/wk for 60min @ 
40%VO2max for 
12weeks 
" Fat Use 
Bruce et al 2006 Obese men 5d/wk for 60min @ 65% 
VO2max for 8 weeks 
" Fat Use 
 
minutes over 4 weeks. After a 1 month wash-out period, these same participants underwent 
interval training at ± 20% of their Fatmax for 4 weeks. Training at the Fatmax, enhanced fat 
oxidation 44%, compared to interval training. Elevated fat oxidation was modestly related to 
reductions in insulin concentrations during a carbohydrate load (r = -0.44; p < 0.05). This finding 
suggests a possible relationship between fat utilization during exercise and insulin sensitivity. 
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The healthful effects of exercise, however, are not limited to increased energy expenditure and 
fat oxidation during exercise, but are extended into the recovery period when insulin sensitivity 
in increased.  
Following aerobic or resistance exercise, carbohydrate oxidation is reduced and fat 
oxidation is elevated in lean (6, 7, 11, 72, 93) and obese (77) individuals. Elevated fat oxidation 
in the fasted-state favors metabolic flexibility (64) and insulin stimulated glucose uptake (8, 48, 
53). Exercise training improves fasting fat oxidation in obese individuals with (110) or without 
prediabetes (40). Goodpaster et al (40) demonstrated that obese men and women without type 
2 diabetes shifted fasting fat utilization from 38% to 52% and enhanced insulin sensitivity by 
approximately 50%. The strongest predictor of insulin sensitivity was elevated fasted fat 
oxidation (r = -0.62; p < 0.05) (40). Thus, exercise training improves the capacity to utilize fat 
and enhances insulin sensitivity.  
In summary, exercise training increases fat oxidation during and after exercise in 
overweight individuals. Given that disturbances in fat metabolism have a role in insulin 
resistance, elevated fat oxidation during or after exercise may be a mechanism by which 
exercise training causes favorable changes in insulin sensitivity (110, 119). Adding a therapy 
that accentuates fat oxidation in the fasted state may lead to greater improvements in metabolic 
flexibility and metabolic health.  
 
Metformin and substrate metabolism.  
Although some studies report that metformin increases non-oxidative glucose disposal 
(23, 24, 85, 111), others report elevated carbohydrate oxidation (29, 74, 92, 96). It is not entirely 
clear why there are such discrepancies in the literature. One possibility is due to weight loss. 
Metformin promotes weight loss, which is both associated with elevated carbohydrate oxidation 
(87). Short-term studies without weight loss however show that metformin raises carbohydrate 
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oxidation in the fasted state. This suggests that metformin elevates carbohydrate oxidation 
independent of weight loss.  
Alternatively, metformin may enhances carbohydrate utilization because it lowers fasting 
NEFA concentrations (29, 92, 96). It has been suggested that lower NEFA concentrations 
during insulin stimulation may favor glucose uptake because of reduced inhibition on key insulin 
signaling proteins (64). Perhaps elevated carbohydrate oxidation during insulin stimulation was 
also a result of lower NEFA and explains the enhanced insulin sensitivity in individuals with 
prediabetes (74). Nevertheless, elevated carbohydrate oxidation during insulin stimulation would 
be expected to enhance metabolic flexibility (64) and favor enhanced insulin sensitivity.  
Long-term studies with metformin however show no change in fat oxidation during the 
fasted or insulin stimulated state when NEFA concentrations do not change (23, 24, 85, 111). 
Musi et al (85) demonstrated no change in carbohydrate or fat oxidation after 10 weeks of 
metformin treatment; however, there were significant improvements in non-oxidative 
carbohydrate metabolism and skeletal muscle glycogen concentrations. A possible explanation 
for the discrepancy between studies on carbohydrate oxidation is that standardized meals were 
provided in some (23, 85, 111), but not all studies (29, 74). Perhaps individuals consumed extra 
carbohydrate on the day(s) prior to the glucose clamp, which increased glycogen stores and  
shifted glucose uptake towards oxidation.  
In summary, metformin lowers blood glucose concentrations by primarily decreasing 
glucose production, and to a lesser extent, elevating whole-body insulin sensitivity. The effect of 
metformin on non-oxidative versus oxidative glucose metabolism remains unclear; however, in 
studies where metformin lowers NEFA concentrations there is a compensatory rise in 
carbohydrate oxidation during fating and insulin stimulated state.  
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Metformin added to exercise.  
Since exercise primarily targets skeletal muscle and metformin predominately affects the 
liver, combining these two treatments may accentuate effects on substrate metabolism and 
insulin sensitivity (86). Few studies have assessed the combination of metformin and exercise 
on metabolic health or fitness parameters (e.g. VO2max, substrate utilization, etc), and most 
studies to date have been conducted in lean healthy individuals (10, 41, 61).  
           In a group of recreationally active individuals, metformin reduced VO2max and heart rate 
max by approximately 3% (10), but metformin was reported to have little effect on submaximal 
exercise VO2, RER, or heart rate. This later observation suggests that minor decreases in 
maximal capacities have minimal effect on submaximal exercise physiology. However, 
decreases in VO2max would be expected to increase the relative intensity of exercise when 
performed at the same absolute workload. If metformin increases the relative intensity of 
exercise and acts to stimulate glucose uptake (85), then it’s likely that metformin would elevate 
carbohydrate oxidation during exercise.  Malin et al (76) however showed that metformin 
enhanced whole-body fat oxidation (see Figure 2.2; pilot study published chapter 5) during 
exercise across a range of exercise intensities (~30 to 70% Wpeak) by approximately 25% in  
Figure 2.4. Metformin raises fat oxidation during exercise in healthy individuals. 
 
recreationally active individuals. These data are contrary to what may be expected given the  
effect of metformin to alter fitness and/or increase glucose uptake. The mechanism by which 
metformin raised fat oxidation is unclear, but may be related to either the direct effect of 
metformin to enhance fat utilization or the indirect effects of limited carbohydrate availability.  
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Metformin has been shown to activate AMPK (85). AMPK is associated with facilitating entry of 
non-esterified fatty acids into the mitochondria for subsequent fat oxidation (75). Metformin has 
also been reported to decrease blood insulin concentrations during exercise in healthy 
individuals. Lower insulin concentrations were associated with elevated circulating non-
esterified fatty acid  concentrations during exercise. Elevated NEFA concentrations would be 
expected to substrate available for potential oxidization (41). However, metformin also acts to 
reduce hepatic glucose production, which could lower the availability of plasma glucose and 
constrain carbohydrate oxidation (95). Use of glucose isotopes during exercise would partially 
address this latter mechanism and provide further characterization of substrate oxidation during 
exercise.  
To date, the only published study characterizing the combined effect of exercise and 
metformin on insulin sensitivity in humans is from a study in overweight sedentary insulin 
resistant individuals following a single bout of exercise (105). AMPK has been suggested to be 
an important regulator of post-exercise whole-body insulin sensitivity (75). Because exercise 
and metformin have been shown to independently activate AMPK in skeletal muscle (84, 85), it 
was hypothesized that combining metformin with exercise, compared to exercise alone, would 
produce additive effects on AMPK in skeletal muscle and, at least partially, contribute to 
enhanced whole-body insulin sensitivity. Metformin or placebo was provided to all participants 
for 2-3 weeks at 2000mg/d. After treatment, individuals exercised for approximately 30 minutes 
at 65% and 10 minutes at 85% VO2peak. Insulin sensitivity was measured approximately 4 
hours post-exercise by the hyperinsulinemic-euglycemic clamp. The results indicated that 
exercise alone enhanced whole-body insulin sensitivity by 54% compared to baseline, but 
metformin blunted the exercise effect. Although these preliminary findings suggest that 
combining metformin with exercise may not be additive, they could have important ramifications 
for the treatment of prediabetes. Individuals with prediabetes are recommended to perform 
repeated bouts of exercise to improve metabolic health. From a practical standpoint, it is 
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important to assess the effect of exercise training and metformin on insulin sensitivity in 
individuals with prediabetes to better understand if exercise and metformin combined is a useful 
treatment option.  
The Indian Diabetes Prevention Program (IDPP) recently tested the efficacy of 
combining lifestyle modification (i.e. exercise and low-fat diet) with metformin on the incidence 
of type 2 diabetes in individuals with prediabetes over 3 years compared to lifestyle 
modification, metformin or placebo (94). All treatments reduced the incidence of type 2 diabetes 
by 40% compared to placebo. This suggests that the combined treatment is not better that 
either treatment alone. However, individuals in the IDDP were typically overweight but not 
obese, highly active, and ate a relatively low-fat diet. Thus, the generalization of these data 
maybe limited to this population. The only study to characterize the effects of training with 
metformin to date was conducted in high fat fed obese Zucker rats (108). For 8 weeks, rats 
performed treadmill exercise and were provided metformin treatment. Exercise training with 
metformin and exercise training alone increased insulin stimulated skeletal muscle glucose 
uptake similarly, but both exercise conditions were better than metformin alone. These findings 
suggest that combining exercise training and metformin is not better than exercise training 
alone. However fasting blood glucose concentrations were slightly lower with the combined 
treatment compared to either exercise training or metformin alone. Because assessing skeletal 
muscle insulin sensitivity does not incorporate the impact of the intervention on other key 
tissues (e.g. liver), it remains possible that whole-body insulin sensitivity would be improved 
when exercise and metformin are combined. Moreover, this previous work (108) only tested 
type I muscle fiber (i.e. soleus) glucose uptake. Given that type II muscle fibers are an important 
depot for glucose storage, it’s possible that studying whole muscle may provide different results.  
To date, no study has directly assessed the combined effects of exercise training with 
metformin on whole-body insulin sensitivity or substrate metabolism in the clinically relevant 
population of men and women with prediabetes. From a clinical perspective, understanding how 
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the combined treatment affects metabolic health may potentially improve the management of 
blood glucose concentrations. From a public health perspective, understanding which treatment 
plan is best at enhancing metabolic health may ultimately lead to greater reductions in the 
incidence of type 2 diabetes.  
 
Conclusion.  
Exercise is a cornerstone therapy for the prevention of type 2 diabetes. Determining the 
impact of exercise and/or metformin on insulin sensitivity and substrate metabolism is important 
to understanding optimal treatments for metabolic health. It is possible that exercise-induced 
adaptations in skeletal muscle, combined with metformin-mediated improvements in liver, may 
produce additive effects on whole-body insulin sensitivity and substrate metabolism. 
Collectively, the current literature supports that:  
1. Exercise training increases insulin sensitivity in a variety of populations, including 
individuals with prediabetes, by primarily targeting insulin-stimulated skeletal muscle 
glucose uptake.  
2. Metformin improves blood glucose homeostasis by reducing hepatic glucose output, 
enhancing hepatic insulin sensitivity and to a lesser extent peripheral insulin sensitivity.  
3. Exercise training enhances whole-body fat oxidation in both the fasted and exercise 
state and this may favor high insulin sensitivity. 
4. Metformin stimulates glucose uptake in skeletal muscle, enhances non-oxidative and 
oxidative glucose metabolism during insulin stimulation, and enhances fat oxidation 
during exercise.  
5. Exercise and metformin have different effects on skeletal muscle and liver that increase 
the propensity of improving whole-body insulin sensitivity and altering substrate 
metabolism in individuals with prediabetes.  
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CHAPTER 3 
METHODS 
 
Overview of study design 
The overall goal of this study was to determine the effect of combining exercise training with 
metformin on metabolic health (AIM 1) and substrate metabolism during exercise (AIM 2) 
compared to either exercise training or metformin alone. To test aim 1, 32 individuals with 
prediabetes were tested in 1 of 4 conditions over 12 weeks: 
1) Placebo (P) 
2) Metformin (M) 
3) Exercise training + placebo (EP) 
4) Exercise training + metformin (EM) 
Sixteen individuals from the exercise conditions were tested in aim 2. Pills were distributed in a 
double-blind manner. An overview of the study design is provided in Figure 3.1.  
Figure 3.1.  Overview of Study Design 
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To address Aim 1 a through f (effect of adding metformin to exercise training on whole-body 
insulin sensitivity and substrate metabolism), insulin-mediated glucose disposal, hepatic glucose 
output and suppression of non-esterified fatty acid s were assessed using the hyperinsulinemic-
euglycemic clamp technique (i.e. glucose clamp) combined with glucose stable isotope tracers. 
Whole-body carbohydrate and fat oxidation were also measured during the glucose clamp by 
indirect calorimetry at baseline and after the intervention with P, M, EP or EM.  
 
To address Aim 2 a through c (effect of adding metformin to exercise training on substrate 
oxidation during exercise), rates of glucose appearance and disposal were assessed using the 
glucose stable isotope dilution method and whole-body carbohydrate and fat metabolism was 
measured via indirect calorimetry at baseline and after approximately 10 weeks of EP and EM.   
 
Subjects 
Overweight to obese (body mass index = 25-45 kg/m2), sedentary (<60 minutes of moderate 
activity per week as measured by questionnaire) men and women between the ages of 25 to 60 
were recruited.  All potential participants performed an oral glucose tolerance test (OGTT) to 
ensure they had prediabetes (i.e. impaired glucose tolerance in the absence or presence of 
impaired fasting glucose concentrations), but were in otherwise good health. All subjects were 
weight stable for at least 3 months (< 5% body weight change) prior to enrollment in the study. 
Subjects with family history of type 2 diabetes were included. Subjects were excluded if they 
use tobacco products, had cardiovascular disease or type 2 diabetes or took dietary 
supplements/medications known to affect substrate metabolism and exercise capacity (e.g. 
chromium, niacin, ephedrine).  
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Screening 
Subjects underwent a 2-hour Oral Glucose Tolerance test (OGTT) after reading and signing the 
informed consent documents approved by the University of Massachusetts institutional review 
board. After a 5-hour minimum fast, individuals had their fasting blood sample was taken from a 
forearm vein. Subjects consumed 75 grams of glucose and blood samples were collected 1 and 
2 hours post-carbohydrate load. Whole-blood glucose was analyzed for determination of blood 
glucose concentrations. Individuals with elevated fasting glucose concentrations (5.5-
6.9mmol/L) and/or elevated 2-hour glucose concentrations (7.8-11.1mmol/L) were included in 
the study. Participants with blood glucose values higher than 6.9mmol/L (fasted) or 11.1 mmol/L 
(2-hour) were recommended to seek medical counsel. However, if those same subjects had 
repeated fasting blood glucose concentrations <6.9mmol/L (indicating they do not have type 2 
diabetes) they were enrolled into the study.   
 
Preliminary testing 
 
Peak oxygen consumption (VO2peak), i.e. cardio-respiratory fitness, was determined using a 
continuous progressive exercise test on a cycle ergometer (SensorMedics 800, Yorba Linda, 
CA). After a 5-minute warm-up, the workload on the cycle ergometer was increased by 
approximately 30 W every 2 minutes until the subject was unable to maintain a pedal cadence 
of 60 rpm. During the test, respiratory gases (VO2 and VCO2) were collected by indirect 
calorimetry using open-circuit spirometry (ParvoMedics Truemax 2400, Consentius 
Technologies, Sandy, UT). Heart rate was monitored throughout the test (Polar, Inc., Lake 
Success, NY). VO2peak and Work peak (Wpeak) were defined as the highest value obtained 
during the test. This test was considered valid if at least 3 of the following criteria are met: a 
plateau in VO2 (< 150 mL/min) between 2 exercise stages, respiratory exchange ratio (RER) > 
1.1, heart rate within 15 beats per minute of age predicted heart rate peak (HRpeak; 220-age), 
or if the participant voluntarily stops the test. Resting metabolic rate (RMR) was assessed in the 
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supine position for 30-minutes via indirect calorimetry using open spirometry after an overnight 
fast. Only the last 2 minutes were used to assess resting energy expenditure and an activity 
factor of 1.4 was used to estimate total daily energy needed. Body composition was measured 
using dual-x-ray absorptiometry (DEXA; Lunar Prodigy, Madison, WI) for determination of body 
fat percentage and fat-free mass (FFM).  
 
Euglycemic hyperinsulinemic clamp and stable isotope tracer infusion 
Insulin sensitivity (AIM 1) was measured before and after the intervention. Subjects were 
provided food (55% carbohydrate, 30% fat, and 15% protein) 24 hours prior to testing to 
standardize diet. After an overnight fast (i.e. 8-12 hours), subjects reported to the laboratory and 
an indwelling catheter was placed in a superficial vein of each forearm for continuous infusion of 
glucose stable isotope solution ([6,6-2H glucose]) and venous blood sampling. Baseline blood 
samples were collected. A priming bolus of 200 mg 6,6-2H glucose was given followed by a 90 
minute infusion of 6,6-2H glucose at a rate of 3.0 mg/min as delivered by peristaltic infusion 
pump (Harvard Apparatus Pump 22, Holliston, MA). Blood samples were collected at 0, 75 and 
90 minutes. Breath samples were collected between 80-90 minutes. The last 2 minutes was 
used for estimation of substrate oxidation. The infusate was then changed to a primed (250 
mU/m2·min) constant infusion (80 mU/m2·min) of insulin diluted in saline containing 4% (v/v) of 
the subject’s own serum. A variable infusion of a glucose and isotope solution (20% glucose + 
2% 6,6-2H) was adjusted every 5 minutes to maintain plasma glucose at approximately 
5mmol/L over 120 minutes. Blood samples were collected for glucose analysis every 5 minutes, 
and insulin, isotopic enrichment, and non-esterified fatty acid  measures were collected at 
minutes 15, 60, 75, 90, 105, and 120. Breath samples were also collected between minutes 
105-120 of the clamp for determination of whole-body substrate oxidation.  
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Submaximal Exercise protocol  
 
Specific to aim 2, substrate metabolism during exercise was determined before and after 10 
weeks training with or without metformin. Changes in estrogen and progesterone during the 
female menstrual phase may impact substrate utilization during exercise (9). Women were 
tested between 5-10 days post-menses and tested after training in the same midfollicular phase; 
i.e., women were tested after approximately 10 weeks of training because we were timing 
measures of exercise substrate metabolism around the midfollicular phase.  
Subjects reported to the laboratory following a 10-12 hour fast and indwelling catheters 
were placed in a superficial vein of each forearm for continuous infusion of glucose stable 
isotope solution ([6,6-2H glucose]) and venous blood sampling. Baseline blood samples were 
collected and a priming bolus of 200 mg 6,6-2H glucose was given followed by a 90 minute 
infusion of 6,6-2H glucose at a rate of 3.0 mg/min delivered by peristaltic infusion pump. Blood 
samples were collected at baseline, 75 and 90 minutes. Subjects were positioned on the cycle 
ergometry and baseline respiratory gases were collected for 8 minutes. Subjects warmed up for 
5 minutes on the cycle ergometer at 25 W. Subjects cycled at 60% of the pre-training VO2peak 
for 45 minutes before and after intervention. Two-minute recovery periods at minutes 15 and 25 
were provided to ensure exercise compliance. Breath and blood samples were collected at 15, 
25, 35, and 45 minutes. Respiratory gases were collected during the first 15 minutes to ensure 
steady-state conditions had been reached, and subjects continued to wear the one-way 
mouthpiece with nose clip for 7 minutes prior to each respective time point. Respiratory gases 
were averaged during the last 2 minutes at each time point for substrate oxidation analysis. 
Substrate oxidation analysis included the respiratory exchange ratio (RER), total rate of 
carbohydrate and fat oxidation, and relative percentage of energy from carbohydrate and fat. 
Blood glucose, lactate, non-esterified fatty acid , glycerol, insulin, rating of perceived exertion 
(RPE), and heart rate were also collected during the last 2 minutes of each exercise time point. 
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Subjects were asked to record dietary intake 24-hour prior to exercise testing and were 
instructed to replicate this diet prior to post-training exercise testing. Dietary compliance was 
monitored by subjects recording any changes in their diet prior to post-testing. In addition, 
subjects were instructed to avoid strenuous activity 24-36 hours prior to testing and all subjects 
were tested at a similar time of day.  
 
One Repetition Maximum 
To determine the effects of the exercise training on strength, 1 repetition maximum (1-RM) was 
assessed in all subjects exercising by performing a progressive resistance exercise test until no 
more weight could be lifted. Subjects were given 5 attempts to reach maximum lifts for: chest 
press, latissimus pulldown, leg press, bicep curl, triceps pushdown, and upright rows. Weight 
lifted was considered maximum if proper technique could not be maintained through the lift or 
the subject voluntarily informed the staff that they could not lift the weight.  
 
Metformin protocol 
Subjects were screened for the presence of any underlying contraindications (e.g. respiratory 
disease, heart failure, renal and hepatic disease) by questionnaire. They were advised about 
the particular risk for lactic acidosis from alcohol consumption while on metformin. Subjects 
were also advised about possible side effects of metformin including, diarrhea, flatulence, 
bloating, nausea, metallic tastes and lethargy. Subjects were instructed to take metformin with 
food in order to minimize side effects. Subjects started treatment with placebo or metformin, at 
500 mg/d and increased each week by 500 mg/d until a dose of 2000 mg/d was reached by 
week 4. Subjects were instructed to take metformin or placebo once in the morning and once in 
the evening. Subjects remained on this dose for 8 weeks prior to post-testing. If subjects missed 
a dose, they were instructed to take the next dose at the respective time. They were asked to 
turn in any pills not taken.  
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Exercise Training 
Detailed dietary, anthropometric and habitual activity data were collected before (PRE), 
during (MID) and after (POST) the 12 week aerobic and resistance training protocol. Subjects 
exercised 3 days a week for approximately 60-75 minutes per exercise session (total 4 
hours/wk: ~400 kcal per session). Table 3.1 shows the progression of aerobic exercises. On the 
first and third day of each week, subjects performed aerobic and resistance exercise, while on 
the second day of the week only aerobic exercise was performed. Cycling was the primary 
mode of aerobic exercise and subjects cycled on the first and third day of each week. 
Table 3.1. Progression of aerobic exercise training 
Week 
Duration 
(min/d) 
Intensity % of Maximum  
Heart Rate 
Frequency 
(d/wk) 
1 20 60 2 
2 30 60 2 
3 45 60 3 
4 45 70 3 
5 45 70 3 
6 to 8 45 70 3 
9 45 70 3 
10 to 12 45 70 3 
 
On the second day, subjects were able to choose any aerobic exercise (e.g. walking, rowing, 
stair master, etc) as long as it was at the appropriate intensity/duration. Prior to exercise, all 
participants warmed-up on a cycle ergometer for 5 minutes. During aerobic training, subjects 
exercised at 70% of their pre-training heart rate peak for 45 minutes. Subjects wore a heart rate 
monitor throughout the exercise so heart rate could be maintained at the proper intensity. The 
last training session was approximately 28 hours before the hyperinsulinemic-euglycemic clamp 
and conducted on the cycle ergometer (approximate energy expenditure = 250-350 kcal) at 70-
75% of pre-training HRpeak for 45 minutes.  
Resistance exercise was performed at 70% of the subject’s 1-RM. Weights were 
increased approximately 5% when 2 sets of 12 repetitions could be lifted while maintaining 
  
 
32 
proper form. Table 3.2 shows the progression for resistance exercises. The resistance training 
program targeted all major muscle groups and included: the chest press, latissimus pull down, 
leg press, bicep curl, triceps pushdown, and shoulder raise. In addition all subjects performed 
calf-raises and abdominal crunches to ensure a whole-body resistance work out. 
Table 3.2. Progression of resistance training. 
 
Blood sample collection 
Blood samples were collected in 3 mL syringes, transferred to vacutainers, spun at 3000 rpm 
and aliquoted to cryotubes for storage at -80°C. Samples for analysis of isotopic enrichment, 
glucose and lactate were transferred to vaccutainers containing sodium fluoride (to inhibit 
glycolysis). Samples for analysis of insulin and non-esterified fatty acid s were also collected in 
vaccutainers containing EDTA (an anticoagulant).  
 
Blood sample analysis 
Plasma glucose and lactate concentrations were determined enzymatically using a 
glucose/lactate analyzer (GL5 Analyzer, Analox Instruments, Lunenberg, MA). Insulin was 
measured by radioimmunoassay (Millipore, St. Charles, MO). Non-esterified fatty acid s were 
measured by enzymatic colorimetry (Wako Chemicals, Richmond, VA). Glycerol was measured 
by spectrophotometry (Sigma Aldrich, St. Louis, MO). Glucose isotopic enrichment was 
measured by high performance liquid chromatography and mass spectrometry (HPLC-MS). 
Week 
Sets 
(n) 
Intensity % of 1 
Repetition Maximum Repetitions (n) 
Frequency 
(d/wk) 
1 1 60 8 to 12 1 
2 1 60 8 to 12 1 
3 2 60 8 to 12 2 
4 2 70 8 to 12 2 
5 2 70 8 to 12 2 
6 to 8 2 70 8 to 12 2 
9 2 70 8 to 12 2 
10 to 12 2 70 8 to 12 2 
  
 
33 
Stored samples were removed from the -80°C freezer and thawed to room temperature. In 
separate microcentrifuge tubes, 300 !L of sample was added into 970 !L of chilled acetone, 
vortexed and chilled in the freezer for 10 minutes. After chilling, the samples were centrifuged at 
17,000 g for 2 minutes. The supernatant was collected using a 1 mL plastic syringe, and filtered 
through a 4 mm, 0.45 !m polyethersulfone, syringe filter into an HPLC vial containing a glass 
insert. The samples were capped and placed in the autosampler compartment for immediate 
analysis. A 10 !L sample was injected and separated on a Shodex Asahipak NH2P-50 4E 
Analytical column, (4.6 X 250 mm, Thompson Instrument Co.) installed on a Agilent 1100 series 
HPLC equipped with a mass spectrometer detector (Bruker). Selected ion monitoring was used 
to compare the abundance of the unlabelled fragment with that of the enriched isotope 
(Chemstation Software). After correcting for background enrichment, the abundance of the 
dideuterated isotope (m/z = 205) was expressed as percentage of total glucose species (m/z = 
203+204+205).  
 
Calculations 
Whole-body insulin sensitivity was the primary outcome measure. Insulin sensitivity was defined 
as the rate of blood glucose disposal (Rd) per unit plasma insulin concentration (steady-state 
plasma insulin: SSPI). Whole-body insulin sensitivity can be calculated during the glucose 
clamp in two ways: 
1) The rate of blood glucose disposal was calculated as the average exogenous glucose 
infusion rate (GIR) during the final 30 minutes of the clamp per SSPI (GIR/SSPI). This 
method assumes that endogenous hepatic glucose production is zero or negligible, an 
assumption that may not be valid in individuals with prediabetes. Since we have a direct 
measurement of endogenous glucose production via glucose isotope tracers, we can 
make more accurate measures of total blood glucose uptake. 
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2) Using isotope-derived glucose flux rates per SSPI: Glucose rates of appearance (Ra) 
and rates of disposal (Rd) was calculated using the non-steady state equations (122).  
  a. Glucose Ra (mg/min) = F-V[(C1 + C2) / 2] [IE2-IE1) / (t2-t1)] 
        [IE2 + IE1) / 2] 
 
b. Glucose Rd (mg/min) = Ra – V[(C2-C1) / (t2-t1)].  
 
Where F is the isotope infusion rate, IE1 and IE2 are enrichments of plasma glucose with 
isotope label at time t1 and t2, C1 and C2 are plasma glucose concentrations, V is the 
estimated volume of distribution for glucose (180 mL/kg). 
 To calculate whole-body insulin sensitivity, the Rd was scaled to the steady-state insulin 
concentrations (SSPI). The Rd/SSPI was calculated using measures from the last 30 minutes of 
the clamp at minutes 90, 105, and 120. Non-oxidative glucose disposal (NOGD) is usually 
assumed to be reasonably equivalent to glucose storage of muscle glycogen. Expired breath 
samples were collected using indirect calorimetry and used to calculate carbohydrate oxidation 
(72). NOGD and carbohydrate oxidation was calculated during the last 30 minutes of the clamp:  
3. NOGD (mg/min) = Rd – CHO oxidation rate.  
To calculate hepatic insulin sensitivity, the suppression of basal hepatic glucose 
production (HGObasal) during the last 30 minutes of the clamp was calculated as: 
4. 1 – (HGOinf/HGObasal) * 100.  
HGObasal is the Ra in the basal state and is defined by the average of 75 and 90min. HGO 
during the infusion (HGOinf) is calculated as: (steady state Ra) – (glucose infusion rate).  
 The percent suppression of non-esterified fatty acids (NEFA) during insulin stimulation is 
defined as suppression of circulating NEFA during the last 30 minutes of the clamp compared to 
basal values and was calculated as: 
5.  1 – NEFAclamp/NEFAbasal * 100.  
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Calculations a and b were also used for the submaximal exercise test to determine 
glucose flux (i.e. Ra and Rd). In addition, several calculations were used to determine 
carbohydrate and fat utilization (calculations 4-7).  Although there are limitations with the use of 
indirect calorimetry as an estimate of substrate oxidation, it has been validated by Romijn et al 
(100) using the 13C/12C ratio technique and concluded that indirect calorimetry could be used to 
accurately determine carbohydrate and fat oxidation at exercise intensities up to 85% VO2peak. 
Thus, energy derived from carbohydrate and fat was determined as (72):  
4. RER = VCO2/VO2 
5. Percent of energy from carbohydrate (CHO) and fat  
 % Energy CHO =  [(RER – 0.71)/0.29] x 100 
 % Energy Fat = 100 - [(RER – 0.71)/0.29] x 100 
6. Rate of total CHO and fat oxidation (91).  
 CHO oxidation rate (g/min) = 1.6946 VO2 – 1.7012 VCO2 
  Fat oxidation rate (g/min) = 4.5850 VCO2 – 3.2255 VO2 
7. An estimate of muscle glycogen utilization (EMGU) was determined by: 
EMGU (mg/min) = Total CHO oxidation rate – blood glucose Rd  
Calculation 7 is based on the assumption that 100% of blood glucose taken up from the blood is 
oxidized. This assumption is unlikely to be true, i.e. the percent of Rd oxidized is probably 70-
90% (36). The calculation thus underestimates glycogen use and is best described as minimal 
muscle glycogen utilization.  
 
Statistics  
 The sample size was estimated to provide sufficient statistical power to detect whether 
the combination of exercise and metformin would elicit larger changes compared to either 
treatment alone. The most metabolically and clinically relevant outcome measure on which to 
base the calculation was whole-body insulin sensitivity. Based on the literature, it was 
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anticipated that insulin sensitivity would increase approximately 30% with a standard deviation 
of 20% with exercise training. Metformin alone is expected to raise whole-body insulin sensitivity 
approximately 15% with a standard deviation of 10%. Based on these estimates for metformin 
versus exercise training and metformin (effect size = 0.69), power was set at 80% and an alpha 
level set to 0.05. Power analysis indicated that 8 subjects per group would be needed to detect 
differences between conditions.  
 Baseline characteristics (e.g. body weight, BMI, body fat %, VO2peak, etc) were 
measured with a one-way analysis of variance (ANOVA) for AIM 1 and AIM2. Statistical 
differences in baseline variables (e.g. body weight, VO2peak, insulin sensitivity, etc.) were 
treated as covariates in order to determine the independent effects of the exercise and/or 
metformin intervention. For AIM 1, group means of: whole-body insulin sensitivity, hepatic 
insulin sensitivity, adipose insulin sensitivity, fasting blood glucose, insulin, non-esterified fatty 
acid s, non-oxidative glucose disposal, and substrate oxidation (i.e. carbohydrate and fat 
oxidation) before and during the glucose clamp were compared at baseline and after the 
intervention with a two-way (time by condition) repeated measures analysis of variance 
(ANOVA). Tukey’s post-hoc analysis was used to detect group mean differences when there is 
a significant interaction. Pearson’s product-moment correlation coefficient would be used to 
examine the relationship between VO2peak, adipose insulin sensitivity, body weight, and non-
oxidative glucose metabolism and whole-body insulin sensitivity. Correlation analysis were done 
comparing NEFA and lactate concentrations and hepatic glucose output.  
For AIM 2, group means of: RER, whole-body carbohydrate and fat oxidation, relative 
percentage of energy from carbohydrate and fat use, blood glucose, lactate, insulin, non-
esterified fatty acid s and glycerol were compared at baseline and after the intervention with a 
three-way (group by time by condition) repeated measures ANOVA. Tukey’s post-hoc analysis 
was used to detect group mean differences when there was a significant 3-way interaction. 
Pearson’s product-moment correlation coefficient was used to examine the relationship between 
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VO2peak, NEFA, glycerol, rates of glucose appearance, estimated muscle glycogen utilization 
and fat oxidation during exercise.  
 
Expected Results & Interpretations 
There are several hypothesizes to be tested by AIM 1, and the outcome measures, compared to 
placebo, are outlined in the below table (Table 3.3).  
Table 3.3. Predicted results for outcomes in AIM 1.   
Outcome Metformin Exercise Training 
and Placebo 
Exercise Training 
and Metformin 
Whole-body insulin sensitivity "  " "" 
Hepatic insulin sensitivity " Slight " Slight " 
Adipose insulin sensitivity " " Slight " 
Fasted hepatic glucose output # # ## 
Fasting glucose and insulin # # ## 
Fasting NEFA  Slight # Slight # Slight # 
Fasting Fat oxidation # " $ 
Insulin stimulated CHO oxidation " $ Slight " 
Non-oxidative CHO metabolism " " "" 
Metabolic flexibility $  " Slight " 
Note: All data are compared to placebo results; carbohydrate (CHO), non-esterified free fatty acid 
(NEFA).   
 
In general, exercise training and metformin was expected to produce additive effects on 
metabolic health. However, not all outcomes are expected to have additive effects. The 
predicted results are discussed below 
1. Combining exercise and metformin was expected to have additive effects on whole-body 
insulin sensitivity, compared to either treatment alone. Combining exercise and 
metformin was expected to enhance insulin sensitivity because each therapy has 
different effects on liver, skeletal muscle, and to a lesser extent, adipose tissue insulin 
sensitivity. Exercise primarily enhances skeletal muscle glucose uptake by increasing 
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non-oxidative glucose metabolism. Metformin has secondary effects on skeletal muscle 
glucose uptake and non-oxidative glucose. As a result, it is expected that non-oxidative 
glucose metabolism would be related the enhanced whole-body insulin sensitivity with 
the combined treatment. Moreover, fasting blood glucose and insulin concentrations are 
both expected to be lower, compared to either treatment alone. Lower concentrations of 
glucose and insulin are expected not only because of enhanced insulin sensitivity, but 
also larger reductions in the rate of glucose appearance. 
 
2. Combining exercise training and metformin may be as effective as exercise training or 
metformin alone on hepatic and adipose insulin sensitivity, fasting concentrations of 
NEFA and insulin-stimulated carbohydrate oxidation.  Exercise training enhances 
hepatic and adipose insulin sensitivity in some studies; however, these effects are often 
negligible or of smaller magnitude when compared to skeletal muscle insulin sensitivity. 
Metformin primarily effects hepatic insulin sensitivity, but has less of an effect on adipose 
insulin sensitivity. Improvements in hepatic and adipose insulin sensitivity are often 
related to changes in NEFA concentrations. The evidence is mixed as to the effects of 
each treatment on lowering NEFA concentrations. Thus, combining exercise with 
metformin may produce similar effects, compared to each treatment alone, on hepatic 
and adipose tissue insulin sensitivity.  
 
3. Combining exercise training and metformin may produce opposing effects on fasting fat 
oxidation and metabolic flexibility, compared to exercise training with placebo. Exercise 
training typically elevates fasting fat oxidation, while metformin lowers fat oxidation. 
Because metformin reduces fat oxidation and produces a compensatory rise in fasting 
carbohydrate oxidation, elevated carbohydrate use was expected to decrease metabolic 
flexibility. During insulin stimulation, exercise training generally does not alter 
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carbohydrate oxidation, but rather increases non-oxidative glucose disposal. Metformin 
has mixed results on increasing non-oxidative glucose disposal and raising insulin-
stimulated carbohydrate oxidation. As a result, combining exercise and metformin may 
either decrease metabolic flexibility or not effect it at all.  
There are several hypothesis to be tested by AIM 2, and the outcome measures are outlined in 
the below table (Table 3.4).  
Table 3.4. Predicted results for outcomes in AIM 2.  
Outcome Exercise training 
and Placebo 
Exercise training  
and Metformin 
Respiratory exchange ratio (RER) # ## 
Percentage of energy from fat " "" 
Glucose $ Slight # 
Lactate # Slight # 
Insulin # ## 
NEFA " "" 
Glycerol " "" 
Estimated Muscle Glycogen Use # ## 
Rate of Glucose Appearance # ## 
Rate of Glucose Disposal #  ## 
  Note: Exercise training with or without metformin results are compared to baseline.  
 
 
In general, exercise training and metformin was expected to produce additive effects on fat 
oxidation during exercise. However, not all outcomes were expected to have additive effects. 
The predicted results are discussed below: 
 
1. Combining exercise training with metformin, compared to exercise training with placebo, 
was expected to have additive effects on enhancing whole-body fat oxidation. Training 
enhances fat oxidation during exercise by, in part, reducing the rate of glucose 
appearance and increasing skeletal muscle oxidative capacity. Adding metformin to 
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training is expected to enhance exercise fat oxidation because metformin constrains 
hepatic glucose output and enhances oxidative enzymes. If metformin constrains hepatic 
glucose output (i.e. decrease rate of glucose appearance), then lower blood glucose 
concentrations would be expected. Lower rates of glucose appearance would also be 
expected to decrease glucose disposal thereby favoring elevated rates of fat oxidation. 
Increases in oxidative capacity would also favor elevated fat oxidation, which would 
reduce skeletal muscle glycogen use. Decreased glucose flux would also lower insulin 
concentrations, which would favor increased concentrations of NEFA and glycerol for 
elevated fat oxidation.  
 
2. Combining exercise training with metformin, compared to exercise training with placebo, 
might increase glucose flux and carbohydrate oxidation during exercise. Elevated 
carbohydrate oxidation would be contrary to the original hypothesis, but it is a plausible 
alternative outcome based on the effect of metformin to stimulate glucose uptake and 
warrants recognition. Training generally lowers the rate of glucose appearance, the rate 
of glucose disposal and estimated muscle glycogen use during exercise. Metformin 
however has the potential to stimulate skeletal muscle glucose uptake during exercise 
and raise muscle glycogen concentrations in the rested state. Exercise increases 
skeletal muscle glucose uptake, compared to rest, and adding metformin may 
accentuate this effect during exercise training. Because metformin increases resting 
concentrations of muscle glycogen, and muscle glycogen concentrations are positively 
related to the rate of glycogen use during exercise, it was also possible that metformin 
may cause greater skeletal muscle glycogen utilization during exercise. If metformin 
enhances glucose flux, it was possible that the combined treatment would not enhance 
fat oxidation during exercise and conceivably favor carbohydrate oxidation.  
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Confounding factors 
1. Reductions in energy intake and/or changes in macronutrient composition (e.g. high 
carbohydrate to low carbohydrate diet) may lead to weight loss. Changes in these 
dietary habits may lead to weight loss and are thus potential confounding factors. By 
design, dietary changes were not rigidly controlled during the course of the study and 
weight loss or gain was allowed to fluctuate. Metformin tends to cause minor weight loss 
and preventing this by having subjects maintain energy balance throughout the study 
would reduce the clinical utility of the findings (89). Instead, weight will be recorded 
biweekly throughout the 12 week protocol. Statistically, weight loss was used as a co-
variate to account for the potential confounding effects of weight loss on insulin 
sensitivity.  
2. Daily habitual physical activity may be a potential confounding factor. By design, habitual 
physical activity was not rigidly controlled during the course of the study and activity 
levels were allowed to fluctuate. The effects of exercise training on habitual physical 
activity patterns is mixed. Some studies show that exercise training causes individuals to 
decrease habitual activity levels, whereas others show it has no effect (50). Individuals 
were encouraged to maintain their normal activity levels at the beginning of the study. 
Habitual physical activity was recorded by use of a pedometer at the beginning, middle 
and end of the study to document if any changes in habitual physical activity occur. 
Statistically, habitual activity was used as a co-variate to account for the potential 
confounding effects of weight loss on insulin sensitivity.  
3. Prediabetes pathology may be a potential confounding factor. By design, individuals with 
impaired glucose tolerance (IGT) were enrolled into the study in the presence or 
absence of impaired fasting glucose tolerance (IFG). As a result, some individuals may 
be enrolled with IGT only or IFG+IGT. Individuals with IGT are primarily characterized as 
having peripheral insulin resistance. Individuals with IFG+IGT are characterized by 
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hepatic and peripheral insulin resistance. Given that exercise targets skeletal muscle, 
while metformin targets the liver, it is possible that the combined treatment may affect 
prediabetes pathologies differently.  
4. Subjects were not blinded to exercise training and this may be a potential confounding 
factor. By design, exercise training was not blinded (i.e. placebo and metformin 
conditions were not provided activity protocols) because the primary objective was to 
determine if exercise training with metformin was better than either treatment alone. If 
metformin was provided with light activity protocols, then it would not address the overall 
question in this study. Many individuals with prediabetes may take metformin without 
exercise/activity. Thus, having metformin and placebo perform light activity protocols 
could reduce the clinical utility of the findings as.  
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Abstract  
Physical activity or metformin contribute to slowing the progression from prediabetes to type 2 
diabetes. Combining the two treatments may have more potent effects on insulin sensitivity 
because each targets a different tissue. Purpose: To evaluate the effects of exercise training 
plus metformin on insulin sensitivity in men and women with prediabetes, compared to each 
treatment alone. Methods: Thirty-two men and women with prediabetes were assigned to: 
placebo (P), metformin (M), exercise training with placebo (EP), or exercise training with 
metformin (EM). P and 2000mg/d of M were distributed in a double-blind fashion and half of the 
subjects underwent exercise training. Insulin sensitivity was measured by the euglycemic 
hyperinsulinemic (80 mU/m2/min) clamp enriched with [6,6-2H] glucose. Results: All 
interventions enhanced insulin sensitivity (p < 0.05) independent of weight loss. EP enhanced 
insulin sensitivity 25-30% more than either EM or M. Higher insulin sensitivity was strongly 
correlated with increased glucose storage (r = 0.85; p < 0.01). Conclusions: Twelve weeks of 
exercise training or metformin enhances insulin sensitivity in individuals with prediabetes, but 
there was no additive effect of combining treatments. Higher insulin sensitivity was mainly 
explainable by increased glucose storage. Subtle differences among condition means suggest 
that adding metformin blunts the full effect of exercise training.  
KEY WORDS: Impaired glucose tolerance, type 2 diabetes, insulin resistance, exercise 
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Introduction 
 Approximately 79 million individuals in the U.S. have prediabetes and are at high risk to 
develop type 2 diabetes (1, 17). Exercise lowers diabetes risk by, in large part, enhancing 
skeletal muscle insulin sensitivity (9, 11, 13, 14, 16). Metformin decreases diabetes risk through 
alternative mechanisms; it mainly reduces hepatic glucose output (7, 8, 15).  
Because exercise or metformin primarily targets different tissues, it is possible that 
combing the two treatments would have more potent effects on insulin sensitivity (20). There are 
few studies testing the efficacy of combining lifestyle modification with metformin (4, 6, 18, 22). 
Despite some showing that the combined treatment promotes 2-5kg more weight loss than the 
lifestyle modification alone (4, 18), there is little (4, 6) or no further (26) improvement in insulin 
sensitivity. However, the direct effects of supervised exercise training plus metformin on insulin 
sensitivity (via euglycemic clamp) remains unclear because exercise was previously based on 
self-reports (4, 6, 18, 22) and insulin resistance was estimated from fasting and/or post-
carbohydrate load measures (4, 6, 22). Therefore, the purpose of this study was to determine 
the effect of combining exercise training with metformin on insulin sensitivity in individuals with 
prediabetes, compared to either treatment alone.  
 
 
Methods 
Overview: In a double-blind, placebo-controlled study design, 32 men and women with impaired 
glucose tolerance (IGT) were enrolled in this study. Prior to testing, individuals were assigned to 
either: placebo (P), metformin (M), exercise training with placebo (EP) or exercise training with 
metformin (EM) for the determination of these treatments effects on insulin sensitivity. 
Subjects: Subjects were non-smoking, weight stable (<5% weight change over last 3mo), free of 
cardiovascular disease or diabetes, and did not take dietary supplements (e.g. chromium, 
niacin) or medications (sulfonylureas, acarbose, etc) that are likely to affect insulin sensitivity. 
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Subjects were excluded if they had any contraindications to metformin (e.g. respiratory disease, 
heart failure, renal and hepatic disease). Subject characteristics are outlined in Table 4.1. Prior 
to testing, all subjects were verbally briefed about the study and signed informed consent 
documents approved by the Institutional Review Board at the University of Massachusetts 
Amherst.  
OGTT Screening: An oral glucose tolerance test (OGTT) was used to determine if subjects had 
prediabetes. After a minimum 5-hour fast, blood samples were taken from a forearm vein. 
Subjects consumed 75 grams of glucose and blood samples were collected 2 hours later. All 
subjects had impaired glucose tolerance (IGT; 2-hour glucose concentrations between 7.8-
11.1mmol/L or 140-199mg/dl). Subjects with IGT who had fasting glucose concentrations 
between 5.5-6.9mmol/L (100-125mg/dl) were also included.  
Metformin or Placebo protocol: Pills were administered to the subjects and they were instructed 
to take metformin or placebo with food in order to minimize potential side effects. Subjects 
started treatment with 500 mg/d of metformin. The dose was increased 500 mg/d each week 
until a clinical dose of 2000 mg/d was reached by week 4. Subjects remained at this dose for 
the last 8 weeks of the 12 week protocol. 
Preliminary testing: Peak oxygen consumption (VO2peak) was determined using a continuous 
progressive exercise test on a cycle ergometer (SensorMedics 800, Yorba Linda, CA). VO2peak 
was defined as the highest value obtained during the test (19). One repetition max (1-RM) tests 
were conducted for the: chest press, latissimus pull down, leg press, bicep curl, triceps 
pushdown, and upright rows. 1-RM was defined as the highest weight lifted with proper 
technique through the full range of motion. Dual-x-ray absorptiometry (DEXA; Lunar Prodigy, 
Madison, WI) was used for determination of body fat, central fat (i.e. from the last floating rib to 
the top of the iliac crest divided by total body fat mass) and fat-free mass (FFM) (5).  
Euglycemic hyperinsulinemic clamp: Subjects were provided food (55% carbohydrate, 30% fat, 
and 15% protein) 24 hours prior to pre- and post-testing. After an overnight fast, subjects 
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reported to the laboratory and indwelling catheters were placed in superficial veins of a forearm 
for the collection of baseline blood samples. A priming bolus of 200 mg 6,6-2H glucose was 
given followed by a 90 minute infusion of 6,6-2H glucose at a rate of 3.0 mg/min by peristaltic 
infusion pump (Harvard Apparatus Pump 22, Holliston, MA). Blood samples were collected at 
75 and 90 minutes. Expired breath samples were collected between 80-90 minutes, with the last 
2 minutes used to estimate substrate oxidation. A primed (250 mU/m2·min) constant infusion (80 
mU/m2·min) of insulin diluted in saline containing 4% (v/v) the subject’s own serum was started. 
After 20 minutes of insulin infusion, a 20% glucose solution containing 2% 6,6-2H was infused at 
a variable rate to maintain plasma glucose at 5mM for the remaining 100 minutes. Blood 
samples were collected for glucose analysis every 5 minutes, and for the measurement of 
insulin, isotopic enrichment of glucose, and non-esterified fatty acids (NEFA) at minutes 75, 90, 
105, and 120. Expired breath samples (VO2 and VCO2L/min) were collected between minutes 
110-120 of the clamp for determination of insulin-stimulated substrate oxidation. Twenty-eight to 
thirty hours before post-intervention measurements, subjects assigned to the training conditions 
performed a standardized exercise bout. Exercise was conducted on a cycle ergometer at 75% 
of pre-training HRpeak for 45 minutes. Based on heart rate, exercise intensity was not different 
between EP and EM (EP = 125.4 ± 4.7 vs. EM = 122.2 ± 4.6; p = 0.64).  
Exercise Training: Exercise was supervised 3-days a week for 60-75 minutes per session (total 
3.5 hours/wk: ~400 kcal per session). Subjects performed aerobic and resistance exercise on 
the first and third day of each week. To minimize muscle soreness, only aerobic training was 
performed on the second day. Participants warmed-up on a cycle ergometer for 5 minutes, 
followed by cycling at 70% of their pre-training HRpeak for 45 minutes. Resistance exercise was 
performed at 70% of the subject’s 1-RM. Weight was increased approximately 5% when 2 sets 
of 12 repetitions could be lifted with proper form. Resistance training targeted all major muscle 
conditions and included: the chest press, latissimus pull down, leg press, bicep curl, triceps 
pushdown, shoulder raise, calf raises, and abdominal crunches. 
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Blood sample collection: Blood samples were collected in 3 mL syringes, transferred to 
vaccutainers, spun at 3000 rpm, and plasma was aliquoted to cryotubes for storage at -80°C. 
Samples for the analysis of glucose isotopic enrichment, glucose and lactate were transferred to 
vacutainers containing sodium fluoride to inhibit glycolysis. Plasma samples for the analysis of 
insulin and NEFA were collected in vacutainers containing the anticoagulant EDTA.  
Analysis of metabolites and hormone: Plasma glucose and lactate concentrations were 
determined enzymatically using a glucose/lactate analyzer (GL5 Analyzer, Analox Instruments, 
Lunenberg, MA). Plasma insulin concentrations were measured by radioimmunoassay 
(Millipore, St. Charles, MO). Plasma NEFA concentrations were measured by enzymatic 
colorimetry (Wako Chemicals, Richmond, VA). Glucose isotopic enrichment was measured by 
high performance liquid chromatography and mass spectrometry as previously described (25).  
Calculations: Standard equations were used to determine glucose rates of appearance (Ra) and 
disappearance (Rd)  (27). Insulin sensitivity was defined as the Rd per unit plasma insulin (I) 
during the final 30 minutes of the clamp. Basal hepatic glucose production, i.e. Ra, was 
averaged during minutes 75 and 90 of the resting isotope infusion. Endogenous hepatic glucose 
production (HGP) during the clamp was defined as the difference between HGPclamp and the 
exogenous glucose infusion rate. The suppression of HGP was defined as [1- 
(HGPclamp/HGPfast)*100%]) and it was used to provide an estimate of hepatic insulin sensitivity. 
Insulin stimulated suppression of NEFA was defined as: [1-(NEFAclamp/NEFAfast)*100%]. 
Carbohydrate oxidation was determined by indirect calorimetry using standard equations (21). 
Non-oxidative glucose disposal (NOGD) was calculated during the final 30 minutes of the clamp 
(NOGD (mg/min) = Rd – rate of carbohydrate oxidation). 
Statistical Analysis:  Condition means were compared using the R statistical software package 
(version 2.4.0, The R foundation, Vienna, Austria, 2006). Mean differences among conditions in 
baseline characteristics were assessed with a one-way analysis of variance (ANOVA). There 
was no statistical difference in any baseline outcome variable. Outcomes were assessed using 
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a two-way (condition by test) repeated measures ANOVA. Baseline insulin sensitivity, weight 
loss, and changes in VO2peak were included as covariates to independently test the effects of 
each treatment. Using the changes in cardiorespiratory fitness or weight loss as covariates did 
not did not alter the treatment effects on insulin sensitivity. When there was a significant 
interaction, Tukey’s post-hoc analysis was used to determine differences between conditions 
and paired t-tests were used to compare within condition means. Pearson’s correlation 
coefficient was used to examine relationships. Significant differences were accepted as % " 
0.05.  
 
Results 
Anthropometrics and Cardio-respiratory fitness. Metformin (M) and exercise training plus 
metformin (EM) reduced body weight by approximately 4kg compared to placebo (P) (p < 0.05) 
and exercise training plus placebo (EP) (p = 0.07; Table 4.2). Although both exercise conditions 
reduced body fat (p < 0.01) and central fat (p = 0.056), only EP increased fat free mass 
compared to P (p < 0.02; Table 4.2). Both exercise conditions increased VO2peak (p < 0.05; 
Table 4.2).  
Fasting Hormone, Metabolites and Substrate use. Although M, EP, and EM lowered plasma 
insulin concentrations 13-25% (effect of time: p < 0.05), only the exercise conditions lowered c-
peptide concentrations compared to baseline (p < 0.05; Table 4.3). Plasma glucose 
concentrations and fasting carbohydrate oxidation did not change after any treatment (Table 
4.3).  
Peripheral Insulin Sensitivity. M, EP and EM enhanced insulin sensitivity (p < 0.05; Figure 4.1) 
relative to baseline. EP enhanced insulin sensitivity 25-30% more than EM and M. All 3 
treatments increased non-oxidative glucose disposal (NOGD; p < 0.05; Figure 4.2) relative to 
baseline. EP increased NOGD 60-70% more than EM and M. There was no effect of treatment 
on insulin stimulated carbohydrate oxidation.  
  
 
65 
Hepatic glucose output and insulin sensitivity. Fasting hepatic glucose output (HGPfast) did not 
change after any treatment (p = 0.2; Table 4.3). Hepatic insulin sensitivity, defined as 
suppression of HGPfast during the clamp, was also unaffected (Table 4.5).  
Non-esterified Fatty Acids (NEFA). EP decreased fasting NEFA concentrations, but EM 
increased NEFA concentrations (p < 0.02; Table 4.3). Exercise and/or metformin had no effect 
on insulin stimulated suppression of NEFA (Table 4.3).  
Correlations: Increased maximal oxygen consumption (r = 0.57; p < 0.05), NOGD (r = 0.85; p < 
0.01) and weight loss (r = -0.42, p < 0.05) were directly correlated with enhanced insulin 
sensitivity. Higher fasting NEFA concentrations were correlated with smaller improvements in 
insulin sensitivity (r = -0.42; p < 0.05). (see S.A.1, S.A.2, S.A.3, and S.A.4). 
 
Discussion 
  Contrary to our original hypothesis, adding metformin partially blunted the effects of 
exercise training on insulin sensitivity in this group of men and women with prediabetes.  
Combining lifestyle modification with metformin has been shown to have both additive 
and non-additive effects. Ateback et al (4) reported that lifestyle modification plus metformin 
reduced body mass, fasting hyperinsulinemia and 2-hour plasma insulin concentrations in 
obese adolescents compared to lifestyle modification alone. Love-Osbourne et al (18) 
demonstrated that lifestyle modification plus metformin caused more weight loss than lifestyle 
modification alone, and weight loss was correlated to lower 2-hour blood glucose 
concentrations.  In other studies, combining metformin with lifestyle modification caused little 
additional health benefits (6, 22, 25). The Indian Diabetes Prevention Program (IDPP) showed 
that low dose metformin (e.g. 500mg/d), lifestyle modification, and the combined treatment 
equally improved insulin sensitivity and reduced the progression from prediabetes to type 2 
diabetes (26).  Our findings are consistent with the previous 3 studies (6, 22, 25) indicating that 
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the combination of exercise and metformin does not enhance insulin sensitivity more than either 
treatment alone.  
Metformin did not add to the effects of training on insulin sensitivity and there are several 
potential reasons. Metformin may have affected the peripheral adaptations to training that 
contributed to enhanced insulin sensitivity. Sharoff et al (25) demonstrated that short-term 
metformin treatment blunted AMPK activation following a single bout of exercise.  If metformin 
attenuated AMPK throughout training in our study, then GLUT4, hexokinase, and glycogen 
synthesis adaptations may have been minimized (12). Without direct measurements of cellular 
mediators or muscle glycogen concentrations, it is not possible to know the role of these factors 
on insulin sensitivity. However, cardiorespiratory fitness and strength were not statistically 
different between exercise conditions, indicating that fitness differences are unlikely to explain 
the current findings.  
Weight loss enhances insulin sensitivity (23, 24) Although EM and M promoted 
approximately 4kg more weight loss than EP, training alone enhanced insulin sensitivity the 
most. Both exercise conditions enhanced insulin sensitivity more than metformin alone and this 
was paralleled by similar reductions in body fat, which is strongly related to insulin sensitivity 
(10). Thus, similar reductions in body fat may explain why training, with or without metformin, 
enhanced insulin sensitivity more than metformin alone. However, similar reductions in body fat 
between exercise conditions, suggest other mechanisms may explain how metformin blunts the 
full effects of training.  
Elevated non-esterified fatty acid (NEFA) concentrations impair insulin sensitivity. We 
previously showed that combining metformin with a single bout of exercise raised NEFA 
concentrations during the clamp and was associated with the blunted improvement in insulin 
sensitivity (25). In this study, exercise training plus metformin raised fasting NEFA 
concentrations, compared to training alone. Although this was moderately associated with 
attenuated insulin sensitivity, there were no differences in NEFA concentrations during the 
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clamp (data not shown). Thus, elevated NEFA concentrations are unlikely to be the primary 
mechanism explaining the attenuated improvements in insulin sensitivity when combining 
metformin with training. More sophisticated measures using lipid isotopes and/or muscle 
biopsies would be needed to substantiate the role of fat metabolism on insulin sensitivity after 
combining metformin and training.  
We originally hypothesized that combining exercise with metformin could have additive 
effects on insulin sensitivity because exercise influences skeletal muscle, while metformin 
affects the liver. In this study, M or EM had no effect on fasting hepatic glucose production 
(HGP) or hepatic insulin sensitivity. The insulin concentrations during the clamp did not fully 
suppress HGP (~85%), suggesting that our subjects had hepatic insulin resistance. It’s possible 
that hepatic insulin sensitivity varied within our subjects and limited our ability to detect 
statistical differences. Baseline hepatic insulin sensitivity, defined as the suppression of 
HGPfasting or the product of HGPfasting and fasting insulin concentrations ((3); data not shown), did 
not correlate with enhanced peripheral insulin sensitivity. Thus, variations in hepatic insulin 
resistance are unlikely to explain why metformin was ineffective at lowering HGP, or why adding 
metformin to training blunted improvements in insulin sensitivity.  
Although not quite statically significant, the 25-30% difference in insulin sensitivity 
between training and M or EM (see Figure 4.3) may be physiologically meaningful. First, our 
sample size may have been too small to detect a difference of that magnitude.  A post-hoc 
power analysis indicated that 16 individuals per condition would have been needed for 80% 
power to detect a statistical difference at an alpha of 0.05. Second, prediabetes pathology may 
have increased inter-individual variability between conditions (2). Prediabetes is defined as 
impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both. We included 
individuals with IGT or IFG + IGT because they are insulin resistant (2). The response to all 3 
interventions was accentuated in the individuals with fasting hyperglycemia, i.e. those with IGT 
+ IFG. (see Figure 4.3). Based on these results, it would be fruitful to study the effects of 
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exercise and/or metformin on subgroups of prediabetes to better understand the effects of 
fasting hyperglycemia (see S.A.4 and S.A.5).   
Summary: Exercise training, independent weight loss, effectively enhanced insulin sensitivity in 
individuals with prediabetes. Adding metformin to training did not accentuate improvements in 
insulin sensitivity, and it may have blunted the full effects of training. We caution that our results 
not be interpreted to indicate that combining exercise with metformin is not a useful therapeutic 
strategy to improve metabolic health. Further work is required to identify the effects of 
combining metformin with training on cardiovascular risk factors as well as insulin sensitivity in 
different subsets of prediabetes.  
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Figure Captions 
  
Figure 4.1. Insulin Sensitivity across all conditions. *Compared to baseline (p < 0.05). 
^Compared to placebo (p < 0.05). Values are mean ± standard error of the mean. 
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Figure 4.2. Non-oxidative glucose disposal across all conditions. †Significant effect of 
test (p < 0.05). *Compared to baseline (p < 0.05). ^Compared to placebo (p < 0.05). Values 
are mean ± standard error of the mean. 
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Figure 4.3. Prediabetes classification and response to each condition. P consisted of 4 
IFG+IGT and 4 IGT. M consisted of 3 IFG+IGT and 5 IGT. EP and EM consisted of 5 
IFG+IGT and 3 IGT. Values are reported as mean change.  
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Table Captions 
 
Table 4.1. Subject Characteristics. No significant differences were observed between 
conditions. Values are mean ± standard deviation. 
 
 P M EP EM 
Age (yr) 49.8 ± 10.9 45.0 ± 7.5 45.4 ± 8.0 49.1 ± 6.6 
Height (cm) 168.1 ± 8.5 165.9 ± 7.1 173 ± 4.3 168.1 ± 8.5 
BMI (kg/m2)  34.0 ± 6.3 33.9 ± 5.2 33.5 ± 4.1 31.2 ± 5.3 
Fasting Glucose (mM) 5.8 ± 0.6 5.6 ± 0.6 5.4 ± 0.4 5.5 ± 0.8 
2-hour Glucose (mM) 9.4 ± 1.3 9.3 ± 1.5 10.2 ± 1.0 9.5 ± 1.7 
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Table 4.2. Body weight, cardiorespiratory fitness and strength. †Significant effect of test 
(p < 0.05). *Compared to baseline (p < 0.05). ^Compared to placebo (p < 0.05). #Compared 
to metformin (p < 0.05). Strength refers to the sum of chest press, leg press and 
latissimus pulldown. Values are mean ± standard error of the mean. 
  P M EP EM 
Body weight (kg) Pre  93.5 ± 6.0  101.5 ± 5.8 95.5 ± 5.1 94.1 ± 6.5 
 Post  93.5 ± 5.7  97.4 ± 5.7*^ 95.0 ± 5.4   89.9 ± 5.6*^ 
Body Fat % † Pre 45.9 ± 3.1 41.4 ± 2.5 42.8 ± 2.5     40.6 ± 2.7 
 Post 45.2 ± 2.8 41.4 ± 2.7 40.6 ± 2.3     38.7 ± 2.6 
Central fat %  Pre 50.1 ± 0.8 43.4 ± 2.5  45.9 ± 2.3 46.1 ± 2.6 
 Post 49.6 ± 0.8 43.3 ± 2.3  44.4 ± 1.9  44.7 ± 2.5 
Fat-free mass (kg) Pre 47.7 ± 2.8 56.6 ± 2.3  52.9 ± 3.7 52.9 ± 3.8 
 Post 48.8 ± 3.1   54.9 ± 2.5^    54.9 ± 2.5# 52.4 ± 3.9 
VO2 peak (ml/kg/min) Pre 21.5 ± 2.3 25.0 ± 2.9  25.5 ± 2.5 27.3 ± 1.8 
 Post 21.2 ± 2.2 25.7 ± 2.6       29.9 ± 2.5*^#  30.0 ± 2.3* 
Strength (kg) † Pre - -      253.7 ± 17.3 223.9 ± 13.9 
 Post - -   286.9 ± 21.2  294.8 ± 15.1 
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Table 4.3. Fasting hormone, metabolite and substrate use values. Non-esterified free fatty 
acids (NEFA). # Significant compared to exercise training plus metformin (p < 0.05). 
†Significant effect to test (p < 0.05). Values are mean ± standard error of the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fasting  P M EP EM 
Pre 5.3 ± 0.2 5.2 ± 0.3   5.3 ± 0.2 5.8 ± 0.2  
Glucose 
(mM) Post 5.3 ± 0.1 5.1 ± 0.2   5.3 ± 0.2 5.4 ± 0.1 
Pre 0.74 ± 0.2 0.76 ± 0.2 0.67 ± 0.1 0.71 ± 0.1  
Lactate 
(mM) Post 0.88 ± 0.4 1.46 ± 0.3 0.70 ± 0.1 0.73 ± 0.1 
Pre 120.8 ± 24.9 144.4 ± 24.2   83.1 ± 11.2 92.9 ± 21.4  
Insulin (pM)† 
Post 129.5 ± 29.4  100.8 ± 18.9 73.1 ± 9.0  75.8 ± 14.3 
Pre 0.87 ± 0.15  1.34 ± 0.16 1.00 ± 0.13 0.95 ± 0.08  
C-peptide 
(nM) Post 0.97 ± 0.14   1.15 ± 0.15   0.86 ± 0.13*   0.69 ± 0.06*^ 
Pre 0.65 ± 0.05 0.56 ± 0.03 0.64 ± 0.04 0.57 ± 0.04  
NEFA  
(mM) Post 0.63 ± 0.03 0.53 ± 0.05 0.54 ± 0.05# 0.61 ± 0.06 
Pre 2.16 ± 0.28 1.36 ± 0.20 1.97 ± 0.25 1.92 ± 0.74  
CHO oxidation 
(mg/kg-FFM/min) Post 2.06 ± 0.22 1.82 ± 0.28 2.06 ± 0.16 1.16 ± 0.49 
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Table 4.4. Clamp hormone and metabolites. Non-esterified fatty acids (NEFA) 
suppression (Supp). †Significant effect of test (p < 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clamp  P M EP EM 
Pre 1462.8 ± 26.7 1570.0 ± 32.2 1444.4 ± 38.3 1319.3 ± 33.8  
Insulin† 
(pM) Post 1450.9 ± 21.9  1255.8 ± 42.3  1265.7 ± 18.7 1151.7 ± 22.6 
Pre 5.0 ± 0.0 5.0 ± 0.0 5.1 ± 0.0 5.0 ± 0.1  
Glucose 
(mM) Post 4.9 ± 0.0 4.9 ± 0.1 5.0 ± 0.0 5.0 ± 0.1 
Pre 0.78 ± 0.1 0.52 ± 0.1 0.53 ± 0.1 0.77 ± 0.1  
Lactate 
(mM) Post 0.57 ± 0.1 0.72 ± 0.2 0.80 ± 0.2 0.78 ± 0.1 
Pre 56.4 ± 4.4 47.6 ± 3.6 51.8 ± 2.5  46.9 ± 2.3     NEFA 
Supp  
(%) Post 59.1 ± 3.7  40.7 ± 6.8  42.5 ± 2.5 51.2 ± 4.9 
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Table 4.5. Total Glucose infusion rate (GIRT). Rate of glucose disposal (Rd) and 
appearance (Ra). Residual Ra refers to total glucose infusion rate minus Ra during the 
clamp. Hepatic insulin sensitivity (HIS). Values are mean ± standard error of the mean.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  P M EP EM 
Pre 5.92 ± 0.32 6.13 ± 1.14 5.30 ± 0.21 5.58 ± 0.58  
Fasting Ra  
(mg/kg-FFM/min) Post 7.89 ± 1.58 
 
6.30 ± 0.75 6.01 ± 0.63 5.75 ± 0.73 
Pre 13.0 ± 2.4  7.9 ± 1.5 9.2 ± 1.1 11.1 ± 2.3  
Clamp Rd  
(mg/kg-FFM/min) Post 10.9 ± 1.3  9.0 ± 1.9 14.1 ± 1.8 11.4 ± 1.5 
Pre 11.89 ± 2.05 9.37 ± 1.40 9.15 ± 1.23 10.38 ± 1.72  
Clamp GIR 
(mg/kg-FFM/min) Post 10.09 ± 1.51 9.89 ± 1.25  12.92 ± 1.84 12.21 ± 0.96 
Pre 3.75 ± 0.63 3.07 ± 0.60 3.73 ± 1.09 3.78 ± 0.83  
CHO oxidation 
(mg/kg-FFM/min) Post 4.00 ± 0.63 2.87 ± 0.35 3.13 ± 0.88 3.89 ± 0.52 
Pre 12.97 ± 2.44 7.94 ± 1.52 9.20 ± 1.05 11.08 ± 2.29  
Clamp Ra 
(mg/kg-FFM/min)  Post 10.89 ± 1.26 9.01 ± 1.88  14.12 ± 1.76 11.42 ± 1.46 
Pre 1.41 ± 0.58 0.36 ± 0.23 0.54 ± 0.22 1.84 ± 1.35  
Clamp Residual Ra 
(mg/kg-FFM/min)  Post 1.62 ± 0.94 0.59 ± 0.38 1.61 ± 0.61 0.85 ± 0.56 
Pre 77.8 ± 9.6 91.6 ± 4.9 90.7 ± 3.6 74.1 ± 12.6  
HIS  
(%) Post 86.3 ± 5.2 89.5 ± 6.1 74.1 ± 9.4 89.2 ± 7.2 
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Abstract 
Exercise and metformin may prevent or delay type 2 diabetes by, in part, raising the capacity for 
fat oxidation. Whether the addition of metformin has additive effects on fat oxidation during and 
after exercise is unknown. Therefore, the purpose of this study was to evaluate the effect of 
metformin on substrate oxidation during and after exercise. Using a double-blind, counter-
balanced cross-over design, substrate oxidation was assessed by indirect calorimetry in 15 
individuals taking metformin (2000 mg/d) and placebo for 8-10d. Measurements were made 
during cycle exercise at 5 submaximal cycle workloads, starting at 30% work peak (Wpeak) and 
increasing by 10% every 8min to 70% Wpeak. Substrate oxidation was also measured for 50’ 
post-exercise. Differences between conditions were assessed using analysis of variance with 
repeated measures and values reported here are means ± SE. During exercise, fat oxidation 
(0.19 ± 0.03 vs. 0.15 ± 0.01g/min); p < 0.01) and percentage of energy from fat (32 ± 3 vs. 28 ± 
3%; p < 0.01) were higher with metformin compared to placebo. Post-exercise, metformin 
slightly lowered fat oxidation (0.12 ± 0.02 to 0.10 ± 0.02g/min; p < 0.01) compared to placebo. 
There was an inverse relationship between post-exercise fat oxidation and the rate of fat 
oxidation during exercise (r = -0.68; p < 0.05). In healthy individuals, metformin has opposing 
actions on fat oxidation during and after exercise. Whether the same effects are evident in 
insulin resistant individuals remains to be determined.   
KEY WORDS: Prediabetes, type 2 diabetes, exercise metabolism, biguanide 
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Introduction 
 Exercise or metformin, a common anti-diabetes drug, oppose insulin resistance and the 
development of type 2 diabetes (Knowler et al., 2002; Orchard et al., 2005). One of the 
mechanisms underlying their efficacy may be increasing the capacity for fat oxidation. There are 
strong data showing inverse relationships between resting fat oxidation and insulin resistance 
(Goodpaster, Katsiaras, & Kelley, 2003; Horowitz, 2003; Kelley & Mandarino, 2000; Winder, 
2000).  
  During low to moderate intensity exercise, the absolute rate of fat oxidation is elevated 
from resting values (Achten, Gleeson, & Jeukendrup, 2002; Braun, Sharoff, Chipkin, & 
Beaudoin, 2004; Brooks & Mercier, 1994; Perez-Martin et al., 2001; Romijn et al., 1993; 
Dumortier et al., 2003). Prior exercise also raises resting fat oxidation for up to 24 hours 
(Broeder et al., 1991; Henderson et al., 2007; Horton, Pagliassotti, Hobbs, & Hill, 1998; Kuo, 
Fattor, Henderson, & Brooks, 2005; Phelain, Reinke, Harris, & Melby, 1997). Fat oxidation 
during and after exercise is elevated by increasing triacylglycerol mobilization, fatty acid uptake 
into tissues, and lipid oxidation (Jeukendrup, 2002). 
Metformin is a biguanide compound used to oppose hyperglycemia in people with 
prediabetes or diabetes (American Diabetes Association, 2007; Nathan et al., 2007). Metformin 
decreases resting hepatic glucose production (Zhou et al., 2001) and may elevate whole-body 
and hepatic fat oxidation (Long & Zierath, 2006; Zhou et al., 2001). Because the mechanism for 
altering fat mobilization, tissue uptake and utilization may not be identical for exercise and 
metformin (Long & Zierath, 2006), adding metformin to exercise could accentuate fat oxidation 
and potentially increase the effects of exercise to oppose insulin resistance. To date, how 
adding metformin to exercise impacts fat oxidation has not been reported.  
Therefore, the purpose of the present study was to assess the effect of metformin on fat 
oxidation during and after exercise in non-obese recreationally active individuals. Healthy 
subjects were selected to isolate the independent actions of metformin from potentially 
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confounding effects of mitochondrial dysfunction (Kelley & Mandarino, 2000), insulin resistance 
(Braun et al., 2004) and/or pharmacological interaction on substrate oxidation. We hypothesized 
that metformin treatment, compared to a placebo condition, would increase fat oxidation during 
and after exercise.  
 
Methods 
Overall Study Design: The effect of metformin on substrate oxidation was tested using a double-
blind, counter-balanced cross-over design in which men and women served as their own 
controls. Subjects were treated with metformin or placebo for 8-10 days before performing a 
submaximal exercise test. Subjects were treated with the alternative treatment for 8-10 days to 
allow adequate washout of the previous treatment. During and after submaximal exercise, 
substrate oxidation was measured by indirect calorimetry using open-circuit spirometry.  
Subjects: Healthy recreationally active (> 3d/wk of either aerobic or resistance training) men 
(n=7) and women (n=8) participated in this study. Subjects were free from cardiovascular or 
metabolic disease, were nonsmokers, and were not taking any dietary supplements (e.g. 
chromium, niacin, ephedrine, etc.) or medications known to impact substrate oxidation. Subject 
characteristics are outlined in Table 5.1. We did not strictly control for menstrual cycle phase, 
but based on questionnaires detailing the date of last menses, half of the women were in their 
follicular phase of the cycle when on metformin. No noticeable differences in substrate use 
occurred between these groups of women. Most well controlled studies using stable isotope 
tracers show that the effects of menstrual cycle phase on substrate oxidation during exercise 
are subtle or non-existent  (Braun & Horton, 2001). Prior to testing, all subjects gave informed 
consent document approved by the Institutional Review Board at the University of 
Massachusetts, Amherst. A total of 15 subjects participated in the entire study.  A subgroup of 
10 subjects (the final 10 subjects recruited for the study) also participated in the measurement 
of blood lactate and post-exercise substrate oxidation.  
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Metformin and Placebo Condition: Subjects were treated with either metformin or placebo for 8-
10 days (Braun et al., 2008). They began treatment on day 1 with 500mg and the dose was 
increased by 500mg per day up to the standard clinical dose of 2000mg (usually occurred after 
4 days). Subjects maintained treatment at 2000mg for 4-5 consecutive days prior to each 
exercise test (see below). Subjects were instructed to take metformin or placebo with food in 
order to minimize potential side effects. Although it was designed to be a double-blind protocol, 
the presence of metallic taste in the mouth and/or gastrointestinal symptoms caused several 
subjects (these side effects were listed in the informed consent document as per IRB 
requirements) and the investigators to suspect which treatment was being given in a few cases. 
Despite this limitation, few subjects were certain which treatment they had been given and 
several were convinced they had metformin when they actually had the placebo.   
Test of peak work capacity: Subjects performed a continuous progressive exercise test on a 
cycle ergometer (SensorMedics 800, Yorba Linda, CA) to determine peak work capacity 
(Wpeak) and oxygen consumption (VO2peak) after 7 days of treatment with metformin or 
placebo. After a 5-minute warm-up, the workload on the cycle ergometer was increased by 30W 
every 2 minutes until the subject was unable to maintain a pedal cadence of 60rpm. During the 
test, respiratory gases (VO2 and VCO2) were collected by indirect calorimetry using open-circuit 
spirometry (ParvoMedics Truemax 2400, Consentius Technologies, Sandy, UT). Heart rate was 
monitored throughout the test (Polar, Inc., Lake Success, NY). Wpeak and VO2peak were 
defined as the highest values obtained during the test. Three subjects obtained a higher Wpeak 
during placebo treatment. Submaximal exercise intensities were scaled to a relative percentage 
of their new peak value to minimize the impact of exercise intensity on substrate use. Each test 
was considered valid if at least 3 of the following criteria were met: a plateau in VO2 (< 150ml), 
respiratory exchange ratio (RER) > 1.1, heart rate within 15 beats per minute of age predicted 
peak heart rate (220-age) or the subject voluntarily stopped the test (Braun et al., 2008). 
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Submaximal Exercise and Post-exercise Tests: Following the test of Wpeak subjects were 
instructed to avoid structured exercise for 24 hours.  The following morning, subjects took their 
last dose or metformin or placebo and reported to the laboratory in the post-absorptive state 
(10-14 hour fast). Baseline respiratory gases were collected for 8 minutes. Subjects warmed up 
for 5 minutes on the cycle ergometer at 25 Watts.  Cycle ergometry was then performed at 5 
submaximal workloads, starting at 30% Wpeak and increasing by 10% every 8 minutes to a final 
workload of 70% Wpeak. Eight-minute exercise stages were selected to make certain steady-
state conditions were reached for accurate measures of substrate use (Bordenave et al., 2007). 
To ensure that submaximal exercise occurred at the same absolute intensity across conditions, 
the intensity was scaled to peak workload, rather than peak VO2, because our laboratory has 
shown that metformin treatment can reduce VO2peak  (Braun et al., 2008). Subjects selected a 
preferred pedal cadence during the initial submaximal test, but were required maintain a pedal 
cadence of 50rpm. Subjects repeated their preferred pedal cadence during the second 
submaximal test. Two-minute active recovery periods at 25W followed each submaximal 
workload to minimize the impact each exercise stage would potentially have on ensuing 
measures of substrate use. Respiratory gases were collected during the last 4 minutes, of each 
8-minute exercise workload.  The last 2 minutes were used to calculate substrate oxidation to 
ensure achievement of steady-state conditions. Whole blood (30µl), rating of perceived exertion 
(RPE), and heart rate were collected during the last 2 minutes of each exercise workload.  
Upon completion of exercise, subjects were moved to a semi-recumbent position and 
respiratory gases were collected continuously for 50 minutes using a ventilated hood system to 
measure substrate oxidation at 20, 30, 40, 50 and 60 minutes after exercise. Respiratory gases 
were averaged for the last 2 minutes at each time point for substrate oxidation analysis. 
Substrate oxidation analysis included the respiratory exchange ratio (RER), total rate of 
carbohydrate and fat oxidation, and relative percentage of energy from carbohydrate and fat. 
When RER exceeded 1.0 during exercise, which occurred 7 times with metformin and 6 times 
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with placebo (all at the final workload) RER was assumed to equal 1.0. Subjects were instructed 
to maintain their normal diet and activity regimen throughout the study and all subjects were 
tested at a similar time of day.  
Blood Analysis: Whole blood lactate concentrations were collected in 30µl capillary tubes and 
were determined enzymatically using a glucose-lactate analyzer (GL5 Analyzer, Analox 
Instruments, Lunenberg, MA).  
Calculations: Although there are limitations to the use of indirect calorimetry to assess substrate 
oxidation, it has been validated using the 13C/12C ratio technique and the authors (Romijn, 
Coyle, Hibbert, & Wolfe, 1992) concluded that indirect calorimetry could be used to accurately 
determine carbohydrate and fat oxidation at exercise intensities up to 85% VO2max. Thus, energy 
derived from carbohydrate and fat were determined as (Kuo et al., 2005):  
1. RER = VCO2/VO2 
2. Percent of energy from carbohydrate (CHO) and fat  
 % Energy CHO =  [(RER – 0.71)/0.29] x 100 
 % Energy Fat = 100 - [(RER – 0.71)/0.29] x 100 
3. Rate of total CHO and fat oxidation were calculated (Peronnet & Massicotte, 1991).  
 CHO oxidation rate (g/min) = 1.6946 VO2 – 1.7012VCO2 
  Fat oxidation rate (g/min) = 4.5850 VCO2 – 3.2255 VO2 
Statistical Analysis:  Data was analyzed using the R statistical software package (version 2.4.0, 
The R foundation, Vienna, Austria, 2006). Paired t-Tests were used to detect differences 
between conditions for anthropometric variables, heart rate peak, VO2peak and Wpeak. A 2-
factor (condition x intensity or time) repeated measures analysis of variance (ANOVA) was used 
to determine differences for RER, relative percentage of energy from carbohydrate and fat, rate 
of total carbohydrate and fat oxidation, lactate, heart rate, submaximal oxygen consumption, 
energy expenditure, and RPE. Tukey's post hoc analysis was performed when significant 
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interactions were observed. Pearson’s correlation was used to assess relationships when 
possible. Significant differences were accepted as % < 0.05.  
 
Results 
Exercise Substrate Oxidation. During submaximal exercise there was no statistical difference 
between conditions for oxygen consumption, energy expenditure, or heart rate (Table 5.2), but 
as expected outcome variables did increase with increasing exercise intensity (p < 0.05). 
Overall, metformin, compared to placebo, significantly lowered RER values across exercise 
intensities (p < 0.03; Figure 5.1). Based on those values, the relative percentage of energy 
derived from fat (p < 0.01; Table 5.3) and rate of total fat oxidation was increased across 
exercise intensities with metformin treatment compared to placebo (p < 0.01; Figure 5.2a and 
5.2b). There was no interaction between treatment and exercise intensity (p = ns), indicating 
that the effect of increasing exercise intensity on the balance between carbohydrate and fat 
oxidation was not different with metformin or placebo.  
Blood Lactate and RPE During Exercise. Metformin significantly increased blood lactate 
concentrations (p < 0.05; Figure 5.3) and RPE values (p < 0.05; Table 5.2) compared to placebo 
at all exercise intensities. Both metformin and placebo had similar patterns of blood lactate and 
RPE values as exercise intensity increased (p < 0.05). There was no interaction between the 
treatment and exercise intensity (p = ns), indicating that blood lactate responded similarly to 
increasing exercise intensity regardless of the treatment. Considering both blood lactate and 
RPE increased significantly, we observed significant correlations between the change (#) in 
blood lactate and the # in RPE (r = 0.74; p < 0.05), indicating that higher blood lactate during 
exercise was associated with higher perceptions of effort.  
Post-exercise Substrate Oxidation. Post-exercise oxygen consumption and energy expenditure 
was not different between metformin and placebo conditions (data not shown) at any time point. 
Post-exercise RER values were higher with metformin treatment compared to placebo (p < 
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0.03; Figure 5.1) and accordingly, metformin slightly lowered the relative percentage of energy 
derived from fat (p <0.03; Table 5.4) and rate of total fat oxidation (0.10 ± 0.02 vs. 0.12 ± 0.02; p 
< 0.01). There was a significant inverse correlation between the # in rate of total fat oxidation 
during exercise and the # in rate of total fat oxidation post-exercise (r = -0.68; p < 0.05), 
indicating that higher fat oxidation during exercise was associated with lower fat oxidation post-
exercise.  
 
Discussion 
Summary of Results. This study demonstrates that metformin alters substrate oxidation during 
and after exercise in healthy recreationally active individuals. The main findings were that, 
compared to placebo, metformin 1.) raised reliance on fat as a fuel source during exercise, 2.) 
increased blood lactate concentrations and rating of perceived exertion (RPE) during exercise, 
and 3.) lowered fat oxidation after exercise.  
Effects of Metformin on Exercise Substrate Oxidation. Treatment with metformin elevated the 
amount of fat oxidized both in absolute (grams of fat) and relative terms (percentage of energy 
derived from fat). Since metformin had no impact on oxygen consumption or energy expenditure 
during exercise, differences in relative exercise intensity cannot explain the elevated fat 
oxidation. As seen in Figure 5.2a and 5.2b, the reciprocal changes in the oxidation of 
carbohydrate and fat can be visually represented using the crossover concept originally 
described by Brooks and Mercier (Brooks & Mercier, 1994).  The addition of metformin visually 
shifted the crossover point from approximately 50% (placebo) to 55% Wpeak indicating 
increased reliance on the use of fat at the same exercise (absolute or relative) intensity. 
Whether the effect of metformin to increase fat oxidation during a single exercise bout would be 
maintained, accentuated or attenuated with regular exercise training needs to be determined.  
Whether the increased use of fat with metformin treatment is a direct result of stimulating 
fat utilization or an indirect effect of increasing fat availability cannot be determined using the 
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current study design. Metformin activates AMP-activated protein kinase (AMPK), which raises 
the capacity for fat oxidation by facilitating entry of fatty acids into the mitochondria (Long & 
Zierath, 2006; Merrill, Kurth, Hardie, & Winder, 1997) for oxidation. Metformin also raises 
circulating fatty acid concentrations (Gudat, Convent, & Heinemann, 1997) increasing lipid 
availability. Lastly, by reducing hepatic glucose production, metformin could lower the 
availability of plasma glucose and constrain carbohydrate oxidation with a compensatory rise in 
the oxidation of fat (Randle, 1998). More sophisticated studies using palmitate and glucose 
tracers would be necessary to evaluate the mechanism underlying the shift in fat use.   
Metformin Increases Blood Lactate Concentrations. Typically, a rise in circulating lactate 
concentration is directly related to the greater use of carbohydrate that parallels increasing 
exercise intensity. Paradoxically, metformin increased blood lactate concentrations at rest and 
at all exercise intensities despite a lower reliance on carbohydrate compared with placebo. 
These data suggest that a shift to greater reliance on non-oxidative carbohydrate metabolism 
and/or less clearance of lactate. Without lactate tracers, we cannot distinguish between the two 
explanations, but the well-characterized effect of metformin to decrease hepatic glucose 
production is consistent with lower lactate clearance (Owen, Doran, & Halestrap, 2000). Our 
results contrast with those of Gudat et al (Gudat et al., 1997), who reported that metformin did 
not increase lactate concentrations during exercise at a single exercise intensity (200 watts) in 
healthy subjects. A possible explanation for this discrepancy is the inter-individual variability 
introduced when exercise is performed at a single absolute intensity. Because there are 
variations in fitness, muscle power, body size, etc. there is a wide range of relative exercise 
intensities that cause considerable variability in the blood lactate response. In the current study, 
individuals exercised at the same relative intensity to minimize variability and increase the 
likelihood of detecting true differences among conditions.  
Metformin and Rating of Perceived Exertion (RPE). Consistent with the elevated circulating 
lactate concentrations, RPE was slightly higher during exercise with metformin treatment 
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compared to placebo. The greatest difference in RPE occurred at 40% Wpeak, which is an 
exercise intensity that falls within the low to moderate intensity range typically recommended for 
previously sedentary individuals in the early stages of exercise programs. If exercise at the 
same absolute intensity “feels” harder with metformin, individuals may be less likely to comply 
with exercise programs. If this difference in RPE turns out to be a common side-effect of 
metformin treatment, practitioners may need to adjust exercise prescription. 
Effects of Metformin on Post-exercise Substrate Oxidation. In contrast with the effect to elevate 
fat oxidation during exercise, metformin increased carbohydrate oxidation after exercise. The 
difference was most evident immediately after exercise and was diminished as time went on. 
The increase in carbohydrate oxidation could be a direct effect of metformin to raise glucose 
use or an indirect consequence of the elevated fat oxidation during exercise. Consistent with the 
latter explanation, there was a strong inverse relationship between fat use during exercise and 
fat use after exercise. Although this association may not be causal, it is consistent with the 
literature. For example, compared to eucaloric high intensity exercise, low intensity exercise 
(higher contribution of fat to total energy expenditure), reduces post-exercise fat oxidization 
(Kuo et al., 2005; Phelain et al., 1997). Henderson and colleagues (Henderson et al., 2007) 
showed that compared to men, women oxidized more fat during exercise but less fat after 
exercise. The consensus among these researchers is that big elevations in fat oxidation after 
hard exercise result from high rates of endogenous carbohydrate use during exercise and a 
consequent directing of carbohydrate to muscle glycogen replenishment rather than oxidation 
(Bielinski, Schutz, & Jequier, 1985; Kiens & Richter, 1998; Kimber, Heigenhauser, Spriet, & 
Dyck, 2003). It is possible that metformin treatment, by lowering carbohydrate use during 
exercise, reduces the stimulus to direct glucose toward storage after exercise. Although resting 
fat oxidation may be lower after exercise with metformin, the increased reliance on carbohydrate 
could be useful in managing hyperglycemia for individuals with established diabetes.  
Limitations. There are several limitations to our study that could affect interpretation of the data. 
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First, the experimental treatment was performed in healthy, recreationally active individuals. 
This was done to minimize the impact of insulin resistance (Braun et al., 2004), mitochondrial 
dysfunction  (Kelley & Mandarino, 2000; Kelley, He, Menshikova, & Ritov, 2002; Simoneau, 
Veerkamp, Turcotte, & Kelley, 1999) and/or potential interaction with other common 
medications. Whether metformin impacts substrate oxidation in individuals with pre-diabetes or 
diabetes remains to be determined. Second, because measuring substrate oxidation with 
indirect calorimetry may be less accurate at high exercise intensity, we did not determine 
substrate oxidation rates at exercise intensities above 70% Wpeak (Romijn et al., 1992). Fat 
oxidation rates may be underestimated during high intensity exercise because RER increases in 
response to non-metabolic CO2 production. Furthermore, following high intensity exercise, 
alterations in sodium bicarbonate pools and retention of CO2 may overestimate fat oxidation. 
Third, the relatively short treatment period used in the current study precludes direct 
extrapolation of these data to the effects of long-term (months/years) treatment with metformin. 
Fourth, the lack of rigid dietary control during the study means that we are not aware of potential 
changes in dietary macronutrients that could affect substrate use. However, since we used a 
cross-over study design in which the order of conditions was balanced and the subjects were 
blinded to the condition, it is unlikely that subjects significantly altered their dietary patterns only 
when they taking metformin. Fifth, we found no difference in the effect of metformin to increase 
fat oxidation in the follicular or luetal phase. We acknowledge however with our small sample 
size and without more sophisticated measures of fat or carbohydrate metabolism we cannot 
completely rule out the role menstrual cycle phase in response to metformin. Sixth, because we 
used a graded exercise test to assess substrate oxidation, we cannot pinpoint the effects of 
metformin at any single exercise intensity in the absence of confounding effects of the 
preceding intensities. In addition, we cannot discern whether the effects on post-exercise 
metabolism were related to the net effect of the entire series of workloads or attributable to just 
the final workload (70% Wpeak). Lastly, 60 minutes of post-exercise measurement may not be 
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sufficient to fully characterize the effects of metformin on post-exercise metabolism. The 
difference between the treatments narrowed considerably in the last 20 minutes and may have 
been negligible or even reversed after 2 or 3 hours.  
Conclusion. Metformin increased the rate of fat oxidation, blood lactate concentrations and 
ratings of perceived exertion (RPE) during submaximal exercise. In contrast, following exercise, 
metformin slightly reduced fat oxidation and that change was strongly correlated with increased 
fat oxidation during exercise. If these results are reproducible in people with pre-diabetes or 
diabetes, they may be useful to understand how the combination of metformin and exercise can 
be used to oppose insulin resistance and, potentially, to prevent/delay the onset of Type-2 
diabetes.  A deeper understanding of the mechanisms underlying these results will require 
further research using more invasive techniques. 
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Figure Captions 
  
Figure 5.1. RER at each submaximal workload and for 60 minutes after exercise. 
*Significant effect of condition (p < 0.03). #Significant effect of intensity (p < 0.05). Values 
are mean ± standard error of the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
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Figure 5.2a and 5.2b. Rate of fat oxidation at each submaximal workload with placebo (a) 
and metformin (b). Significant effect of condition (p < 0.01). Significant effect of intensity 
(p < 0.05). Values are mean ± standard error of the mean.  
 
 
Figure 5.2a. 
 
Figure 5.2b.  
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Figure 5.3. Blood lactate at each submaximal exercise workload. *Significant effect of 
condition (p < 0.05). #Significant effect of intensity (p < 0.05).  
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Table Captions 
 
Table 5.1. Subject Characteristics. Women n = 8 and Men n = 7. Values are mean ± 
standard deviation. No significant differences were observed between conditions.  Bpm = 
beats per minute 
 
 
 Placebo Metformin 
Age (yr) 25.0 ± 4.4 25.0 ± 4.4 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 
Body weight (kg) 69.2 ± 12.7 68.9 ± 12.8 
BMI (kg/m2)  22.9 ± 2.7 22.8 ± 2.7 
Heart rate peak (bpm) 184.7 ± 8.3 181.8 ± 10.1 
VO2 peak (L/min) 3.2 ± 0.7 3.2 ± 0.7 
VO2 peak (ml/kg/min)  47.6 ± 6.8 46.9 ± 6.8 
Work peak (Watts) 241.3 ± 54.3 235.7 ± 55.3 
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Table 5.2. Values are reported as mean ± standard error of the mean. *Significant main 
effect of condition; p < 0.05. #Significant effect of intensity (p < 0.05). RPE= rating of 
perceived exertion.  
 
 
Variable Condition Rest 30% 
Wpeak 
40% 
Wpeak 
50 % 
Wpeak 
60% 
Wpeak 
70% 
Wpeak 
Placebo 74 ± 2.4 108 ± 2.0 126 ± 2.4 143 ± 2.8 156 ± 2.1 169 ± 2.3  
Heart Rate 
(bpm) # Metformin 75 ± 2.3 110 ± 2.9 124 ± 2.4 140 ± 3.1  154 ± 3.3 168 ± 3.3 
Placebo 4.20 ± 0.1 18.4 ± 0.7 22.5 ± 0.8 28.3 ± 1.5 31.7 ± 0.8 36.6 ± 1.4  
Oxygen 
consumption 
(ml/kg/min) # 
Metformin 4.11 ± 0.2 18.4 ± 0.7 22.9 ± 0.8 26.7 ± 1.1 31.4 ± 1.2 36.6 ± 1.4 
Placebo 1.8 ± 0.4  6.3 ± 0.4 7.7 ± 0.5  9.3 ± 0.5 10.9 ± 0.6 12.8 ± 0.8  
Energy 
Expenditure 
(kcal/min) # 
Metformin 1.5 ± 0.1 6.3 ± 0.4 7.8 ± 0.5   9.6 ± 0.5 10.8 ± 0.7 12.9 ± 0.8 
Placebo - 9.3 ± 0.4 11.1 ± 0.4 12.8 ± 0.3 14.6 ± 0.4 16.6 ± 0.3  
RPE *# 
Metformin - 9.4 ± 0.3 11.7 ± 0.2 13.3 ± 0.3 14.7 ± 0.3 17.3 ± 0.3 
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Table 5.3. Relative percentage of energy across all submaximal workload. *Significant 
effect for condition (p < 0.01). #Significant effect of intensity (p < 0.05). Values are mean ± 
standard error of the mean.  
 
 
Variable Condition Rest 30% 
Wpeak 
40% 
Wpeak 
50 % 
Wpeak 
60% 
Wpeak 
70% 
Wpeak 
Placebo 41.1 ± 3.1 60.7 ± 2.7 69.4 ± 2.7 78.3 ± 3.2 87.4 ± 2.6 97.8 ± 0.7  
CHO *# 
Metformin 39.7 ± 3.3 54.7 ± 2.5 63 ± 2.4 74.3 ± 3.3  83.0 ± 3.2 92.4 ± 2.4 
Placebo 58.9 ± 3.1 39.3 ± 2.7 30.6 ± 2.7 21.7 ± 3.2 12.6 ± 2.6 2.2 ± 0.7  
Fat *# 
Metformin 60.3 ± 3.3  45.3 ± 2.5 37 ± 0.8 25.7 ± 3.3 17.0 ± 3.2 7.6 ± 2.4 
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Table 5.4. Percentage of energy expenditure attributable to carbohydrate and fat 
oxidation at each time point after exercise. *Significant effect of condition (p < 0.03).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Condition 20min 30min 40min 50min 60min 
Placebo 7.4 ± 2.6 3.7 ± 1.6 6.2 ± 2.4 11.6 ± 3.7 21.9 ± 4.5  
CHO * 
Metformin 16.1 ± 5.2 15.3 ± 5.5 21.9 ± 5.2 19.2 ± 6.7  13.6 ± 3.7 
Placebo 92.6 ± 2.6 96.3 ± 1.6 93.8 ± 2.4 88.4 ± 3.7 78.1 ± 4.5  
Fat * 
Metformin 83.9 ± 5.2  84.7 ± 5.5 78.1 ± 5.2 80.1 ± 6.7 86.4 ± 3.7 
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Abstract  
Exercise training increases fat utilization during exercise and we previously showed that 
metformin raised fat utilization during exercise in healthy individuals. It is unknown if metformin 
raises fat utilization further after training in individuals prescribed this agent. Purpose: To 
determine the effect of combining metformin with exercise training on substrate utilization during 
exercise in individuals with impaired glucose tolerance (IGT). Methods: Using a double-blind 
design, 16 men and women with IGT underwent exercise training plus metformin (2000 mg/d; 
EM) or exercise training plus placebo (EP). Substrate utilization during exercise at 60% of pre-
training VO2peak was assessed before and after 10 weeks of endurance and resistance training 
by indirect calorimetry and the isotope dilution method. The pre and post-training group means 
were compared across conditions using analysis of variance with repeated measures. Results: 
Fat utilization increased (p < 0.001) and muscle glycogen decreased (p < 0.001) after EM and 
EP. Blood glucose utilization increased after EM compared to EP (p < 0.04). Conclusion: 
Metformin did not enhance the effects of training on fat utilization during exercise. Training, with 
or without metformin, had similar effects on fat and glycogen utilization, but only metformin 
increased the reliance on blood glucose during exercise after training. These findings suggest 
that training with metformin has subtle effects on substrate utilization during exercise in 
individuals with impaired glucose tolerance.  
KEY WORDS: Prediabetes, type 2 diabetes, substrate metabolism, resistance training 
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Introduction 
 Individuals with impaired glucose tolerance (IGT) are at high risk for type 2 diabetes (1, 2, 
23). Lifestyle modification, which consists of low-fat diet and increased physical activity, 
opposes the progression from IGT to type 2 diabetes (16). To prevent this transition, the 
American Diabetes Association (ADA) strongly recommends habitual exercise. Metformin, a 
commonly prescribed oral medication that reduces hyperglycemia, also delays the transition to 
type 2 diabetes. As a result, the ADA recommends that physicians consider metformin along 
with lifestyle changes for people with IGT (20). But, we know very little about the effects on 
combining exercise with metformin in individuals with IGT. 
 Although the exact mechanism by which exercise improves insulin sensitivity is unclear, 
enhancing fat utilization may be one potential mechanism because it is associated with reduced 
insulin resistance (12, 27, 28). Endurance training increases fat utilization during exercise in 
lean healthy individuals (10, 11, 15). We previously demonstrated that metformin increased fat 
utilization during exercise in healthy, recreationally active individuals (17). It is possible that 
metformin elevated fat utilization by constraining hepatic glucose output and lowering the 
availability of blood glucose for subsequent oxidation(8, 14). Whether metformin affects fat 
utilization or hepatic glucose output during exercise in individuals with IGT after training has yet 
to be investigated. Therefore, the primary purpose of this study was to determine the effects of 
combining exercise training and metformin on exercise fat utilization in men and women with 
IGT. We hypothesized that exercise training with metformin would increase fat utilization during 
exercise more than exercise training alone. Since the primary mechanism of action for 
metformin is to lower hepatic glucose output, we also hypothesized that elevated fat utilization 
would be paralleled by reduced hepatic glucose output.  
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Methods 
Study overview: Using a double-blind design, 16 men and women were assigned to either 
exercise training plus metformin (EM) or exercise training plus placebo (EP) for 10 weeks. 
Subjects were non-smoking, weight stable (<5% weight change over last 3mo), free of 
cardiovascular disease or type 2 diabetes, and did not take dietary supplements or medications 
that affect substrate metabolism (e.g. chromium, niacin, ephedrine). Subjects were excluded if 
they had any contraindications to metformin (e.g. respiratory disease, heart failure, renal and 
hepatic disease). Women were tested between 5-10 days post-menses and tested after training 
in the same midfollicular phase; i.e., women were tested after approximately 10 weeks of 
training because we timed measures of exercise substrate metabolism around the midfollicular 
phase. As a result, the precise duration of training varied slightly between women depending on 
their menstrual cycle. Prior to testing, all subjects were verbally briefed about the study and 
signed informed consent documents approved by the Institutional Review Board at the 
University of Massachusetts Amherst.  
OGTT Screening: An oral glucose tolerance test (OGTT) was used to determine if subjects had 
impaired glucose tolerance. After a minimum 5-hour fast, blood samples were taken from a 
forearm vein. Subjects consumed 75 grams of glucose and blood samples were collected 2 
hours later. All subjects had impaired glucose tolerance (IGT; 2-hour glucose concentrations 
between 7.8-11.1mmol/L or 140-199mg/dl). Subjects with IGT who had fasting glucose 
concentrations between 5.5-6.9mmol/L (100-125mg/dl) were also included.  
Preliminary testing: Peak oxygen consumption (VO2peak) was assessed by performing a 
continuous progressive exercise test on a cycle ergometer (SensorMedics 800, Yorba Linda, 
CA). After a 5-minute warm-up, the workload was increased by approximately 30W every 2 
minutes until the subject was unable to maintain a pedal cadence of 60 rpm. During the test, 
respiratory gases (VO2 and VCO2L/min) were measured by indirect calorimetry (ParvoMedics 
Truemax 2400, Consentius Technologies, Sandy, UT). Heart rate was also monitored 
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throughout the test (Polar, Inc., Lake Success, NY). VO2peak was defined as the highest values 
obtained during the test using standard criteria (19). One repetition max (1-RM) tests were also 
conducted for the: chest press, latissimus pull down, leg press, bicep curl, triceps pushdown, 
and upright rows. 1-RM was defined as the highest weight lifted with proper technique through 
the full range of motion. Body composition was measured using dual-x-ray absorptiometry 
(DEXA; Lunar Prodigy, Madison, WI) for the determination of body fat and fat-free mass (FFM). 
These data were previously presented (see Chapter 4), but are reported in the results for clarity.   
Metformin or Placebo protocol: Pills were administered to the subjects and they were instructed 
to take metformin or placebo with food in order to minimize potential side effects. Subjects 
started treatment with 500 mg/d of metformin. The dose was increased 500 mg/d each week 
until a clinical dose of 2000 mg/d was reached by week 4. Subjects remained at this dose for 
the last 6 weeks of the 10 week protocol. 
Exercise Training: Exercise was supervised 3-days a week for 60-75 minutes per session (total 
3.5 hours/wk: ~400 kcal per session). Subjects performed aerobic and resistance exercise on 
the first and third day of each week. To minimize muscle soreness, only aerobic training was 
performed on the second day. Participants warmed-up on a cycle ergometer for 5 minutes, 
followed by cycling at 70% of their pre-training HRpeak for 45 minutes. Resistance exercise was 
performed at 70% of the subject’s 1-RM. Weight was increased approximately 5% when 2 sets 
of 12 repetitions could be lifted with proper form. Resistance training targeted all major muscle 
conditions and included: the chest press, latissimus pull down, leg press, bicep curl, triceps 
pushdown, shoulder raise, calf raises, and abdominal crunches. 
Submaximal Exercise protocol: At baseline and after 10 weeks of training, subjects reported to 
the laboratory after a 10-12 hour fast. Indwelling catheters were placed in a superficial vein of 
each forearm for continuous infusion of glucose stable isotope ([6,6-2H glucose]) and blood 
sampling. After baseline blood samples were collected, a primed (bolus of 200 mg 6,6-2H 
glucose) continuous infusion of 6,6-2H glucose was delivered for  90 minutes at 3.0 mg/min by 
    
 111 
peristaltic infusion pump. Blood samples were collected at 75 and 90 minutes. Following the last 
blood sample, subjects were moved to a cycle ergometer and expired respiratory gases were 
collected for 8 minutes. Subjects warmed up on the cycle ergometer at 25 W for 5 minutes. 
Exercise was performed for 45 minutes at 60% of the pre-training VO2peak before and after 
training. Two-minute break periods were provided at 15 and 25 minutes to facilitate completion 
of exercise. Breath and blood samples were collected at 15, 25, 35, and 45 minutes. Expired 
gases were collected during the first 15 minutes to ensure steady-state conditions were 
reached, and expired gases were collected for 7 minutes prior to each time point. During the last 
2 minutes at each time point, expired gases were used to calculate substrate utilization. 
Substrate utilization analysis included: the respiratory exchange ratio (RER), rate of total 
carbohydrate and fat oxidation, and percent of total energy expenditure derived from 
carbohydrate or fat (see calculations below). Blood concentrations of glucose, lactate, non-
esterified free fatty acids (NEFA), glycerol, and insulin, the rating of perceived exertion (RPE) 
and heart rate were also collected during the last 2 minutes of each time point. Subjects 
recorded dietary intake 24-hour prior to baseline testing and replicated this diet prior to post-
training testing. There was no statistical difference in energy or macronutrient intake between 
conditions (data not shown). Subjects refrained from exercise 24-36 hours prior to testing and 
all subjects were tested at a similar time of day.  
Blood sample collection: Blood samples were collected in 3 mL syringes, transferred to 
vacutainers, spun at 3000 rpm and aliquoted to cryotubes for storage at -80°C. Samples for 
analysis of glucose isotopic enrichment, glucose and lactate were transferred to vacutainers 
containing sodium fluoride. Samples for analysis of insulin, glycerol and non-esterified fatty 
acids (NEFA) were collected in vacutainers containing the anticogagulant EDTA. 
Analysis of metabolites and hormone: Plasma glucose and lactate concentrations were 
determined enzymatically using a glucose/lactate analyzer (GL5 Analyzer, Analox Instruments, 
Lunenberg, MA). Plasma insulin was measured by radioimmunoassay (Millipore, St. Charles, 
    
 112 
MO). NEFA and glycerol were measured by enzymatic colorimetry (Wako Chemicals, 
Richmond, VA). Glucose isotopic enrichment was measured by high performance liquid 
chromatography and mass spectrometry (HPLC-MS) as previously described (25).  
Calculations: Standard equations were used to assess rates of glucose disposal (Rd) and 
glucose rates of appearance (Ra) (29).  
      Glucose Ra (mg/min) = F-V[(C1 + C2) / 2] [IE2-IE1) / (t2-t1)] 
        [IE2 + IE1) / 2] 
 
  Glucose Rd (mg/min) = Ra – V[C2-C1) / (t2-t1)].  
Where F is the isotope infusion rate, IE1 and IE2 are enrichments of plasma glucose with 
isotope label at time t1 and t2, C1 and C2 are plasma glucose concentrations, V is the 
estimated volume of distribution for glucose (180 mL/kg).  
Rates of carbohydrate and fat oxidation were estimated from VO2, VCO2 and RER using 
standard equations (21). Estimated muscle glycogen utilization (EMGU) was calculated as: 
EMGU (mg/min) = total rate of carbohydrate oxidation– blood glucose Rd. This estimate is 
based on the assumption that 100% of blood glucose taken up from the blood is oxidized. This 
assumption is unlikely to be true, i.e. the percent of Rd oxidized is probably 70-90% (10). The 
calculation thus underestimates glycogen use and is best described as minimal muscle 
glycogen utilization.  
Statistical Analysis:  Group means were analyzed using the R statistical software package 
(version 2.4.0, The R foundation, Vienna, Austria, 2006). Unpaired t-tests were used to compare 
group means among subject characteristics and post-training % of VO2peak. Baseline group 
means were assessed by a one-way analysis of variance (ANOVA) and there were no statistical 
differences between conditions for any outcome. Group means of: VO2peak, work peak, heart 
rate peak, and body mass were compared at baseline and after the intervention with a two-way 
(group by test) repeated measures ANOVA. Group means of: Ra, Rd, EMGU, RER, 
carbohydrate and fat oxidation, percentage of energy from blood glucose, muscle glycogen and 
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fat utilization, as well as metabolites and hormones were compared at baseline and after the 
intervention with a three-way (group by time by test) repeated measures ANOVA. Tukey’s post-
hoc analysis was used to detect group mean differences when there was a significant 3-way 
interaction. Significant differences were accepted as % " 0.05.  
 
Results  
Subject Characteristics. Exercise training plus metformin (EM) and training plus placebo (EP) 
conditions were similar for sex (EM and EP = 3F/5M), age (EM = 49.1 ± 6.6 vs. EP = 45.4 ± 
8.0yr; p = 0.32) and 2-hour glucose concentrations (EP = 9.46 ± 1.70 vs. EP = 10.23 ± 1.02mM; 
p = 0.28). Both training groups increased VO2peak; p < 0.01; Table 6.2). Body mass was 
reduced in EM compared to EP (p <0.05; Table 6.2). Fasting metabolic characteristics were 
similar between groups after training (Table 6.3). 
Exercise Characteristics. Submaximal exercise oxygen consumption, expressed relative to body 
weight was not altered during exercise after training in either EM or EP. Metformin blunted the 
reduction in the pre-training VO2peak percentage during exercise after training, although this 
was not statistically significant (EM = 54.5 ± 1.2 vs. EP = 50.8 ± 2.8%; p = 0.11). However, heart 
rate and RPE during exercise were lower after training in both groups (p < 0.05; Table 6.4). 
Exercise Substrate Oxidation. RER was lowered after training by both EM and EP (p < 0.05; 
Figure 6.1a and 6.1b). Based on RER values, the total rate of fat oxidation increased (p < 0.01; 
data not shown) and the total rate of carbohydrate oxidation decreased (p < 0.01; data not 
shown) during exercise after training in both groups.  
Exercise Glucose Flux. Plasma isotopic enrichment was not different during exercise in either 
EM or EP after training (data not shown). Glucose Ra (Figure 6.2a and 6.2b) and Rd (Figure 
6.2c and 6.2d), were also not different after training in EM or EP (group by test effect; p = 0.11).  
    
 114 
Relative Percentage of Energy Expenditure. The contribution of fat utilization to total energy 
expenditure increased (p < 0.001) and estimated muscle glycogen utilization decreased (p < 
0.001; Figure 6.3) during exercise after training in both EM and EP. The percent of total energy 
expenditure attributable to blood glucose oxidation during exercise increased after training in 
EM compared to EP (group by test effect: p < 0.04 Figure 6.3). 
Blood Metabolites and Hormone During Exercise. Although neither training group effected 
plasma glucose concentrations during exercise, plasma lactate concentrations decreased 
similarly during exercise after training in both EM and EP (p < 0.05; Table 6.4). The training 
alone condition had higher plasma non-esterified fatty acid (NEFA) concentrations at baseline 
compared to the training plus metformin condition (p < 0.01; Table 6.4). NEFA concentrations 
were elevated across the exercise time-points after training in EM compared to EP (group by 
test effect: p < 0.03). Plasma insulin concentrations were lower across the exercise time-points 
after training in the EM compared to EP (p < 0.01; Table 6.4).  
 
Discussion 
Overview: Metformin might enhance the capacity for fat oxidation. As a result, we hypothesized 
in the current study that metformin would accentuate the effects of training on fat utilization 
during exercise in individuals with impaired glucose intolerance (IGT). Contrary to our 
hypothesis, metformin did not accentuate the effects of training on fat utilization during exercise 
in these men and women with IGT. Combining metformin with exercise training increased fat 
utilization and decreased muscle glycogen oxidation to the same extent as training alone.  
Effect of exercise training & metformin on fat utilization. Endurance training increases fat 
utilization during exercise at the same absolute workload as pre-training in lean healthy (4, 9, 
15) and overweight insulin resistant individuals (6, 7). We originally demonstrated that 
metformin raised fat oxidation during an acute bout of exercise in healthy individuals (17). This 
suggested that metformin had the potential to raise fat oxidation during exercise after training. 
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Although it’s hard to directly compare our previous work to the present study because of 
differences in subject population (i.e. healthy vs. IGT), administration of metformin (1 week vs. 
10 weeks), and exercise protocols (i.e. acute ramped progressive exercise test vs. a single 
submaximal test), our current findings suggest that metformin does not accentuate the effects of 
training on fat utilization during exercise when performed at the same absolute workload. 
The lack of elevated fat utilization with the combined condition was somewhat surprising, 
given that elevated plasma non-esterified fatty acids (NEFA) concentrations have been 
associated with increased fat utilization (22). However, we are not the first to show that 
metformin raises NEFA concentrations during exercise (13). From our work and others, it is not 
possible to know if NEFA concentrations increased during exercise as a result of elevated 
lipolysis, reduced re-esterification, or decreased uptake in the liver and/or skeletal muscle. More 
sophisticated measures, such as palmitate and glycerol tracers, would be needed to determine 
the effect of metformin on lipid flux during exercise. However, plasma glycerol concentrations 
might be considered a crude measure of lipolysis (24). In our study, we found that they did not 
change after training with metformin, suggesting that metformin did not increase lipolysis. 
Alternative mechanisms may therefore explain the effects of the combined condition on elevated 
NEFA concentrations during exercise. Smith et al (26) showed that metformin reduced skeletal 
muscle FATCD/36 transporter concentrations, suggesting that metformin may reduce NEFA 
uptake after training. Thus, metformin might have subtle effects on lipid metabolism during 
exercise after training.  
Effect of exercise training & metformin on carbohydrate utilization. Endurance training reduces 
total carbohydrate oxidation during exercise when performed at the same absolute workload as 
pre-training in lean healthy men and women (5, 10, 11). In our study, training, with or without 
metformin, decreased total carbohydrate utilization during exercise in these men and women 
with IGT. Since blood glucose utilization did not decrease after training, the reduction in total 
carbohydrate oxidation is explained by reduced reliance on glycogen. Decreased glycogen 
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utilization after training was similar between training conditions. Thus, metformin does not alter 
the glycogen sparing effect of training in individuals with IGT.  
Endurance training decreases glucose flux (i.e. Ra and Rd) during exercise when 
performed at the same absolute workload as pre-training in healthy individuals (4). However, 
Minsink et al (18) demonstrated that 12 months of lifestyle modification, including and aerobic 
and resistance exercise, had no effect on reducing glucose flux during exercise in individuals 
with IGT. Consistent with this finding, we found that 10 weeks of training, with or without 
metformin, had no effects on lowering hepatic glucose output or glucose uptake during exercise 
in individuals with IGT. Together, these findings suggest that training may have different effects 
on glucose flux during exercise in individuals with IGT compared to normal glucose tolerance.  
Effect of exercise training & metformin on maximal oxygen consumption. Relative to baseline, 
training plus metformin increased VO2peak (scaled to body weight) by approximately 10% 
whereas training alone improved VO2peak by 20%. These findings are consistent with our 
earlier work (3) and indicate that metformin may partially blunt the effects of training on cardio-
respiratory fitness in individuals with IGT. Health professionals should be cognizant of this 
potential “side effect” because it could have important implications for designing exercise 
programs. If the blunting effects of metformin on maximal oxygen consumption were significant, 
submaximal exercise effort could be affected.  
Effect of exercise training & metformin on Rating of Perceived Exertion (RPE). Relative to 
baseline, training decreases RPE during submaximal exercise at the same absolute intensity. 
We showed that metformin increased RPE during exercise in healthy men and women (17). 
Despite subtle differences in maximal and submaximal oxygen consumption (i.e. expressed as 
% VO2peak) between conditions in the current study, metformin did not blunt the effects of 
training on lowering RPE. It’s unclear why metformin increased RPE in healthy individuals but 
not in these men and women with IGT. Differences in study design (i.e. cross-over vs. 
prospective cross-sectional) complicate the interpretation. Thus, our data indicates that training 
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with metformin does not affect perceived exertion during exercise and exercise should not “feel” 
harder.  
Limitations. There are some limitations to this study that may affect the interpretation of our 
data. First, we tested individuals after training at the same pre-training absolute workload. Our 
findings may not be applicable to situations where individuals are tested at the same relative 
exercise intensity after training. Second, the inclusion of individuals with IGT in the presence of 
impaired fasting glucose (IFG) may have affected the response to training. After exercise 
training, fat utilization during exercise increased more in individuals with IGT than those with 
IFG+IGT. This observation suggests that individuals of different prediabetes classifications (e.g. 
IFG vs. IGT vs. IFG+IGT) may increase the capacity for fat utilization differently following 
exercise training (see S.B.1 and S.B.2). Thus, it would be beneficial for future work to determine 
the impact exercise has on substrate utilization in individuals based on the classification of 
prediabetes.  
Conclusion. Endurance and resistance training, with or without metformin, increased fat and 
lowered glycogen utilization during exercise in men and women with impaired glucose 
tolerance. Metformin did not accentuate the effects of training on fat utilization during exercise. 
However, changes in non-esterified fatty acid concentrations suggest that metformin has some 
effects on lipid metabolism during exercise. Similar training effects on fat oxidation during 
exercise after training, with and without metformin, suggest that alternative mechanisms are 
likely to account for differences in insulin sensitivity. More invasive measures are required to 
understand the mechanism by which metformin and exercise interact to affect insulin sensitivity 
(Chapter 4), as this will provide better insight into the potential effect of the combined treatment 
on preventing/delaying the onset of type 2 diabetes.  
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Figure Captions 
 
Figure 6.1a and 6.1b. RER values during exercise before and after training with 
metformin (a) and placebo (b). *Significant effect of test (p < 0.03). #Significant effect of 
time (p < 0.05). Values are mean ± standard error of the mean. 
 
Figure 6.1a  
 
 
 
Figure 6.1b  
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Figure 6.2a, 6.2b, 6.2c, and 6.2d. Rate of glucose appearance before and after training 
with metformin (a) and placebo. Rate of glucose disposal before and after training with 
metformin (c) and placebo (d). There was no statistical difference between conditions 
before or after training. Values are mean ± standard error of the mean.  
 
 
 
Figure 6.2a 
 
 
 
 
Figure 6.2b 
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Figure 6.2c 
 
 
 
 
Figure 6.2d 
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Figure 6.3. Relative Percentage of energy from blood glucose (Glc), estimated muscle 
glycogen use (EMGU) and fat. Values are mean ± standard error of the mean.  
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Table Captions 
 
Table 6.1. Anthropometric and Fitness Characteristics. Rating of perceived exertion 
(RPE). *Significant effect of test; p < 0.05. ^Significant group by test interaction (p < 0.05). 
Values are reported as means ± standard error of the mean. 
 
 EM EP 
 Pre Post Pre Post 
BMI (kg/m2) 33.2 ± 1.9 31.8 ± 1.6^ 33.5 ± 1.5 33.3 ± 1.6 
Body Fat (kg) 38.5 ± 4.0 35.3 ± 3.4* 40.8 ± 3.1 38.4 ± 2.9* 
Fat-free mass (%) 56.6 ± 2.6 58.4 ± 2.5* 55.4 ± 2.2 57.3 ± 2.3* 
VO2 peak (ml/kg/min)  27.3 ± 1.8 30.0 ± 2.3* 25.5 ± 2.5 29.9 ± 2.5* 
HR peak (bpm)       166 ± 7      165 ± 4      170 ± 6    167 ± 6 
Work peak (watts) 155 ± 12 187.5 ± 15.3* 163 ± 20 197 ± 23* 
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Table 6.2. Metabolic Fasting Characteristics. No significant effect of training for any 
outcome. Values are reported as means ± standard error of the mean.  
 
 
 EM EP 
Baseline Pre Post Pre Post 
Glucose (mM) 5.91 ± 0.23 5.60 ± 0.28 5.38 ± 0.17 5.21 ± 0.26 
Lactate (mM) 0.9 ± 0.2 1.0 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 
NEFA (mM) 0.50 ± 0.06  0.48 ± 0.05 0.59 ± 0.06 0.54 ± 0.06 
Glycerol (mM) 0.17 ± 0.02  0.18 ± 0.01 0.12 ± 0.03 0.12 ± 0.03 
Insulin (pM) 91.5 ± 15.7 75.7 ± 10.9 89.0 ± 7.9 75.5 ± 7.4 
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Table 6.3. Submaximal Exercise Characteristics. *Significant effect of test; p < 0.05. 
Values are reported as means ± standard error of the mean. 
 
 EM EP 
Baseline Pre Post Pre Post 
Heart rate (bpm) 75 ± 1 75 ± 1 72 ± 3 82 ± 3 
Oxygen cost (ml/kg/min) 2.7 ± 0.3 2.8 ± 0.3 2.9 ± 0.3 3.1 ± 0.3 
Exercise     
Heart rate (bpm) 128 ± 6 118 ± 4* 138 ± 7 122 ± 5* 
RPE 14 ± 1 12 ± 1* 14 ± 1 11 ± 1* 
Oxygen cost (ml/kg/min) 17.0 ± 1.1 16.2 ± 1.2 15.6 ± 1.6 15.2 ± 1.7 
Pre-training VO2peak (%) 61.1 ± 0.4 58.6 ± 1.9 61.6 ± 0.4 59.7 ± 1.9 
    
 
Table 6.4. Submaximal metabolites and hormone characteristics. *Significant effect of test; p < 0.05. †Significant group by 
test interaction (p < 0.05). # Significant effect of time (p < 0.05). ^Significant group by test interaction (p < 0.05). Values are 
reported as means ± standard error of the mean. 
 EM EP  
Exercise 
Test 15min 25min 35min 45min 15min 25min 35min 45min 
Pre 5.74 ± 0.29 5.58 ± 0.39 5.49 ± 0.39 5.42 ± 0.37 5.60 ± 0.22 5.25 ± 0.21 5.28 ± 0.30 5.10 ± 0.33  
Glucose 
(mM)
 
Post 5.65 ± 0.24 5.49 ± 0.31 5.51 ± 0.31 5.57 ± 0.37 5.40 ± 0.40 5.17 ± 0.25 5.32 ± 0.21 5.23 ± 0.22 
Pre 2.7 ± 0.3 2.6 ± 0.3 2.5 ± 0.3 2.2 ± 0.3 2.7 ± 0.3 2.7 ± 0.4 2.3 ± 0.3 2.3 ± 0.4  
Lactate* 
(mM)
 
Post 1.4 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 1.5 ± 0.2 1.3 ± 0.1 1.5 ± 0.2 1.4 ± 0.2 1.5 ± 0.2 
Pre 0.36 ± 0.04 0.34 ± 0.03 0.41 ± 0.03 0.49 ± 0.06 0.59 ± 0.04 0.59 ± 0.04   0.61 ± 0.05 0.66 ± 0.05  
NEFA$^# 
(mM)
 
Post 0.39 ± 0.04 0.42 ± 0.04 0.48 ± 0.04 0.49 ± 0.07 0.54 ± 0.03 0.52 ± 0.03   0.59 ± 0.05 0.59 ± 0.05 
Pre 0.31 ± 0.05 0.35 ± 0.06 0.34 ± 0.04 0.40 ± 0.05 0.25 ± 0.06 0.28 ± 0.09 0.38 ± 0.12 0.38 ± 0.05  
Glycerol# 
(mM) 
Post 0.31 ± 0.06 0.35 ± 0.03  0.40 ± 0.04 0.45 ± 0.06 0.27 ± 0.07 0.28 ± 0.05  0.28 ± 0.12 0.34 ± 0.07 
Pre 76.3 ± 7.5 72.1 ± 10.3 70.1 ± 11.3 71.2 ± 8.4 63.2 ± 7.4 52.7 ± 5.0   48.6 ± 4.4   43.0 ± 3.6  
Insulin^# 
(pM)
 
Post 61.0 ± 9.3 65.6 ± 11.1 71.2 ± 10.0 57.7 ± 7.1 56.0 ± 5.5 63.0 ± 6.2 55.3 ± 4.9 50.6 ± 5.1 
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Abstract  
Individuals with impaired glucose tolerance (IGT) are at elevated risk for cardiovascular 
disease. Although regular exercise or metformin may reduce cardiovascular disease (CVD) 
risk, the efficacy of combining treatments has not been investigated. Purpose: To determine 
the effects of exercise training plus metformin on reducing the level of CVD risk factors in 
individuals with IGT compared to each treatment alone. Methods: Subjects (n = 32) were 
assigned to either: placebo (P), metformin (M), exercise training plus placebo (EP), or 
exercise training plus metformin (EM). In a double-blind design, P or 2000mg/d of M were 
administered over 12 weeks and half were trained 3 days/week for approximately 60 
minutes/session (70% heart rate peak and 70% 1-RM max). CVD risk factors included: body 
weight, blood pressure, blood lipids and C-reactive protein (CRP). Results: M and EM 
decreased body weight compared to P and EP (p <0.05), while all treatments lowered waist 
circumference (time effect: p < 0.05). M and EP lowered systolic blood pressure (p < 0.05), 
diastolic blood pressure (p < 0.05), and CRP (M: p = 0.06; EP: p < 0.05) compared to P. All 
treatments increased HDL (p< 0.05; EM: p = 0.06) compared to P and lowered 
triacyglycerols (time effect: p < 0.05). Conclusion: Metformin, with or without training, 
reduced body weight compared to training alone and all 3 treatments lowered WC and TAG 
and raised HDL. Combining metformin with training did not have additive effects on reducing 
CVD risk factors. Metformin may blunt the full effects of training on specific CVD risk factors 
in people with IGT.   
KEY WORDS: Prediabetes, Metabolic Syndrome, Diabetes, Obesity, Hypertension 
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Introduction 
 Individuals with impaired glucose tolerance (IGT) are at elevated risk for 
cardiovascular disease  (CVD) (5, 8, 20, 33, 46) and approximately half of these individuals 
have the metabolic syndrome (43). CVD risk is largely explained by insulin resistance and 
excess body weight (24, 50). Treatments that enhance insulin sensitivity or lower body 
weight may lower CVD risk in individuals with IGT.   
Exercise reduces CVD risk by enhancing insulin sensitivity (12, 19, 28, 29) and 
lowering blood lipids (e.g. Triacylglcerol, low-density lipoproteins, etc), blood pressure, and 
C-reactive protein (3, 18, 26). Metformin lowers CVD risk by improving insulin sensitivity (36, 
42) and reducing hyperglycemia and body weight (10, 11). It has been suggested that 
individuals with IGT and at least 1 CVD risk factor (e.g. hypertension, triacylglycerol, low 
HDL, hyperglycemia, etc) be considered for metformin treatment while participating in a 
regular exercise program (47). However, no study has determined the efficacy of combining 
metformin with exercise training on CVD risk factors in individuals with IGT. We previously 
showed that metformin blunted the effects of training on insulin sensitivity in individuals with 
IGT (Chapter 4). Whether the combined treatment opposes the reduction in the level of CVD 
risk factors remains unclear. Therefore, the purpose of this study was to determine the 
effects of combining metformin plus exercise training on reducing the levels of CVD risk 
factors in men and women with IGT, compared to either treatment alone. Given the blunting 
effects of metformin on training induced improvements in insulin sensitivity, we hypothesized 
that the combined treatment would oppose the reduction in the levels of CVD risk factors 
compared to either treatment alone.  
 
Methods 
Overview: In a double-blind, placebo-controlled study design, 32 men and women with 
impaired glucose tolerance (IGT) were enrolled in this study. Cardiovascular disease (CVD) 
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risk factors were defined as: body weight, blood pressure, blood lipids (triacylgylcerol, total 
cholesterol, high density and low density lipoproteins), and C-reactive protein. Prior to 
testing, individuals were assigned to either: placebo (P), metformin (M), exercise training 
plus placebo (EP) or exercise training plus metformin (EM).  
Subjects: Subjects (characteristics in Table 7.1) were non-smoking, weight stable (<5% 
weight change over last 3mo) and free of CVD or type 2 diabetes. Individuals on blood 
pressure (M; n = 1; EP; n = 1; EM; n = 3) or cholesterol (M; n = 1; EP; n = 1; EM; n = 1) 
medication were enrolled and asked to continue treatment throughout the study. Subjects 
were excluded from the study if they had any underlying contraindications to metformin (e.g. 
respiratory disease, heart failure, renal and hepatic disease). All subjects were verbally 
briefed about the study and signed informed consent documents approved by the 
Institutional Review Board at the University of Massachusetts Amherst.  
OGTT Screening: An oral glucose tolerance test (OGTT) was used to determine if subjects 
had impaired glucose tolerance. After a minimum 5-hour fast, blood samples were taken 
from a forearm vein. Subjects consumed 75 grams of glucose and blood samples were 
collected 2 hours later. All subjects had impaired glucose tolerance (IGT; 2-hour glucose 
concentrations between 7.8-11.1mmol/L or 140-199mg/dl). Subjects with IGT who had 
fasting glucose concentrations between 5.5-6.9mmol/L (100-125mg/dl) were also included.  
Metabolic syndrome: Subjects meeting the ATP III criteria were also considered to have the 
metabolic syndrome (23). There were similar numbers of individuals with the metabolic 
syndrome in each condition (M = 6; EP = 7 and EM = 6). 
Preliminary testing: Time to exhaustion was used to characterize cardio-respiratory fitness 
using a continuous progressive exercise test on a cycle ergometer (SensorMedics 800, 
Yorba Linda, CA) (41). One repetition max (1-RM) tests were performed in subjects 
assigned to EM and EP. Subjects performed a progressive resistance exercise test for the 
chest press, latissimus pull down, leg press, bicep curl, triceps pushdown, and upright rows. 
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Weight lifted was considered maximum if proper technique could be maintained throughout 
the full range of motion.  
Metformin or Placebo protocol: Pills were administered to the subjects and they were 
instructed to take metformin or placebo with food in order to minimize potential side effects. 
Subjects started treatment with 500 mg/d of metformin. The dose was increased 500 mg/d 
each week until a clinical dose of 2000 mg/d was reached by week 4. Subjects remained at 
this dose for the last 8 weeks of the 12 week protocol. 
Exercise Training: The training protocol was previously described (see Chapter 4), but in 
short, subjects exercised 3 days/week for 60-75 minute per session (approximately 
190minutes/week total). Subjects cycled for 45 minutes at 70% of their pre-training heart 
rate peak 3days/week, and performed whole-body resistance exercise at 70% of the 
subject’s 1-RM 2days/week. Pedometers (Omron HJ112) were provided to all subjects at 
week 0, week 6 and week 12 to characterize habitual ambulation. Pedometers were worn 
around the waistband for 7 consecutive days and the data were averaged for analysis.  
Body Weight & Waist Circumference: Body weight was recorded without shoes to the 
nearest 0.1kg on a calibrated scale. Body weight was recorded in the morning fasted for the 
first and last measurement. Additional measurements were taken bi-weekly at consistent 
times of day for each subject. Waist circumference was measured with a plastic tape 
measure to the nearest 0.25cm approximately 2cm above the umbilicus in the standing 
position. Bi-weekly waist circumference measures were taken at the same time as body 
weight. Food intake was assessed using 3-day food journals. Subjects selected 3 days (one 
regular and 2 irregular days) at week 0 and kept the same 3 days through the entire study. 
Food journals were analyzed (by the same investigator S.C.) using a commercially available 
software program (Fitday, El Segundo, California). The 3-day food journal was averaged to 
provide an estimated of caloric intake at week 0, 6, and 12.  
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CVD risk factor collection: Subjects were provided food (55% carbohydrate, 30% fat, and 
15% protein) 24 hours prior to pre- and post-testing. After an overnight fast, subjects 
reported to the laboratory. Systolic (SBP) and diastolic (DBP) blood pressure were 
determined following a minimum 5-10 minute quiet sitting period and measurements were 
standardized to the left arm using an automated system (Mark of fitness, Inc., Shrewsbury, 
NJ). After these measures, indwelling catheters were placed in a superficial vein of a 
forearm and baseline blood samples were collected in 3 mL syringes. Plasma samples for 
the analysis of glucose were transferred to vacutainers containing sodium fluoride to inhibit 
glycolysis. Plasma samples for the analysis of total cholesterol (TC), high-density 
lipoproteins (HDL), and triacylglycerol (TAG) were collected in vacutainers containing the 
anticoagulant EDTA. Serum samples for the analysis of C-reactive protein (CRP) were 
collected in vacutainers containing the serum separator SST. 
Plasma analysis: Plasma glucose, TC and HDL concentrations were determined 
enzymatically (GL5 Analyzer, Analox Instruments, Lunenberg, MA). TAG concentrations 
were measured by colorimetic assay (Sigma Alrich, St. Louis, MO). CRP concentrations 
were measured using high-sensitivity ELISA kit (Diagnostic Systems Laboratory, Webster, 
TX).  
Calculations: Mean arterial pressure (MAP) was calculated as: MAP = 2/3(DBP) + (1/3SBP) 
(40). The cardiac risk ratio was calculated as total cholesterol divided by HDL (32). Low 
density lipoprotein (LDL) concentrations were estimated using the Friedwald equation (LDL 
= TC – HDL – (TG* 0.2) (21).  
Statistical Analysis:  Data were analyzed using the R statistical software package (version 
2.4.0, The R foundation, Vienna, Austria, 2006). Baseline subject characteristics were 
measured between conditions by a one-way analysis of variance (ANOVA). There was no 
statistical difference in any baseline value except for DBP. Using baseline DBP as a co-
variate did not affect the response to the treatments. All other condition means were 
    
137 
analyzed before and after the intervention with a 2-way (condition by test) repeated 
measures ANOVA. Because baseline CRP concentrations were not normally distributed, the 
data were log transformed for statistical analysis. When there was a significant condition by 
test interaction, Tukey’s Post hoc analysis was used to detect between conditions 
differences and paired t-tests were used to compare within condition differences. Paired- t-
tests were used to determine changes within the treatment conditions for the metabolic 
syndrome Z-score and ATP III score as described previously (30). Sex specific Z-scores 
were used to describe the differences in ATP III criteria between men and women. The 
equations used were: Z-score =  [(40-HDL)/10.7] + [(TAG-150/88.5)] + [(FPG-100)/11.9] + 
[(WC-102)/14.3] + [(MAP-100)/8.8] for men, and Z-score = [(50-HDL)/11.0] + [(TAG-
150/88.5)] + [(FPG-100)/11.9] + [(WC-88)/13.6] + [(MAP-100)/8.8] for women. McNemar’s 
test was used to assess the prevalence of the metabolic syndrome (i.e. yes/no) after each 
treatment. Pearson’s correlation was used to examine relationships between weight loss, 
cardio-respiratory fitness, CVD risk factors and insulin sensitivity (Chapter 4). Significant 
differences were accepted as ! ! 0.05.   
 
Results 
Fitness and strength characteristics. Exercise training plus metformin (EM) and exercise 
training plus placebo (EP) increased time to exhaustion by approximately 15-20% compared 
to placebo (P; p < 0.05; P: pre = 10.3 ± 1.1 vs. post = 10.3 ± 1.1; M: pre = 12.0 ± 0.7 vs. post 
= 11.0 ± 0.6; EP: pre = 13.4 ± 1.2 vs. post = 15.1 ± 1.2; EM: pre = 13.0 ± 0.9 vs. post = 16.3 
± 1.3). EP and EM both increased leg strength (EP: pre = 205.0 ± 11.8 vs. post = 241.4 ± 
12.8; EM: pre = 214.0 ± 18.2 vs. post = 247.1 ± 18.8; time effect: p < 0.05), but EM 
increased chest strength more than EP (EP: pre = 112.5 ± 10.1 vs. post = 126.5 ± 10.7; EM: 
pre = 91.3 ± 7.5 vs. post = 130.0 ± 8.3; p < 0.05).  
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Weight loss & Central Obesity. Metformin (M) and EM decreased body weight more than P 
and EP (p < 0.05; Figure 7.1). All treatments decreased waist circumference by 2-3% 
throughout the intervention (time effect: p < 0.01; Figure 7.2).  
Blood pressure and C-reactive protein (CRP). Compared to baseline, SBP and DBP 
increased with placebo (P; p < 0.05). M and EP lowered SBP (p < 0.01), but all 3 treatments 
lowered DBP compared to P (p < 0.05; Table 7.2). Given the changes in blood pressure, M 
and EP decreased MAP with compared to P (p < 0.05; Table 7.2). EP and M lowered CRP 
by approximately 20% compared to P (EP: p < 0.05 and M: p = 0.06 respectively; Table 
7.4).  
Fasting Hyperglycemia: Plasma glucose concentrations were previously reported (see 
Chapter 4), but are shown here as condition mean differences (i.e. change between pre and 
post measures). Exercise training and/or metformin had no effect on fasting glucose 
concentrations (P = -0.1 ± 0.2mM; M = -0.2 ± 0.3mM; EP = 0.0 ± 0.3mM; EM = -0.4 ± 
0.2mM).  
Triacylglycerol (TAG) and Cholesterol: Exercise and/or metformin lowered TAG by 
approximately 13% (time effect: p < 0.05; Table 7.3) but had subtle effects on total 
cholesterol (time effect: p = 0.08) or LDL. All 3 treatments increased HDL concentrations by 
8-13% compared to P (M or EP; p < 0.05 and EM; p = 0.06; Table 7.3). Each treatment also 
improved the cardiac risk ratio (p < 0.05; Table 7.3).  
Metabolic syndrome: Exercise training and/or metformin reduced the metabolic syndrome Z-
score compared to baseline (EP; p = 0.07 and EM or M; p < 0.05). Although each treatment 
reversed the metabolic syndrome (M = 6 to 1; EP = 7 to 4; EM 6 to 3; p < 0.05), only EP and 
M reduced ATP III score (p < 0.05) compared to baseline (Table 7.4). 
Correlation Analysis: Reductions in TAG concentrations were associated with enhanced 
insulin sensitivity (r = -0.60; p < 0.05). Decreased CRP concentrations were associated with 
reductions in systolic blood pressure (r = 0.46; p < 0.05).  
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Discussion 
Overview. Our findings indicate that metformin may blunt the full effects of training on 
lowering the cardiovascular disease risk factors, systolic blood pressure and C-reactive 
protein, in individuals with impaired glucose tolerance (IGT). 
Effects of exercise and/or metformin on weight & central obesity. Although the effects of 
training on weight loss are mixed (7, 14, 31), metformin commonly promotes weight loss 
upwards of 5kg (see review (13)). Some, (2, 9, 38) but not all (45), show greater weight loss 
when metformin is added to lifestyle modification. In this study, exercise training plus 
metformin promoted more weight loss than training, but not metformin. Previously we 
showed that the weight loss with metformin was comprised of both fat and fat-free mass, 
whereas training plus metformin was only body fat (Chapter 4). Maintenance of muscle 
mass may be important for continued weight loss success (27, 39). The exact mechanism 
by which metformin reduces body weight remains unclear, but it is either related to 
increased energy expenditure or reduced caloric intake. Ambulation and resting metabolic 
rate did not change after any treatment (see S.C.1 and S.C.2), suggesting that metformin 
did not increase energy expenditure. Although metformin, with or without exercise, non-
significantly lowered caloric intake, we observed a significant correlation between weight 
loss and reduced caloric intake (see S.C.3 and S.C.4). Thus, these observations suggest 
that reductions in caloric intake may explain the effects of metformin on weight loss (35, 44, 
53).  
Effects of exercise and/or metformin on blood pressure and C-reactive Protein. Although 
exercise is known to lower blood pressure (3), the effects of metformin are mixed (15, 22, 
34, 36). Few have characterized the combined treatments effects on blood pressure (1, 16).  
We found that metformin blunted the effects of exercise on lowering systolic, but not 
diastolic, blood pressure in individuals with IGT. It is difficult to directly compare these 
previous studies (1, 16) to our own because of differences in the subjects underlying 
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pathophysiology, exercise protocols, dietary manipulation, and interaction of other 
medications. Because we observed no associations between weight loss, reductions in 
central obesity, cardio-respiratory fitness, or insulin sensitivity and systolic blood pressure, 
our findings suggest that alternative mechanisms explain the blunting effects of the 
combined treatment on lowering systolic blood pressure.  
C-reactive protein (CRP), a marker of vascular inflammation, has been associated 
with elevated blood pressure in individuals with IGT (24). Consistent with previous work (6, 
25, 26, 49), we demonstrated that metformin or exercise training alone reduced CRP 
concentrations. However, combining treatments had no effect on CRP concentrations. We 
observed a significant correlation between CRP and systolic blood pressure, suggesting that 
reduced inflammation was associated with lower systolic blood pressure. It is unclear how 
the combined treatment blunted reductions in CRP concentrations or systolic blood 
pressure, but it may be related to nitric oxide synthesis (51), which altered vascular 
reactivity. Whether reduced AMPK activation in tissues other than skeletal muscle, such as 
the endothelium, is responsible for altered nitric oxide production and accounts for the 
blunting effects of the combined treatment on systolic blood pressure warrants further 
investigation (37, 48). 
Effects of exercise and/or metformin on triacylglycerol. Exercise or metformin are known to 
lower triacylgylcerol concentrations (18). Most have characterized the effects of lifestyle 
modification and metformin on triacylglycerol (1, 2, 9). Andrealis et al (1) indicated that 
combining metformin with lifestyle modification had similar effects to lifestyle modification 
alone on lowering TAG in individuals with IGT. In contrast, metformin with lifestyle 
modification reduced TAG concentrations more than lifestyle modification alone in 
overweight insulin resistant adolescents (2, 9). In the current study, exercise training and/or 
metformin lowered TAG concentrations, which were associated with enhanced insulin 
sensitivity (r = -0.60; p < 0.05 (see S.C.5). The obese insulin resistant adolescents may 
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have responded better to metformin with lifestyle modification than adults with IGT because 
they were more insulin sensitive based on glucose tolerance. Severe insulin resistance 
could result in higher TAG concentrations through persistent inhibition of lipoprotein lipase. 
Thus, our results suggest that exercise and/or metformin may reduce the delivery of fatty 
acids to skeletal muscle and improve insulin sensitivity (33). 
Effects of exercise and/or metformin on cholesterol. Although exercise or metformin raise 
HDL concentrations (15, 17, 42), the effectiveness of each treatment on lowering total 
cholesterol and LDL is mixed (15, 17, 36, 52). Few have characterized the effects of 
exercise plus metformin on total cholesterol, HDL, or LDL. Andrealis et al (1) reported that 
adding metformin to lifestyle modification further reduced total cholesterol and LDL 
concentrations in individuals with IGT. Driscoll et al (16) demonstrated that the exercise 
training plus metformin had no effect on total cholesterol, LDL or HDL compared to 
metformin alone in HIV infected patients. In this study, we demonstrated that exercise 
and/or metformin raised HDL concentrations and non-significantly lowered total cholesterol 
and LDL. Elevated HDL concentrations are consistent with our current reductions in TAG 
concentrations (33). A possible reason we did not detect statistically significant reductions in 
total cholesterol or LDL is because of inter-subject variability between conditions. Only 3 
subjects in each treatment condition had total cholesterol concentrations above the CVD risk 
factor threshold of 5.2mM (i.e. 200 mg/dl). We observed a relationship between elevated 
baseline concentrations and the response to exercise and/or metformin, suggesting that 
individuals with elevated cholesterol concentrations responded “better” to the exercise 
and/or metformin than individuals with cholesterol values within normal range (4). 
Nonetheless, exercise and/or metformin improved the cardiac risk ratio (i.e. total 
cholesterol:HDL), suggesting that these treatments may reduce certain aspects of CVD risk 
in individuals with IGT (32).  
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Effects of exercise and/or metformin on the metabolic syndrome: Although lifestyle 
modification or metformin reduces the incidence of the metabolic syndrome (43), few have 
assessed the combined treatments effect on lowering metabolic syndrome risk factors (1). 
Andreadis et al (1) demonstrated that adding metformin to lifestyle modification reduced the 
incidence of the metabolic syndrome more than lifestyle modification alone. We showed that 
exercise training and/or metformin reduced the metabolic syndrome Z-score, indicating that 
all treatments lowered the severity of the metabolic syndrome. In line with this, all treatments 
reduced the incidence of the metabolic syndrome. However, our findings indicated that only 
exercise training or metformin reduced the ATP III score, implying that these treatments 
reversed more metabolic syndrome risk factors than the combined treatment.  The 
combined treatments blunting effect on reversing the ATP III score was primarily explained 
by blunting reductions in systolic blood pressure (data not shown). Thus, our findings 
suggest that combining metformin with exercise may oppose the reversal of some metabolic 
syndrome risk factors in individuals with IGT and potentially alter the incidence of the 
metabolic syndrome in individuals with IGT.  
Limitations. Some aspects to this study may limit our interpretation of the data. First, 
pedometers were used to assess habitual physical activity. It is possible that activity 
intensity increased or individuals stood/took more breaks in sedentary behavior, which 
increased energy expenditure and contributed to the weight loss seen with metformin. 
Second, error with food recording or quantification might have limited our ability to detect 
statistical significance. Since subjects selected the days they recorded food intake, their 
overall eating patterns may have been affected. Lastly, we used an aerobic and resistance 
training program combined with 2000mg/d of metformin. Thus, our findings may not be 
applicable to different exercise modes/intensities combined with other doses of metformin.  
Conclusion. Metformin and/or exercise training lowered blood pressure and triacylglycerol 
as well as raised HDL concentrations in individuals with impaired glucose tolerance. The 
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novel observation in this study is that combining metformin with exercise training did not 
promote additive effects on any cardiovascular disease risk factor measured in this study. 
Metformin may blunt the full effects of exercise training on lowering systolic blood pressure 
and C-reactive protein. If these findings are reproducible, then these data may have adverse 
clinical consequences for lowering cardiovascular disease risk in individuals with IGT and/or 
the metabolic syndrome. 
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Figure Captions 
 
Figure 7.1. Change in body weight over the 12 week protocol. ^Significant effect of M 
and EM compared to P (p < 0.05). Significant effect of M(*) and EM(‡) compared to 
baseline (p < 0.05). Values are reported as mean change. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^ * * 
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Figure 7.2. Change in waist circumference over the 12 week intervention. *Significant 
effect of time (p < 0.05). Values are reported as mean change. 
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Table Captions 
 
Table 7.1. Subject Characteristics. Beat per minute (bpm). No significant differences 
were observed between conditions. Values are mean ± standard deviation. 
 
 P M EP EM 
Sex 6F/2M 4F/4M 5F/3M 5F/3M 
Age (year) 49.8 ± 10.9 45.0 ± 7.5 45.4 ± 8.0 49.1 ± 6.6 
BMI (kg/m2)  34.0 ± 6.3 33.9 ± 5.2 33.5 ± 4.1 31.2 ± 5.3 
Body weight (kg)  93.5 ± 6.0 101.5 ± 5.8 95.5 ± 5.1  94.1 ± 6.5 
VO2 peak (ml/kg-ffm/min) 41.2 ± 8.2 43.4 ± 10.3 45.7 ± 9.4 48.2 ± 4.9 
Fasting Glucose (mM) 5.8 ± 0.6 5.6 ± 0.6 5.4 ± 0.4 5.5 ± 0.8 
2-hour Glucose (mM) 9.4 ± 1.3 9.3 ± 1.5 10.2 ± 1.0 9.5 ± 1.7 
Steps per day 4984 ± 2104 5028 ± 2047 5871 ± 1912 6444 ± 1529 
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Table 7.2. SBP (systolic blood pressure), DBP (diastolic blood pressure), and MAP 
(mean arterial pressure). *Significant compared to baseline; p < 0.05. ^ Compared to P 
(p < 0.05). Values are means ± standard error of the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Condition Test SBP 
(mmHg) 
DBP 
(mmHg) 
MAP 
(mmHg) 
Pre 126.1 ± 3.1 76.8 ± 2.8 92.3 ± 0.85  
P 
Post 134.5 ± 5.4* 82.9 ± 2.3* 99.1 ± 1.2 
Pre 134.0 ± 3.8 82.9 ± 2.9 98.9 ± 1.2  
M 
Post 123.9 ± 2.7*^ 78.9 ± 1.7^ 92.9 ± 0.6^ 
Pre 136.8 ± 2.4 88.1 ± 2.1 103.3 ± 0.7  
EP 
Post 128.0 ± 3.9^ 81.4 ± 2.0^* 95.9 ± 1.0*^ 
Pre 126.8 ± 5.6 82.1 ± 2.9 96.0 ± 1.3  
EM 
Post 126.3 ± 5.1 78.5 ± 2.5^ 93.3 ± 1.2 
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Table 7.3. TC (total cholesterol), LDL (low-density lipoprotein), HDL, (high density 
lipoprotein), TAG (triacylglycerol), CRP (C-reactive protein), CRR (cardiac risk ratio). * 
Significant compared to baseline; p < 0.05. "Significant effect of test; p < 0.05. ^ 
Compared to P (p < 0.05). $Compared to P (p =0.06). Values are means ± standard 
error of the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Condition Test TC 
(mM) 
LDL 
(mM) 
HDL 
(mM) 
CRR " TAG 
(mM) 
CRP 
(ng/ml) 
Pre 4.4 ± 0.2 2.3 ± 0.2 1.5 ± 0.1 3.1 ± 0.2 1.4 ± 0.2 90.2 ± 20.8  
P 
Post 4.5 ± 0.2 2.5 ± 0.2 1.4 ± 0.1 3.4 ± 0.2 1.5 ± 0.2 114.3 ± 33.2 
Pre 4.8 ± 0.3 2.2 ± 0.4 1.5 ± 0.1 3.3 ± 0.3 2.4 ± 0.4 100.4 ± 19.3  
M 
Post 4.5 ± 0.4 1.9 ± 0.3 1.7 ± 0.1^ 2.7 ± 0.2^ 1.9 ± 0.3 94.5 ± 30.2$ 
Pre 4.9 ± 0.3 2.1 ± 0.1 1.6 ± 0.1 3.1 ± 0.2 2.4 ± 0.2 72.0 ± 19.9  
EP 
Post 4.7 ± 0.3 2.0 ± 0.2 1.7 ± 0.1^ 2.8 ± 0.2* 2.1 ± 0.3 55.7± 22.0*^ 
Pre 4.9 ± 0.5 2.4 ± 0.5 1.5 ± 0.1 3.2 ± 0.3 1.9 ± 0.4 64.0 ± 17.1  
EM 
Post 4.5 ± 0.3 2.1 ± 0.3 1.7 ± 0.1*$ 2.8 ± 0.3*^ 1.6 ± 0.3 58.5 ± 15.2 
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Table 7.4. Effect of each condition on metabolic syndrome Z-Score and ATP III score. 
*Pre to post observation was statistically different from baseline; p < 0.05. $p = 0.07. 
Values are mean ± standard error of the mean.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Condition Test Z-score ATP III 
Pre 1.40 ± 0.53 3.50 ± 0.11  
M 
Post -1.56 ± 0.22*   2.00 ± 0.12* 
Pre 0.52 ± 0.36 3.57 ± 0.08  
EP 
Post -1.04 ± 0.41$   2.28 ± 0.20* 
Pre 0.68 ± 0.42 3.16 ± 0.08  
EM 
Post -1.00 ± 0.43* 2.50 ± 0.20 
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Abstract  
Exercise or metformin is suggested to reduce the risk for developing type 2 diabetes. 
Combining these treatments may confer greater benefits on insulin sensitivity and 
cardiovascular disease risk as well as impact exercise capacity. In this article we highlight 
the recent progress in the literature on this topic because understanding the effects of 
combining exercise and metformin may provide better insight to preventing/delaying type 2 
diabetes.  
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Introduction 
In the United Sates (U.S.), approximately 25 million individuals have type 2 diabetes 
(1). The mortality and medical costs associated with type 2 diabetes makes this disease an 
important public health concern. One approach to reduce the incidence of type 2 diabetes is 
to specifically target individuals at risk (e.g. insulin resistant, metabolic syndrome, 
prediabetes). Although the exact cause for type 2 diabetes remains unknown, a key 
component underlying this disease is insulin resistance (see below). Thus, identifying 
treatments that enhance insulin sensitivity may be advantageous for reducing the incidence 
of diabetes.  
Several large clinical trials have shown the beneficial effects of lifestyle modification 
(i.e. low-fat diet and increased physical activity) on delaying/preventing type 2 diabetes (7, 
37, 50)). However, few have determined the independent effects of exercise on diabetes 
prevention (49). Because exercise tolerance might be impaired in individuals at risk for type 
2 diabetes, pharmacological interventions may also be helpful to promote the prevention of 
diabetes. Metformin, a common anti-diabetes medication, has been shown to reduce the 
incidence of type 2 diabetes and is suggested to be combined with regular exercise (46). 
There are few studies however characterizing the efficacy of combining exercise plus 
metformin on metabolic health (8, 18, 24, 32, 43, 54). If the interaction between exercise 
and metformin are additive, then combining these treatments deserves to be encouraged. 
However, if one treatment attenuates the other, combining treatments would be 
counterproductive. Our recent work showed that metformin attenuated the effects of 
exercise on metabolic health in individuals with insulin resistance, suggesting to us that 
exercise alone may be “better” than the combined treatment (54) (Chapter 4 and 7). This 
review article will focus on recent data centered on the efficacy of combining exercise with 
metformin on insulin sensitivity, cardiovascular disease risk, and exercise capacity in 
individuals at risk for diabetes.  
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Insulin resistance affects blood glucose regulation.   
Insulin resistance is a key component in the development of hyperglycemia and type 
2 diabetes (51). Although blood glucose concentrations are affected by distinct tissues in the 
fasted (e.g. brain and kidney) and insulin stimulated state (e.g. digestive tract, liver, muscle 
and adipose tissue), blood glucose homeostasis is in general a balance between 
endogenous glucose production and glucose uptake (Figure 8.1). Endogenous glucose 
production consists of hepatic glucose production with small contributions from the kidney 
(approximately 15-25%) (3). Glucose uptake into peripheral tissues, such as skeletal muscle 
(approximately 80%), is primarily a result of insulin. The inability of insulin to suppress 
glucose production and/or increase glucose uptake in the aforementioned tissues is referred 
to as insulin resistance. Insulin resistance often leads to metabolic abnormalities that 
include, but are not limited to, dyslipidemia, hypertension, and hyperglycemia (51). As a 
result, insulin resistance not only increases risk for type 2 diabetes but also for 
cardiovascular disease (19). Thus, identifying treatments that enhance insulin sensitivity is 
critical to the prevention of type 2 diabetes and cardiovascular disease.  
 
Exercise or Metformin affects Insulin Sensitivity 
It has been well established that exercise enhances insulin sensitivity in individuals 
across the glucose tolerance continuum (i.e. normal glucose tolerant to type 2 diabetes) 
(see reviews: (26, 30)) and contributes to the lowering blood glucose concentrations (27). 
Metformin is an orally administered drug that is routinely used to lower blood glucose 
concentrations in individuals with type 2 diabetes. More recently, metformin has been 
considered a useful agent in those with prediabetes (52). Although metformin improves 
whole-body insulin sensitivity in some (16, 40), but not all studies (54, 56, 59), it’s 
mechanism of action is different than exercise. The primary tissue affected by metformin is 
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the liver (see review: (35)), whereas exercise largely improves skeletal muscle glucose 
uptake (36).  
 
Does combining exercise with metformin have additive effects on insulin sensitivity? 
Because each treatment targets a different tissue (i.e. skeletal muscle vs. liver), we 
hypothesized that combining treatments would have an additive effect on insulin sensitivity. 
Recently, our lab determined the effect of combining exercise plus metformin on whole-body 
insulin sensitivity in overweight, sedentary, insulin resistant individuals following a single 
bout of exercise (54). Metformin or placebo was provided to all participants for 2-3 weeks at 
2000mg/d, after which individuals exercised for approximately 30 minutes at 65% and 10 
minutes at 85% VO2peak. Insulin sensitivity was measured approximately 4 hours post-
exercise by the hyperinsulinemic-euglycemic clamp. The results indicated that exercise 
alone enhanced whole-body insulin sensitivity by 54% compared to baseline, but when 
metformin was added to exercise there was no change in insulin sensitivity (Figure 8.2). 
Because 5-adenosine monophosphate kinase (AMPK) has been suggested to be an 
important regulator of post-exercise insulin sensitivity (20, 44, 45), we also assessed the 
combined treatments effect on AMPK in skeletal muscle. Metformin blunted the effects of 
exercise on skeletal muscle APMK activation, suggesting that combining exercise and 
metformin may attenuate the action of cellular mediators to enhance insulin sensitivity. The 
clinical impact of these findings (54) however remained unclear. Although individuals with 
insulin resistance are at risk for type 2 diabetes, individuals with prediabetes are of greater 
concern because of the increased rates of progression to type 2 diabetes (37). In addition, 
repeated bouts of exercise are recommended to reduce diabetes risk (15). Therefore, from a 
practical standpoint, it was important to assess the effect of training plus metformin on 
metabolic health in individuals with prediabetes.  
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Our lab designed a study to determine the effects of combining exercise training and 
metformin on insulin sensitivity in men and women with prediabetes (Chapter 4). For 12 
weeks, individuals with prediabetes were assigned to 1 of 4 groups: placebo, metformin, 
exercise training plus placebo, or exercise training plus metformin. All individuals received 
either metformin at 2000mg/d or placebo, while half participated in a progressive aerobic 
and resistance training program at 70% of their heart rate peak and 1-repetition max. 
Whole-body insulin sensitivity was measured approximately 28-30 hours post-exercise by 
the hyperinsulinemic euglycemic clamp. The results indicated that metformin or exercise 
training enhanced whole-body insulin sensitivity by approximately 55% and 90% compared 
to baseline, respectively. Adding metformin to exercise training enhanced whole-body 
insulin sensitivity by only 65% compared to baseline (Figure 8.3), implying that metformin 
blunted the improvement in insulin sensitivity after training.  
Although not quite statistically significant, exercise training plus placebo enhanced 
insulin sensitivity by approximately 30% more than either metformin, with or without training 
(Chapter 4). We may not have detected statistical differences between groups because of 
the inter-subject variability introduced by including different subsets within the prediabetes 
category. Prediabetes includes impaired glucose tolerance (IGT), impaired fasting glucose 
(IFG) concentrations, or both (i.e. IFG+IGT). Peripheral insulin resistance (e.g. skeletal 
muscle) is a primary defect in individuals with IGT, whereas hepatic and peripheral insulin 
resistance characterizes individuals with IFG+IGT (2). Individuals with IFG+IGT might be 
expected to respond more favorably to exercise and/or metformin than individuals with IGT 
because metformin primarily affects the liver and exercise largely affects skeletal muscle. 
Subgroup analysis indicated that all treatments accentuated insulin sensitivity in individuals 
with IFG+IGT compared to IGT alone (Chapter 4). These findings are in line with current 
recommendations suggesting many Americans with IFG+IGT be considered for metformin 
while exercising (52). Regardless, our findings indicate that the combined treatment blunted 
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the improvement in insulin sensitivity from exercise in people with IGT, in the absence or 
presence fasting hyperglycemia (i.e. IFG + IGT). This suggests that exercise plus metformin 
may impair the optimal benefit of exercise on insulin sensitivity in individuals with IGT.  
Our results are not the first to show that the combined treatment does not have 
additive effects on insulin sensitivity (25, 33, 50, 55). The direct comparison between studies 
is complicated by differences in the subject population (e.g. animal vs. human or 
prediabetes vs. type 2 diabetes), measurement of insulin sensitivity (e.g. surrogate or 
clamp), and exercise protocols (e.g. recommended vs. supervised). However, the 
consistency of the findings across methods, protocols, and subjects strengthens the 
conclusion that metformin does not add but opposes the effects of exercise on insulin 
sensitivity (54) (Chapter 4).  
Although we did not design our training studies (Chapter 4 and 7) to determine the 
cellular mechanism by which metformin and/or exercise affected insulin sensitivity, but the 
combined treatments blunting effect on insulin sensitivity may be related to altered 
peripheral adaptations. We previously showed in human skeletal muscle that short-term 
metformin treatment attenuated AMPK activation (54). If this effect persisted throughout 
exercise training, then it is possible that the attenuated AMPK minimized adaptations in 
skeletal muscle (e.g. GLUT4, hexokinase, glycogen synthase, etc) favoring glucose uptake 
(28). It is unclear why metformin would blunt the activation of AMPK, but it may be related to 
the antioxidant properties of metformin. Ristow et al (53) demonstrated that antioxidants 
blunted the exercise training effect on enhancing insulin sensitivity in overweight men. 
Attenuated insulin sensitivity was associated with bunted mitochondrial adaptations (e.g. 
PGC1-alpha, citrate synthase, etc). Since metformin might reduce reactive oxygen species 
(ROS) (6), it is tempting to speculate in our study (Chapter 4) that metformin reduced ROS 
production and minimized AMPK activation when combined with exercise training. Further 
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work is required to elucidate the cellular mechanisms by which metformin acts on skeletal 
muscle adaptations to better understand its effects on whole-body insulin sensitivity. 
 
Does combining exercise with metformin have additive effects on cardiovascular 
risk? 
Insulin resistance is associated with several cardiovascular disease (CVD) risk 
factors, including: hyperglycemia (51), hypertension (13), dyslipidemia (38) and 
inflammation (19). Because metformin attenuated the effects of exercise on enhancing 
insulin sensitivity, we thought it would be relevant to determine the combined treatments 
effect on hyperglycemia, blood pressure, dyslipidemia, and inflammation in individuals with 
prediabetes (Chapter 7). 
 After 12 weeks, metformin, exercise training, or the combined treatment had no 
effect on fasting glucose concentrations (Chapter 4). Although metformin would be expected 
to lower fasting glucose concentrations (29), a likely reason why we did not detect 
decreased glucose concentrations is because most of our subjects had fasting 
normoglycemia (i.e. IGT only). Subgroup analysis indicated that only metformin, with or 
without training, lowered fasting glucose concentrations in individuals with IFG+IGT (Figure 
8.4). This suggests that metformin is mostly effective at lowering fasting glucose 
concentrations when they are elevated (39). Thus, if the primary outcome is management of 
blood glucose concentrations, then our findings indicate that metformin, with or without 
exercise, may be most appropriate choice for individuals with mild fasting hyperglycemia 
(i.e. 100-125mg/dl; IFG+IGT).  
We found that metformin or exercise training lowered systolic blood pressure and C-
reactive protein (CRP) by approximately 7% and 25%, respectively, in men and women with 
prediabetes. The combined treatment blunted reductions on systolic blood pressure and 
CRP by 0% and 8%, respectively (Chapter 7). Others have found that combining metformin 
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and lifestyle modification (i.e. low-fat diet/increase physical activity) has little or no further 
improvement in blood pressure (4, 5, 14). In contrast to our findings, Driscoll et al (17) 
demonstrated that the combination of exercise training with metformin for 12 weeks lowered 
systolic blood pressure compared to metformin alone in HIV infected patients. CRP was not 
assessed in the HIV infected patients so it is not possible to know if differences in vascular 
inflammation account for the differences in systolic blood pressure between studies. We 
found a moderate correlation between CRP and systolic blood pressure (Chapter 7), 
implying that reduced inflammation was associated with lower systolic blood pressure. 
Reductions in systolic blood pressure and CRP were not associated with changes in insulin 
sensitivity, suggesting that the blunting effect of metformin on reducing CRP and systolic 
blood pressure was independent of improved insulin sensitivity. It is possible that CRP 
affected nitric oxide production, which affected vascular reactivity (58). Thus, the blunting 
effect of exercise and metformin on CRP and systolic blood pressure may be, to some 
extent, mediated by decreased nitric oxide production. Whether reduced AMPK activation in 
tissues other than skeletal muscle, such as the endothelium, is responsible for altered nitric 
oxide production remains to be seen (41, 54). Further work is required to elucidate the 
mechanism by which combining metformin with exercise affects blood pressure and CRP 
concentrations in individuals with insulin resistance since this has potential implications for 
hypertension and cardiovascular health.  
We found that metformin and/or exercise training lowered triacylglycerol (TAG) and 
raised HDL (Chapter 7), suggesting that all three treatments have some effects at improving 
blood lipids. Our findings are consistent with previous work (4) that showed the combination 
of metformin with lifestyle modification had similar effects on lowering TAG in individuals 
with prediabetes. In contrast, metformin with lifestyle modification reduced TAG 
concentrations more than lifestyle modification alone in overweight insulin resistant 
adolescents (5, 14). Potentially important differences in age, insulin resistance, and exercise 
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protocols may have affected the response to the intervention (5, 14, Chapter 4 and 7). 
These findings together, however, indicated that combining metformin with exercise training 
effectively lowers TAG, which may contribute to the reduction in insulin resistance and 
diabetes risk (Chapter 7).  
Although lifestyle modification or metformin reduced the incidence of the metabolic 
syndrome (47), few have assessed the combined treatments effect on lowering metabolic 
syndrome risk factors (4). Andreadis et al (4) demonstrated that adding metformin to lifestyle 
modification reduced the incidence of the metabolic syndrome more than lifestyle 
modification alone. However, our findings indicate that combining metformin and exercise 
does not promote greater cardiovascular health compared to either treatment alone. In fact, 
combining treatments may have blunting effects. In subgroup analysis, we stratified 
individuals according to criteria from the National Cholesterol Education Program ATP III for 
the metabolic syndrome (22). Our results indicated that metformin reversed the metabolic 
syndrome in 5 of 6 individuals, while both training, with or without metformin, reserved the 
metabolic syndrome in 3 of the 6 and 7 individuals respectively (Figure 8.5a). The combined 
treatments blunting effect on reversing the ATP III risk factors were primarily explained by 
blunting reductions in systolic blood pressure (Figure 8.5b, 8.5c, 8.5.d). Thus, our findings 
indicate that the combined treatment is not “better” at reversing the metabolic syndrome and 
that exercise may blunt the effects of metformin. Future work is needed to determine the 
clinical ramifications of combining metformin and exercise on affecting the incidence of 
cardiovascular disease in individuals with the metabolic syndrome. 
 
Does metformin affect exercise capacity? 
Affecting the ability to exercise can have a beneficial or detrimental impact on the 
metabolic response to exercise. Metformin has been shown to increase skeletal muscle 
oxidative enzyme concentrations (57), suggesting an increased ability to consume oxygen 
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and produce energy. Although improving skeletal muscle oxidative capacity may lead to 
improved exercise tolerance, metformin has been reported to inhibit complex I in the 
mitochondria (12, 48). Alterations in the ability of the mitochondria to utilize oxygen may 
detrimentally affect cardio-respiratory fitness and exercise capacity. Since metformin may 
potentially affect energy metabolism, we were interested in determining the effect of 
metformin on exercise capacity.  
We conducted a 7-10 day study to determine the effects of metformin on exercise 
capacity in a group of recreationally active men and women (8). Recreationally active men 
and women were selected to minimize the confounding effects of mitochondrial dysfunction 
in individuals with insulin resistance (34). We found that short-term administration of 
metformin at 2000mg/d reduced VO2peak, heart rate peak and exercise duration by 
approximately 3-5%. This was in contrast to previous work (32) showing no effect of a single 
dose of metformin at 1000mg/d on maximal oxygen consumption in healthy men. A 
potentially important difference between studies is that we provided metformin for 
approximately 1 week at a higher dose (1000 vs. 2000mg/d), which more effectively lowers 
glucose concentrations (21). Thus, our findings may be more representative of the 
individuals chronically exposed to metformin. However, the physiologic relevance of these 
data is limited. If the effect of metformin on attenuating VO2peak persisted over a prolonged 
period time and were replicated in a clinical population, then health professionals would 
potentially need to adjust exercise prescriptions to account for the increased relative 
exercise intensity.  
Malin et al (see Chapter 4) recently compared the effects of combining metformin 
plus exercise training compared to either treatment alone on cardio-respiratory fitness in 
individuals with prediabetes. Although training, with or without metformin, improved 
VO2peak, training with metformin increased VO2peak by approximately 10% whereas 
training alone improved VO2peak by 20%. Thus, metformin non-significantly blunted the 
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effects of training on increasing VO2peak compared to training alone. Training, with or 
without metformin, however similarly increased exercise duration and workload peak 
compared to baseline. Metformin alone had no effect on any maximal cardio-respiratory 
fitness outcome. These findings indicate that metformin has subtle effects on cardio-
respiratory fitness after training in individuals with prediabetes and was consistent with our 
earlier work (9). However, it is worth noting that metformin may improve exercise capacity in 
other clinical populations (31). Taken together, metformin may have a small negative effect 
on maximal oxygen consumption in individuals with prediabetes. Health professionals 
should be cognizant of this potential “side effect” because it could have important 
implications for designing exercise programs. If the blunting effects of metformin on oxygen 
consumption were significant, evaluation of effort and energy metabolism during 
submaximal exercise would be important.  
 
Does metformin affect submaximal exercise metabolism or perception of effort? 
The effects of exercise training on substrate metabolism and perception of effort 
have been well documented (see review: (10)). In short, endurance training reduces the 
perception effort and increases the reliance on fat by sparing muscle glycogen utilization 
during exercise at the same pre-training absolute workload.  
Given the potential effects of metformin on VO2peak (8), a potentially important effect 
of decreased cardio-respiratory fitness when performed at the same absolute workload is an 
increase in the relative intensity of exercise. Exercise at a higher intensity would be 
expected to shift fuel metabolism towards carbohydrate utilization and increase the 
perception of effort. As a result, we designed a study to test the effect of metformin on 
exercise substrate utilization (42).  Metformin was administered for 7-10 days to 
recreationally active men and women. Individuals exercised on a cycle ergometer between 
30-70% of their work peak (Wpeak). Importantly, men and women exercised at the same 
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absolute and relative intensity to determine the independent effects of metformin. Using 
indirect calorimetry, we found that metformin enhanced whole-body fat oxidation (see 
Chapter 5) during exercise by approximately 25% across the range of exercise intensities 
(~30 to 70% Wpeak). Metformin also increased blood lactate concentrations across the 
range of exercise intensities and this correlated with an increased perception of effort. 
Increased fat oxidation was contrary to our original hypothesis (8). From these data, we 
were not able to discern whether metformin restrained carbohydrate metabolism (e.g. 
decreased hepatic glucose output and blood glucose concentrations) thereby indirectly 
elevating fat oxidation or directly enhanced fat oxidation. Our findings were however 
consistent with previous work showing that metformin reduced the “anti-lipolytic 
environment” and favored fat oxidation (23). Whether metformin added to the effects of 
training on fat oxidation during exercise in a clinically relevant population was of significant 
interest. Given that elevated fat oxidation has been suggested to be a potential mechanism 
for increasing insulin sensitivity (11), the potential for the combined treatment to enhance fat 
oxidation and affect insulin sensitivity was intriguing.  
We determined the effects of adding metformin to a 10-week training program on 
substrate metabolism in individuals with prediabetes (Chapter 6). Men and women 
exercised on a cycle ergometer at 60% of their pre-training VO2peak, and we used indirect 
calorimetry and the isotope dilution method to determine fat oxidation and glucose flux 
during exercise. Although training, with or without metformin, lowered heart rate and the 
perception of effort, metformin tended to attenuate the reduction in submaximal oxygen 
consumption (i.e. 55% vs. 50% VO2peak; p = 0.11). However, we found that training, 
independent of metformin, enhanced fat oxidation during exercise. This was somewhat 
surprising given that metformin increased plasma non-esterified fatty acids (NEFA) and 
decreased plasma insulin concentrations, suggesting that metformin enhanced lipolysis. 
However, we used plasma glycerol concentrations as a crude surrogate of lipolysis and 
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demonstrated that training, with or without metformin, had no effect on glycerol 
concentrations. This suggested that lipolysis was not enhanced. A possible explanation for 
this increase in NEFA concentration is that metformin reduced NEFA clearance. Smith et al 
(55) demonstrated that metformin decreased skeletal muscle FATCD36 transporter in 
rodents. Thus, in this study, reduced skeletal muscle clearance of NEFA may have 
explained why metformin increased circulating NEFA concentrations during exercise without 
subsequently enhancing fat oxidation. Future work using palmitate and glycerol tracers 
would be required to determine the effect of metformin on lipid metabolism during and after 
exercise. Using lipid stable isotopes may also clarify the negative associations between 
elevated blood lipids (i.e. NEFA) and insulin sensitivity in our studies ((54) Malin chapter 4). 
If combining metformin with training detrimentally affects insulin sensitivity through 
alterations in lipid metabolism, then other treatments (i.e. diet/ pharmacology) may be 
needed to correct for the effects of metformin on fat metabolism and insulin sensitivity. 
Collectively, the literature suggests that metformin alters submaximal exercise energy 
metabolism, with little to no effect on the perception of effort during exercise. Thus, there 
seems to be little translational effect of metformin on maximal exercise to submaximal 
exercise tolerance when performed at the same absolute workload. However, the current 
work is limited in characterizing the different combinations of metformin and exercise. Future 
research looking at the effects of metformin on different exercise intensities/modes could 
provide greater insight into this potential interaction.  
 
Clinical implications/ramifications of combining exercise with metformin 
Although the Indian Diabetes Prevention Program demonstrated that lifestyle 
modification plus metformin reduced the incidence of type 2 diabetes to a similar extent as 
lifestyle modification or metformin alone, it does not provide insight into the efficacy of 
exercise on diabetes prevention (50). Exercise enhances insulin sensitivity and contributes 
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improved glycemic control (27). Whether combining metformin with exercise adds to the 
prevention type 2 diabetes is less clear. To date, there are no large-randomized clinical trials 
that determine the effectiveness of combining metformin with exercise on 
delaying/preventing the onset of type 2 diabetes. Thus, the question becomes, should 
clinicians prescribe metformin and have individuals exercise? Our findings indicate that 
metformin blunted the effects of exercise on insulin sensitivity, regardless of the basis for 
prediabetes classification (i.e. IGT vs. IFG+IGT) (Chapter 4). The combined treatment also 
blunted reductions in systolic blood pressure and CRP concentrations in individuals with IGT 
(Chapter 7). Moreover, we found that only metformin or exercise training reversed risk 
factors for the metabolic syndrome. If our findings are replicated in the “real world”, then 
there would be potentially important clinical ramifications. If metformin blunts the effects of 
exercise on enhancing insulin sensitivity, then more individuals treated with metformin plus 
exercise may develop type 2 diabetes than those participating in exercise alone. Individuals 
treated with metformin plus exercise might not also derive the same cardio-protective effects 
on systolic blood pressure and develop more cardiovascular abnormalities compared to 
exercise training alone. Our findings also highlight the importance of tailoring exercise 
treatment to individuals based on their respective pathology. Since exercise training 
accentuated insulin sensitivity in individuals with IFG+IGT more then individuals with IGT, it 
suggests that these individuals may derive more metabolic benefit from exercise alone. 
Future work should look to characterize the effects of exercise training on insulin sensitivity 
across the prediabetes spectrum (i.e. IFG vs. IGT vs. IFG+IGT), as this will improve our 
overall understanding of the role exercise has in preventing/delaying type 2 diabetes. Based 
on our findings, we suggest that exercise be considered a key part of the first line therapies 
for improving insulin sensitivity and cardiovascular health (e.g. blood pressure, TAG, etc) in 
insulin resistant individuals. If exercise training is ineffective at improving blood glucose 
regulation in these individuals, then pharmacological agents, like metformin, may be 
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considered as an additional therapy to exercise. Future work should be cognizant of other 
drug-exercise-drug interactions. We suggest others consider investigating the effects of 
multiple drug combinations and exercise to see if these treatments have no effect, add, or 
oppose changes in metabolic health outcomes.  
 
Conclusions  
Insulin resistance is a key component in the progression from normal glucose 
tolerance to impaired glucose tolerance to frank type 2 diabetes. Insulin resistance is 
associated with dyslipidemia, hypertension, and inflammation, all of which increase risk for 
cardiovascular disease. Because exercise or metformin improve insulin sensitivity, they 
should be considered for preventing/delaying cardiovascular disease and type 2 diabetes. 
Although our work demonstrates the effectiveness of exercise training for improving insulin 
sensitivity and lowering cardiovascular disease risk factors, we find that metformin blunts the 
full effects of exercise on insulin sensitivity, systolic blood pressure, and C-reactive protein 
in individuals with insulin resistance. Together, these observations suggest that exercise 
alone may provide more benefit to individuals at risk for type 2 diabetes than either 
treatment alone. However, we caution that our data should not be over interpreted to mean 
that individuals should not take metformin and exercise. If the question is, should individuals 
be treated with exercise plus metformin or metformin alone, then our data supports the 
combined treatment because of its effects on insulin sensitivity and cardio-respiratory fitness 
compared to metformin alone. Thus, from a public health perspective, co-prescribing 
treatments is likely to have “better” effects than metformin alone. However, metformin may 
be the more desirable treatment depending on the outcome of interest. If the primary 
outcome is hyperglycemia, then our findings indicate that metformin, with or without training, 
is better for lowering blood glucose concentrations in people with fasting hyperglycemia (i.e. 
IFG+IGT) compared to insulin resistant, normoglycemic individuals (e.g. IGT). From a basic 
    
173 
science perspective, it is also important that we understand how these two treatments work 
together on reducing diabetes risk. More studies are needed (e.g. animal and in vitro) to 
describe the cellular mechanism by which metformin and exercise interact to affect insulin 
sensitivity and cardiovascular health. Overall, our findings suggest that choosing the most 
appropriate treatment is likely to depend on the persons risk factor (e.g. hyperglycemia, 
blood pressure, etc) or underlying pathology (e.g. IGT or IFG+IGT or metabolic syndrome). 
Ultimately, further research in the aforementioned areas will help determine which treatment 
plan is best for preventing/delaying the progression to type 2 diabetes.  
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Figure Captions. 
Figure 8.1. Blood glucose regulation: the role of liver and skeletal muscle insulin 
resistance.   
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Figure 8.2. Effects of metformin, exercise or exercise plus metformin on insulin 
sensitivity in insulin resistant individuals.. Open bars, baseline; hatched bar, exercise 
only; black bars, metformin; gray bar, exercise + metformin. *Significantly different 
from placebo baseline (p < 0.0001). Rd/I, rate of glucose uptake per unit insulin. 
Values are mean ± standard error of the mean (54). 
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Figure 8.3. Insulin Sensitivity across all conditions. Significant effect of test (p < 0.05). 
*Compared to baseline (p < 0.05). ^Compared to placebo (p < 0.05). Rd/I, rate of 
glucose uptake per unit insulin. Values are mean ± standard error of the mean. 
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Figure 8.4. Change (i.e. difference of pre and post measures) in fasting plasma 
glucose (FPG) in response to each respective condition. Note that metformin, with or 
without training, lowered FPG more than EP.   
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Figure 8.5a. Effect of exercise training with placebo (EP), exercise training with 
metformin (EM) and metformin (M) on reversing the metabolic syndrome in 
individuals with IGT. * Significantly different compared to pre-test (p < 0.05).  
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Figure 8.5b. Effect of exercise with metformin on risk factors related to the metabolic 
syndrome. Note triacylglycerol (TAG) and fasting blood glucose (FBG) are reduced.  
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Figure 8.5c. Effect of exercise with placebo on risk factors related to the metabolic 
syndrome. Note systolic and diastolic blood pressure (SBP and DBP), triacylglycerol 
(TAG), and HDL are reduced.  
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Figure 8.5d. Effect of metformin on risk factors related to the metabolic syndrome. 
Note systolic and diastolic blood pressure (SBP and DBP), triacylglycerol (TAG), and 
FBG are reduced.  
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APPENDIX A 
 SUPPLEMENTARY FIGURES FOR CHAPTER 4 
 
Supplement A.4.1. The change (difference of pre and post measures) in insulin 
sensitivity (i.e. rate of glucose disposal (Rd)/plasma insulin (I) concentrations) 
correlated with the change in non-oxidative glucose disposal (NOGD).  
 
 
 
 
Supplement A.2. The change (difference of pre and post measures) in cardio-
respiratory fitness (i.e. VO2peak) correlated with the change in insulin sensitivity (i.e. 
rate of glucose disposal (Rd)/plasma insulin (I) concentrations).  
 
 
    
191 
Supplement A.3. The change (i.e. difference of pre and post measures) in body weight 
correlated with the change in insulin sensitivity (i.e. rate of glucose disposal 
(Rd)/plasma insulin (I) concentrations).  
 
 
 
Supplement A.4. Change (i.e. difference of pre and post measures) in fasting plasma 
non-esterified fatty acids (NEFA) correlated with insulin sensitivity (i.e. rate of 
glucose disposal (Rd)/plasma insulin (I) concentrations).   
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Supplement A.5. Change (i.e. difference of pre and post measures) in fasting plasma 
glucose (FPG) in response to each respective condition. Data expressed as group 
mean. Note that metformin (M) and exercise training with metformin (EM) lowers FPG 
more than exercise training with placebo (EP) in individuals IFG+IGT compared to 
IGT.   
 
 
 
 
Supplement A.6. Change (i.e. difference of pre and post measures) in fasting plasma 
insulin (FPI) concentrations in response to each respective condition. Data expressed 
as group mean. Note that insulin concentrations tend to decrease more after each 
respective treatment in individuals with IFG+IGT compared to IGT.   
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APPENDIX B 
 SUPPLEMENTARY FIGURES FOR CHAPTER 6 
 
Supplement B.1. Effects of exercise training on substrate utilization (expressed as the 
respiratory exchange ratio (RER)) in individuals with impaired glucose tolerance 
(IGT). Data expressed as group mean ± SEM (n = 4). Note that exercise training 
lowered RER values more in individuals with IGT than individuals with IFG+IGT.  
 
 
Supplement B.2. Effects of exercise training on substrate utilization (expressed as the 
respiratory exchange ratio (RER)) in individuals with impaired fasting glucose (IFG) 
concentrations plus impaired glucose tolerance (IFG+IGT). Data expressed as group 
mean ± SEM (n = 4).  
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APPENDIX C 
 SUPPLEMENTARY FIGURES FOR CHAPTER 7 
 
Supplement C.1. Effects of placebo (P), metformin (M), exercise training with placebo 
(EP) and exercise training with metformin (EM) on ambulation in individuals with 
prediabetes. Data expressed as group mean ± SEM. 
 
 
Supplement C.2. Effects of placebo (P), metformin (M), exercise training with placebo 
(EP) and exercise training with metformin (EM) on resting metabolic rate (RMR) in 
individuals with prediabetes. Data expressed as group mean ± SEM. 
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Supplement C.3. Effects of placebo (P), metformin (M), exercise training with placebo 
(EP) and exercise training with metformin (EM) on caloric intake in individuals with 
prediabetes. Data expressed as group mean ± SEM.   
 
 
 
Supplement C.4. The change (i.e. difference of pre and post measures) in caloric 
intake correlated with the change in body weight. 
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Supplement C.5. The change (i.e. difference of pre and post measures) in 
triacylglycerol (TAG) correlated with the change in insulin sensitivity (i.e. rate of 
glucose disposal (Rd)/plasma insulin (I) concentrations). 
 
 
 
 
